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Studies of gut immunity must be carried out on intestinal fluid and jejunal
biopsies. Recent work from Edinburgh has shown that the Whole Gut Lavage
(WGL) technique is a non-invasive, direct and reliable method of obtaining
intestinal fluids. My thesis describes the use of WGL technique in a variety of
studies of gastrointestinal mucosal immunity. I started by confirming, in a
serial lavage study, the validity of taking any clear fluid stools passed per
rectum to be representative of the rest of the lavage effluent. The effect of the
newly licensed oral live typhoid vaccine Ty21a on gut immunity was
investigated in a group of 22 healthy British volunteers. Later on, the intestinal
immune responses to naturally-acquired salmonella infection were investigated
in a group of patients who had had the infection within the preceding 12
months. Results obtained in these studies were compared with results obtained
from healthy individuals, patients with inflammatory bowel disease (IBD) and
African children from Sierra Leone. Because previous studies had shown that
cigarette smoking modifies the systemic and local immune responses and
produces a decrease in the concentration of salivary IgA of smokers compared
to control non-smokers, I investigated further the effect of heavy smoking and
non-smoking in healthy volunteers on gut immunity and the effect of
administration of the live oral vaccine Ty21a on the intestinal mucosal immune
responses of smokers and non-smokers. In the course of the above studies, I
found that there were patients who had very low or absent intestinal IgA but
had normal levels of IgA in the serum. Therefore, I investigated further this
phenomenon by counting plasma cells in the lamina propria of intestinal
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The intestinal immune system is largely independent from the systemic immune
system and the process of obtaining fluids directly from the gut is regarded as the
optimal method or the " gold standard " for the investigation of the local intestinal
immunity. However, investigations of the local intestinal immunity have been
hampered by the difficulty of obtaining direct access to the intestinal secretions.
Extensive studies into the local intestinal immune system have been carried out
both in man and animals, extrapolating determinations of levels of antigen-specific
antibodies in serum, colostrum, saliva or antibody production in vitro by
circulating peripheral blood lymphocytes (PBL) to the gut. However, indirect
measurements of the local immune response do not necessarily reflect the findings
at the intestinal level and studies showed that systemic immune responses are not
correlated with the intestinal immune responses.
Repeated intestinal intubation to obtain intestinal secretions for the measurement of
immunoglobulins and specific antibodies concentrations have been carried out as a
direct approach to the local intestinal immune system. However, repeated intestinal
intubation is inconvenient for the patient, invasive, labour-intensive and a time-
consuming procedure. Furthermore, repeated intestinal intubation is not suitable
for the very young or very old individuals. In addition, secretions obtained from
the jejunum may not be representative of the whole gut.
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Whole gut lavage (WGL) has recently been available for use in man and was found
to be safe, reliable, non-invasive and a direct approach to study the intestinal
mucosal immunity. The activity of protease enzymes, found in large amount in the
human intestinal secretions, could be prevented by treating the specimens with
protease inhibitors.
Alms of the study
1. To validate the use of a single clear fluid specimen passed per rectum during
WGL as a representative of the rest of the WGL effluent in research into gut
immunity.
2. To study gut immunity in heavy smokers and non-smokers, comparing levels of
intestinal immunoglobulins and antigen-specific antibodies in both groups.
3. To investigate the intestinal immune responses to salmonella antigens, by using
the newly licensed live oral typhoid vaccine Ty21a as an antigen, in a group of
British healthy volunteers and also to examine the intestinal immune responses
in a group of patients who had had natural infection with Salmonella spp.
4. To check and confirm the presence of a previously unrecognised condition,
intestinal IgA deficiency. In fact, this aim arose in the course of my research
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into gut immunity when I found several subjects who had absent or near absent
IgA in the intestinal secretions but had normal levels of IgA in serum.
Approach
In the first instance protocols for a clinical study based on the use of whole gut
lavage fluid were validated by establishing methods for collection and processing
WGL specimens to be used as materials for quantitative investigations of intestinal
immunoglobulins and specific antibodies both in healthy volunteers and patients
with a variety of gastrointestinal diseases. A modified enzyme-linked
immunosorbent assay (ELISA) technique was developed for the isotype-specific
measurement of anti-Salmonella typhi LPS antibodies concentrations applicable to
gut lavage fluids and serum. A standard (ELISA) technique was employed for the
quantitative study of immunoglobulin concentrations in WGL fluid. A blood
sample was collected from one of the gastrointestinal laboratory staff three weeks
after she had TAB vaccine (parenteral vaccine against typhoid, paratyphoid A and
paratyphoid B infection) and she was found to have a high titre of specific anti-
Salmonella typhi LPS antibodies in serum. The serum then was divided into small
aliquots and stored at -70 °C to be used as a standard for the isotype-specific
ELISA. The antibodies of interest in these assays were those from a group of
patients who had had naturally-acquired salmonella infection and a group of British
adult healthy volunteers who had the oral typhoid vaccine Ty21a.
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Following these technical developments, 1 started my clinical research by
investigating 4-6 serial lavage samples from patients with a variety of
gastrointestinal diseases to examine the validity of using the first clear sample as a
representative for the gut lavage output. Later on, to study the influence of heavy
smoking and non-smoking on the gut immunity, a group of young healthy
volunteers were recruited from the computerised data of the Clinical Research
Centre of the University of Edinburgh and were divided into heavy smokers and
non-smokers. A number of gastrointestinal laboratory staff and their relatives who
wished to participate in this study were also recruited.
To study intestinal immunity following a naturally-acquired salmonella infection
and the duration of the intestinal immune response, a group of patients who had
had Salmonella typhi or non-typhoidal salmonella infection (salmonellosis) in the
preceding twelve months and who were admitted, treated, discharged and wished
to take part in my study were referred from the City Hospital. I then examined
levels of specific antibodies to the oral typhoid vaccine Ty21a and compared these
levels with the levels of specific antibodies in the naturally-acquired salmonella
infection as well as in patients with up-regulated intestinal humoral immunity
(inflammatory bowel disease).
Finally, preliminary clinical and immunological investigations were performed in a
group of patients who were found to have very low or no IgA at all in their lavage
fluids but to have normal levels of IgA in serum. Immunological investigations
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were extended to previously collected, processed and stored WGL fluids during
the years 1991 and 1992 screening for intestinal IgA deficient patients. A blind
microscopic examination of a mixture of intestinal biopsies from patients with
intestinal IgA deficiency and a group of patients with a variety of gastrointestinal




REVIEW OF THE LITERATURE
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Section 1
THE GUT AS AN IMMUNE ORGAN
Introduction
The interaction between host and external environment occurs along two major
surfaces, the skin and the mucosal surface. The mucosal surface involves an
area much larger than the area covered by the skin (the surface area of the
2 2
small intestine is about 300-400 m" compared with 1.8 m for the skin). The
intestinal immune system is separate from the systemic immune system and the
gut is regarded as the largest immune organ in the body. Furthermore, the
intestine is regarded as the largest immunoglobulins and antibodies forming
organ in the human body and plays a protective role in the host defence against
constant challenge by a wide spectrum of potentially harmful antigens.
The clinical importance of the mucosal defence system can be appreciated if
one were to assess the implication of the infectious diarrhoea world-wide.
Around 750 million episodes of diarrhoea caused by infectious agents occur
every year among children below the age of 5 years in Asia (excluding China),
Africa and Latin America and 5-10 million children world-wide die every year
because of diarrhoeal diseases (World Health Organisation, 1984). The wide
spectrum of gastrointestinal infections among patients with the Acquired
Immunodeficiency Syndrome (AIDS) is another example of the important role
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played by the mucosal defence system in healthy individuals. Therefore, an
understanding of the mechanisms of the intestinal immune defence system will
have a major implication for the prevention of diarrhoeal diseases e.g. by
vaccination.
Historical review
The presence of a local intestinal immune system independent from the
systemic immune system is not a new concept. Besredka (1919) reported that
rabbits were protected against dysentery following orally administered killed
Shigella bacillus, regardless of the immune response in the serum. Later on,
Davis (1922) reported the presence of locally produced antibodies against the
dysentery bacillus in the stools of infected persons before such antibodies
appeared in serum. However, the interest in the intestinal mucosal immune
system significantly increased only late in the 1960s after the discovery by
Tomasi and Zigelbaum (1963) of IgA as a predominant immunoglobulin in the
external secretions such as saliva, colostrum and lacrimal secretions. Locally
produced IgA in saliva and colostrum was described by Hanson (1961), Tomasi
et al (1965) and Chodirker et al (1963) in more detail. Secretory IgA (SIgA)
was found to be different from serum monomeric IgA and to have unique
chemical and immunological properties because of its dimeric character as well
as its association with a secretory component (SC), which is an epithelial
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glycoprotein. Tomasi et al (1965) had postulated that the SC is involved in the
transport of IgA (and IgM) across the mucosal membrane into the gut lumen
via a process called transcytosis. Accordingly, it was postulated that the
dimeric SIgA is not transudated from serum but locally synthesised. This was
shown definitively by Brandtzaeg (1974) who established a common epithelial
transport model for dimeric IgA and pentameric IgM. Another important
discovery by Crabbe et al (1965) has made a major contribution into the
knowledge of the mucosal immune system. They demonstrated that the
intestinal immunoglobulin-producing cells, unlike the other lymphoid tissue
immunoglobulin-producing cells, were predominantly IgA-producing cells and
that IgA-producing cells are 20 times as numerous as IgG-producing cells in
the intestinal mucosa.
During the last two decades intensive studies into the regulatory mechanisms of
the intestinal immune response have been carried out. The molecular and
cellular interactions that regulate maturation and differentiation of lymphocytes
into IgA-producing cells have been studied in animals (Clough et al, 1971;
Torrigiani, 1972; Guy-Grand et al, 1975) and humans (Mestecky and McGhee,
1987; Conley and Delacroix, 1987; Brandtzaeg et al, 1985). However, the
mechanism by which an intestinal immune response is established and regulated
is, as yet, not well-understood.
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Basic concept of gut immunity
The gut provides an important immunological barrier, in addition to its
physiological function as the site of absorption of dietary nutrients, against a
constant challenge by infectious, toxic and immunogenic materials. Potentially
harmful antigens such as bacteria, viruses, protozoa and helminths are
selectively excluded from entering into the systemic circulation by a process
known as "Immunological Exclusion".
Immunological and non-immunological mechanisms of the mucosal defence
system are involved in the defence against infectious agents. The non-
immunological mechanisms include the following, (a) Intraluminal factors:
such as gastric acid, bile salts, pancreatic proteases, and lysozymes; (b)
Mucosal surface: these include mucous coat, enterocyte membrane integrity
and epithelial tight junctions (Russell and Walker, 1990); (c) Normal bacterial
flora: gut commensals produce endogenous antibiotics that are directly harmful
to particular pathogens (MacKowiak, 1982); (d) Intestinal peristalsis.
The immunological defence is produced by the gut-associated lymphoid tissue
(GALT) and involves the secretory immunoglobulins, mostly SIgA as the
hallmark of the mucosal immune system and to a lesser extent IgM. The
mucosa-associated lymphoid tissue (MALT) consists of the gut-associated,
bronchus-associated and duct-associated lymphoid tissues and collectively
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represent the largest lymphoid organ in the human body (Tomasi et al, 1980;
Bienenstock, 1984; Bienenstock and Befus, 1984). GALT is composed of
lymphoid aggregates, in Peyer's patches (PPs) and in the solitary lymphoid
follicles (scattered throughout the gastrointestinal tract including the appendix)
and lymphocyte populations in the gut epithelium (Intraepithelial Lymphocytes;
IELs) and in the lamina propria (Trepel, 1974; Brandtzaeg, 1985; Owen,
1977).
Pever's Patches (PPs)
In humans, PPs are well developed early in foetal life and at birth there are
about 100 PPs increasing to about 250 PPs at the mid-teens then decreasing to
about 100 PPs between the age of 70 and 95 years (Cornes, 1965). However, it
is only shortly after birth that germinal centres appear in PPs (Bridges et al,
1959), which indicates the dependence of germinal centre formation on
antigenic stimulation. PPs may be anatomically and functionally divided into
three areas; the dome, the follicles and the interfollicular areas. The dome is
covered by an epithelium containing specialised cells called "M" (for
microfold) cells. M cells are involved in the transport of antigens inward across
the PPs epithelium via a process known as pinocytosis. M cells are thin cells
(the thickness of the cytoplasm is only 0.1-0.3 pm) and the underlying
lymphocytes are as close as 0.3 pm from the gut lumen (Guy-Grand et al,
1975; Owen, 1977; Bockman and Cooper, 1975). M cells are described below
in more detail.
The follicles, or B-cells zones, with germinal centres contain 60-70% of the
membrane-bound IgA positive (mIgA+) B cells. These cells are regarded as the
immediate precursor of IgA-producing plasma cells and the PPs are thought to
be the site where the initial commitment of B cells to produce IgA is made
(Butcher et al, 1982). Two types of mIgA+ B cells are found in PP germinal
centres; small resting memory B cells and large dividing B cells (Butcher et al,
1982; Lebman et al, 1987). The final differentiation of B cells into IgA-
producing plasma cells, however, does not occur in B cells zone of PPs but in
the distant effector sites of the gut mucosa.
The third area in PPs is the parafollicular (or interfollicular) area, or T cell
area (McGhee et al, 1989). The majority of T cells in the parafollicular area
are CD3+, CD4+, CD8", and CD5+ (Guy-Grand et al, 1975). These are
known to be inducer cells or T helper (Th) cells. However, a significant
number of CD4", CD8+ suppressor/cytotoxic T cells are also found in PPs
(Guy-Grand et al, 1975). The presence of large numbers of Th cells in PPs
supports the suggestion that PPs are the site of induction of the intestinal
immune response. Morphological and functional studies of PPs have revealed
the presence of unique T lymphocytes and dendritic cells that regulate the
differentiation of B cells and influence their maturation and immunoglobulin
isotype switching to predominantly IgA-producing B cells (McGhee et al,
1989).
Intestinal M Cells
Kumagai (1923) demonstrated that there was selective uptake of dead
mycobacteria from the lumen of the gut into PPs and the appendiceal lymphoid
tissues. However, the distinctive description of M cells was only made by
Schmedtje more than 40 years later when he described them as
"lymphoepithelial cells" overlying the lymphoid nodules (Schmedtje, 1965). In
humans, about 10% of PPs dome epithelial cells are M cells while in rabbits M
cells constitute up to 50% of the dome epithelium (Trier, 1991).
Under electron microscopy, human M cells appear as short, irregular networks
of folds that strikingly contrast the regular carpet-like appearance of the
microvilli on adjacent absorptive cells (Owen and Jones, 1974). The apical
plasma membrane of M cells differs considerably from that of the adjacent
absorptive cells; for example it is selectively adherent for reovirus type 1,
some strains of E. coli and cholera toxin B-subunit, and facilitates their
transepithelial transport (Trier, 1991). Furthermore, luminal SIgA and some
lectins were found to bind selectively to the apical membrane of M cells (Trier,
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1991). This unique structure of M cells has led to the concept that M cells are
the site of antigen sampling.
The passage of intact molecules across the gut is at variance with the role of
the gut as a molecular barrier. However, macromolecules and micro-organisms
that survive intraluminal degradation have the potential to adhere selectively to
the apical surface of M cells then be endocytosed into M cells or transported
across the cytoplasm of M cells crossing to the underlying immunocomponent
cells of PPs. M cells are involved in transepithelial transport of
macromolecules that adhere selectively to the apical surface of M cells, such as
cholera toxin B-subunit and certain lectins, by adsorptive endocytosis whereas
molecules that do not adhere to the apical surface of M cells, such as albumin,
are transported by a fluid phase endocytosis (Neutra et al, 1987). Micro¬
organisms such as some viruses (Sicinski et al, 1990), bacteria (Owen et al,
1986) and even protozoa, for example Cryptosporidium may also adhere
selectively to the apical surface of M cells and be transported to the underlying
lymphoid cells of PPs (Marcial and Madara, 1986). The interaction of bacteria
with M cells seems to be influenced by the virulence of the organism as well as
the host immune factors. Most of the commensal intestinal bacteria, which
constitute the normal gut flora do not generally adhere to the apical surface of
M cells of healthy mammals whose intestinal flora has not been disturbed
(Trier, 1991). Pathogens such as the RDEC-1 strain of E. coli, an
enteroadherent organism that produces diarrhoea in rabbits without invasion or
production of classic enterotoxins, and V. Cholerae may adhere selectively to
or invade M cells with minimal damage (Inman and Cantey, 1983; Owen et al,
1986). Other virulent pathogens such as Salmonella typhi and Shigella flexneri
use M cells as a portal of entry into the systemic circulation and produce
extensive dome ulceration with destruction of the PPs epithelium (Kohbata et
al, 1986; Wassef et al, 1989).
The regulatory mechanism by which macromolecules and micro-organisms
either selectively adhere to or invade M cells, and the mechanisms by which
these macromolecules and micro-organisms are taken up into or transported
across the cytoplasm of M cells are not, as yet, well understood. Studies in
rabbit (Kato, 1990) and mouse (Roy and Varvayanis, 1987) showed that there
is selective adherence of intraluminal SIgA to M cells of these animals. In
another study, the delivery of reovirus type 1 specific monoclonal IgA
antibodies into the intestinal lumen of mice resulted in marked inhibition of
viral entry to or replication in the mucosa following oral challenge with
reovirus type 1 (Weltzin et al, 1989). One interpretation of the above
observations is that the selective adherence of specific IgA antibodies to M
cells may inhibit rather than facilitate the uptake of micro-organisms or
antigenic macromolecules to which specific IgA antibodies are directed. This




The secretion of SIgA into external body fluids, including those of
hepatobiliary and gastrointestinal tract, is the hallmark of the mucosal immune
system. In humans, the combined daily synthesis of systemic and SIgA was
estimated as 66 mg/kg body weight per day of which 40 mg/kg body weight
per day is the SIgA that is secreted into the lumen of gut in adults (Conley and
Delacroix, 1987), i.e. approximately 3g of SIgA is transported into the gut
lumen of the average adult per day. The total daily production of IgG, IgM,
IgD and IgE was estimated as 34, 8, 0.4 and 0.02 mg per kg body weight
respectively (Conley and Delacroix, 1987). Therefore, the overall daily
production of SIgA is larger than all other isotypes combined. In humans, IgA-
producing cells in the systemic and secretory compartments markedly
outnumber those secreting other isotypes. Enumeration of immunoglobulin-
producing cells in various tissues showed that 1-2 m of human intestine
contained more immunoglobulin-producing cells (predominantly of the IgA
isotype) than did all other tissues combined (Brandtzaeg and Baklien, 1976;
Brandtzaeg et al, 1991). Since the majority of infectious agents are encountered
in the lumen and mucous membrane of the gut, then the need for synthesis and
secretion of such a large amount of IgA is obvious.
Structure of SIgA. IgA is found in two different molecular forms, monomeric
(mlgA) and polymeric (plgA) (Mestecky and McGhee, 1987; Conley and
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Delacroix, 1987; Mestecky et al, 1986). In humans, immunochemical and
biochemical studies showed that there are two subclasses of IgA: IgAl and
IgA2 and that these two subclasses have different distribution in various body
fluids (Mestecky and McGhee, 1987; Mestecky and Russell, 1986; Delacroix
et al, 1982). In humans, 85-99% of IgA in serum is in the monomeric 7S form
(Mestecky and Russell, 1986) and up to 85% of IgA in serum is IgAl subclass.
SIgA, on the other hand, is mainly found in 1 IS polymeric form, usually as
dimers. However, trimers, tetramers and pentamers are produced in lesser
amount (Mestecky et al, 1986). While serum IgA is predominantly monomeric
IgAl, in external secretions, IgA is predominantly polymeric and up to 95%
of IgA in gastrointestinal secretions is secretory IgA with an increased
proportion of IgA2 subclass (IgAl:IgA2 is 70:30 in gastrointestinal secretions
compared with 85:15 in serum) (Delacroix et al, 1982; Kerr, 1990).
The distinctive feature of IgA is its ability to form polymers by having special
heavy chain constant-region (CH) terminal extensions with an extra cysteine
residue which can participate in cross-linking monomeric subunits together via
disulfide bonds (Mestecky and McGhee, 1987). The typical monomeric IgA
molecule is composed of two a heavy and two light chains (either k or X)
linked by covalent (disulfide) and non-covalent bonds (Mestecky and McGhee,
1987; Mestecky et al, 1986). The typical dimeric molecule of SIgA , on the
other hand, is composed of two monomeric IgA subunits linked together by
disulfide bonds, one Secretory Component (SC) and one J (joining) chain
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linked to the Fc region of the polymers (Halpern and Koshland, 1973;
Koshland, 1985; Mestecky and McGhee, 1987). J chain is acquired during the
process of polymerisation in plasma cells while SC is acquired during the
selective transport of SIgA through the epithelial cells (Mestecky et al, 1991).
J chain is a glycoprotein that is found in polymeric IgA and IgM of many
species. It is produced in B cells and in plasma cells during the various stages
of differentiation of these cells. The function of J chain has been found not
only to link IgA monomers together via disulfide bonds (Garcia-Pardo et al,
1981; Brandtzaeg and Prydz, 1984) but also to enable plgA to bind to SC
although SC does not bind directly to the J chain (Eiffert et al, 1984).
Polymeric IgA containing J chain has been shown to have an increased
resistance to proteolytic enzymes (Koshland, 1985).
The most important feature of SIgA is the presence of an associated
glycoprotein piece called the secretory component (SC). SC is responsible for
the selective transport of plgA across the epithelial cells. It also has been found
to stabilise the quaternary structure of IgA and increase its resistance to the
proteolytic enzymes (Brown et al, 1976). SC is found in three molecular forms
(Mestecky et al, 1991): (a) as a membrane protein on the basolateral surface of
the epithelial cells where it functions as a receptor for polymeric
immunoglobulins (polymeric immunoglobulin receptor; plgR), (b) as a
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component of polymeric immunoglobulins and (c) as a free glycoprotein found
in many external secretions. The molecular structure of SC is composed of a
single polypeptide chain with 549-558 amino acids and large amounts of
carbohydrates folded into five domains (homology regions) each comprises
104-114 amino acid residues and contains intrachain disulfide bridges (Eiffert,
1984). The fifth domain contains an additional intrachain disulfide bond which
is involved in the disulfide bridges that connects SC to the a chains of one of
the monomers in dimeric IgA. PIgR is synthesised and expressed on the surface
of epithelial cells of the gastrointestinal and respiratory tracts, acinar and ductal
cells in exocrine tissues as well as the lining cells of uterus (Mestecky et al,
1986; Brandtzaeg, 1985). Polymeric IgA with J chain binds to the plgR at the
basolateral surface of the epithelial cells, is transported across the cytoplasm of
epithelial cells via endocytotic vesicles and then secreted at the epithelial
surface as SIgA (Brandtzaeg and Baklien, 1976). Part of the receptor cleaves
off and remains attached to the pig and is known as SC. Because cells involved
in producing SC and transporting SIgA are constitutively synthesising and
secreting SC, thus SC can be found as free SC in the secretions (Brown et al,
1976).
Source of Intestinal IgA. In serum, the bone marrow has been regarded as a
major source of IgA in mice (Benner et al, 1981) as well as in humans (Conley
and Delacroix, 1987). It was postulated that mature B cells leave the bone
marrow to become activated following interaction with T cells and antigen-
presenting cells in the peripheral lymphoid organs, then return to the bone
marrow where they differentiate into immunoglobulin-producing plasma cells
(Benner et al, 1981). On the other hand, GALT, represented by PPs, have
been regarded as the source of IgA-producing plasma cells found in distant
mucosal tissues including the intestine, mammary, lacrimal, salivary and
uterine glands as well as the respiratory tract (Mestecky and McGhee, 1987).
During early ontogeny, B and T lymphocytes precursors, presumably of bone
marrow origin, migrate to PPs, via interfollicular postcapillary venules
(Mestecky et al, 1991; Brandtzaeg et al, 1991). Thereafter, preferential
compartmentalisation occurs.
Function of SIgA. The function of SIgA is mainly to provide an
immunological barrier against a variety of foreign antigens including food
antigens, bacteria, viruses, parasites, and toxins. Possible mechanisms by
which SIgA may protect against enteric infection are described below, (a)
direct action by immobilisation, agglutination and prevention of bacterial
adherence to the mucous membrane and (b) combination with bacterial
products such as toxins or enzyme resulting in inactivation and destruction of
these products by the proteolytic enzymes of the intestine (World Health
Organisation, 1979; Bienenstock and Befus, 1985).
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Attachment of micro-organisms to epithelial cells is thought to be mediated by
receptors such as GM1 on the epithelial cells (to which cholera toxins bind) and
specific attachment sites on the pathogens such as fimbria and pili (Tse and
Chadee, 1991). Adherence of micro-organisms to the epithelial cells may be
prevented by coating of the micro-organisms with SIgA resulting in blocking of
the sites of attachment retaining the micro-organisms within the mucous layer
(Childers et al, 1989). Once the mobility of the pathogens is reduced, they are
susceptible to proteolytic enzymes and may be easily swept out by peristalsis.
In animals, studies have shown that intestinal loops of orally immunised mice
were partially protected by specific IgA against live Vibrio Cholerae (Fubara
and Freter, 1973). Similar observation has been made in studies on E. coli
(strain RDEC-1) in a rabbit model, in which specific IgA antibodies in milk
protected the animal from diarrhoea (Boedeker et al, 1987). In the case of
Salmonella, SIgA attached to the organisms may prevent their adherence to the
intestine by causing a decrease in hydrophobicity and in negative charges of the
organisms (Magnusson et al, 1979; Magnusson and Stendhal, 1982).
In humans, among the most convincing results of studies on the antimicrobial
function of SIgA is the work of Ogra et al (1968) who showed that oral
immunisation with live poliovirus vaccine, but not with killed poliovirus
vaccines, produced an intestinal immune response with the production of SIgA
antibodies. The intestinal immune response was associated with significant
protection against poliovirus. In clinical studies, oral cholera vaccine,
consisting of the nontoxic but highly immunogenic B subunit of cholera toxin
together with heat- and formalin-killed whole cell V. Cholerae organisms (B-
WC), has been found to stimulate gut mucosal anti-toxin and anti-bacterial IgA
(Svennerholm et al, 1984) and administration of this vaccine has been
associated with long-term protection against V. Cholerae (Clemens et al, 1986;
Clemens etal, 1990).
The role of SIgA in excluding potentially dangerous immunogens is not limited
to the prevention of bacterial antigens from reaching the systemic circulation
but also plays an important role in limiting uptake of potentially harmful food
antigens across the intestinal epithelium. SIgA, together with some food
antigens, form immune complexes that can not bind to the surface of absorptive
cells (Walker et al, 1975). In patients with selective IgA deficiency and new¬
born infants with transient IgA deficiency, high titres of antibodies against food
antigens can be detected in their serum (Cunningham-Rundles et al, 1978;
Eastham et al, 1978).
In some circumstances, ingestion of an antigen may lead to oral tolerance
rather than induction of intestinal immune response. Oral tolerance is described
as an antigen-specific hyporesponsiveness of systemic humoral or cellular
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immunity induced by antigen feeding prior to systemic challenge (Bruce and
Elson, 1990). Absence of oral tolerance may result in autoimmune diseases
such as autoimmune enteropathy and pernicious anaemia (Roitt et al, 1965),
coeliac disease and cow's milk enteropathy (Bruce and Elson, 1990; Mirakian
et al, 1986). Recovery from cow's milk enteropathy was recently found to be
positively correlated with the presence of intestinal SIgA against milk proteins
(Isolauri et al, 1992). Thus, ingestion of an antigen may (a) induce oral
tolerance (b) initiate a local immune response; and (c) (very rarely) may result
in inappropriate systemic immune responses (Sanderson and Walker, 1993).
As cited above, prevention of potentially harmful antigens, by SIgA, from
reaching the systemic circulation has been suggested to occur through the
"immune exclusion" mechanism. Therefore, it seems that the protective
function of SIgA is not limited to the mucosal surface but it may function
within the mucosa itself, i.e. in the lining epithelium and the lamina propria, to
prevent pathogens that succeeded in gaining access to the mucosa from
reaching the systemic circulation. In a study in vitro (Mazanec et al, 1993),
virus titres were reduced when monoclonal IgA antibodies specific for viral
envelope proteins were added to an epithelial model system, polarised
monolayer cells of Madin Darby canine kidney (MDCK), infected with Sendai
or influenza viruses suggesting intracellular viral neutralisation by specific IgA.
Furthermore, antigens that have been absorbed intact across the mucosal
epithelium may form immune complexes with locally produced IgA antibodies
in the lamina propria (Husby et al, 1985). In addition, Mazanec and colleagues
(Mazanec et al, 1993) have suggested an excretory function for SIgA. They
demonstrated, in a study in vitro, that immune complexes containing dimeric
IgA, but not monomeric IgA or IgG antibodies, were readily transported across
the epithelial cells into the apical medium (representing the external surface).
Therefore, it appears that polymeric IgA is involved in an efficient local
removal of potentially dangerous antigens in the form of immune complexes
from the mucosa, thereby preventing harmful systemic immune reactions.
Induction and expression of mucosal immune responses
Mucosal immune response can be divided into afferent (induction) and
efferent (effector) phases. The afferent phase of the mucosal immune response
starts by selective transport of antigens by M cells into PPs. Antigens are then
taken up by antigen-presenting cells (APCs) (accessory cells) such as
macrophages and dendritic cells. Antigens are taken up by APCs via a process
called endocytosis then degraded, by a serious of degradative enzymes present
in the endocytotic vesicle, into small antigenically distinct peptides (Brandtzaeg
et al, 1989). These peptides interact with class II Major Histocompatibility
Complexes (MHC) antigens to form complexes which are then re-expressed on
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the cell surface. Only cells expressing class II MHC molecules can serve as
antigen-presenting cells (Brandtzaeg et al, 1989; Mayer, 1990). Class II MHC
molecules are found on macrophages, dendritic cells, B-cells, activated T-cells
and, in some circumstances, on intestinal epithelial cells (Elson et al, 1986).
Processed antigens bound to class II MHC molecules on the surface of APCs
can be recognised by the receptor of specific helper T cells (Th) which then
become activated and secrete lymphokines such as IL-2, IFN-y, B-cell growth
factors and differentiation factors (Mayer, 1990).
Activated APCs synthesise and release IL-1, which is an important factor
mediating the interaction between APCs and T cells contributing to activation
of T cells and the release of IL-2 (Elson et al, 1986; James, 1991). Activated T
cells release factors which act on IgM-bearing B cells (mIgM+) to switch to
IgA-bearing B cells (m!gA+) (Kawanishi et al, 1983a; Kawanishi et al, 1983b).
Live micro-organisms, as particulate antigens, are processed by macrophages
and dendritic cells in PPs resulting in an efficient mucosal immune response
whereas killed micro-organisms, as soluble antigens after being degraded by
proteolytic enzymes and transformed into small peptides, are processed by
macrophages present in lamina propria of the villi rather than in PPs resulting
in tolerance rather than immune response (Biewenga et al, 1993; Pavli et al,
1990). Despite the fact that dendritic cells are non-phagocytic cells and antigen
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processing occurs outside the cell, yet they are regarded as the most potent
APCs (Steinman and Cohn, 1973). This may be due to the fact that dendritic
cells are rich in class II MHC molecules and have strong avidity to T cells
(Nussenzweig and Steinman, 1980). Dendritic cells have been found to
constitute the main APC population in the dome area of PPs (Biewenga et al,
1993). However, dendritic cells cannot work independently and can only work
as a part of the accessory cells network (Witmer-Pack et al, 1987).
Factors influencing IgA B cells differentiation
There is an increasing evidence that the immunoglobulin isotype switch of B
cells to IgA-producing cells is a directed process under the control of cellular
and soluble factors called lymphokines. Kawanishi et al (1983) have suggested
that the presence of activated T cells is necessary for the isotype switch to IgA
production in murine B cells. Further studies by Spalding and Griffin (1986)
showed that dendritic cells derived from PPs stimulated pre-B cells to switch to
IgA-producing B cells. Furthermore, "stromal" cells may be involved in the
induction of sIgM+ B cells to switch to sIgA+ B cells (Strober and Harriman,
1991). Although the nature of the cell involved in IgA B cells switching is not
known, the above studies suggest that there must be a cell within PPs that is
involved in IgA B cell switching.
Other studies showed that lymphokines are also involved in the process of IgA
B cell switching and differentiation. IL-4 was suggested to be an important
factor that, in certain circumstances, together with transforming growth factor-
(3 (TGF-P) support the early switching of mIgM+ to mIgA+ B cells (Strober
and Harriman, 1991; Biewenga et al, 1993). Regulation of secretion of IL-4
and other co-factors involved in isotype switching and differentiation of B cells
may be controlled by helper T cells. In this model, two types of helper T cells
were initially described, Thl and Th2 (Cherwinski et al, 1987). Thl cells have
been suggested to produce IL-2 and INF-y while Th2 cells produce IL-4, IL-5
and IL-6. While Th2 cells promote the production of IgA, IFN-y from Thl
cells acts on Th2 cells resulting in suppression of IgA production (Biewenga et
al, 1993). However, the precise mechanism that controls activation and
inhibition of Thl and Th2 is not, as yet, well-understood.
Terminal differentiation of IgA-producing B cells (post-switch step) into IgA-
secreting plasma cells occurs/the lamina propria but not in PPs. Therefore,
stimulated (switched) mIgA+ B cells migrate to the mesentric lymph nodes, to
the thoracic duct, and then to the systemic circulation. From the systemic
circulation, stimulated mIgA+ B cells selectively migrate to the effector sites of
the mucosal immune response i.e. the lamina propria. Lymphocyte "homing" is
a process in which IgA committed B cells migrate to the organ where antigenic
stimulation initially occurred. Once there, the lymphocytes differentiate into
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antibody-secreting plasma cells and die within a few days (Husband and
Gowans, 1978).
Differentiation of mIgA+ B cells in the lamina propria requires the
presence of IL-5 while the final differentiation and maturation of activated B
cells to IgA plasma cells require the presence of IL-6 and IL-2 together
(Strober and Harriman, 1991).
Finally, better understanding of the mechanisms regulating IgA induction and
secretion may help not only in developing methods for protection against
mucosal pathogens but also in the management of immunological disorders that
may be caused by mucosal immune dysfunction.
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Section 2
INVESTIGATION OF THE INTESTINAL
IMMUNE SYSTEM
Introduction
Traditional methods for studying systemic immune responses depend heavily on
detection of antibodies in serum while study of human intestinal immunity has been
hampered by the difficulty of obtaining access into the intestinal secretions.
Instead, studies of the intestinal immune system have frequently relied on indirect
methods for investigation of the intestinal immune responses to antigens such as
determination of levels of antigen-specific antibodies in serum (Levine et al, 1989;
Levine et al, 1988; Megasena et al, 1989), saliva (Jertborn et al, 1984) and
colostrum (Jertborn et al, 1986) or peripheral blood lymphocytes (Czerkinsky et al,
1987; Kantele, 1990; Kantele et al, 1986; Forrest, 1992a). However, it is now
widely accepted that the intestinal immune system is largely independent from the
systemic immune system and the findings in serum do not necessarily reflect the
immunity at the intestinal levels. Therefore, development of direct methods for
investigation of the mucosal immune system has become necessary.
Obtaining intestinal fluids in which to study the intestinal immune system has been
regarded as the "gold standard" by which other methods may be compared.
Therefore, as a direct approach to the intestinal fluids, saline lavage was used
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(Svennerholm et al, 1984; Svennerholm et al, 1982). However, saline lavage may
be contraindicated in certain groups of patients such as cardiac, renal and liver
disease patients. Another method of direct approach to the intestinal fluids is
intestinal intubation with direct sampling of jejunal fluids (Forrest et al, 1991;
Forrest et al, 1992; LaBrooy et al, 1980; LaBrooy et al, 1982). However,
intestinal intubation is an invasive and inconvenient technique for the patient as
well as for the investigator. Furthermore, intestinal intubation is a labour-intensive
and time-consuming procedure.
The use of faecal extracts to study gut immunity
In an attempt to overcome the difficulty of obtaining direct access into the intestinal
secretions, and because of the lack of other reliable methods in the past, some
workers used faecal extracts to study the intestinal immune responses to natural
infections or to orally administered antigens (El-Hawy et al, 1983; Reed and
Williams, 1971; Northrup et al, 1970; Plaut and Keonil, 1969; Chodirker and
Tomasi, 1963). However, the damaging effects of the proteolytic enzymes in the
intestinal secretions on the immunoglobulins and specific antibodies in faecal
extracts resulted in misleading results. Furthermore, interpretation of the results of
measurement of immunoglobulins and antibodies in the faecal extracts depends on
the faecal weight, and because of the variation in water contents of faecal
specimens, there have been problems in the interpretation of results based on faecal
31
samples. O'Mahony and colleagues (1990) reported that analysis of semi-liquid
early faecal specimens obtained during the process of whole gut lavage (WGL)
contained negligible quantities of IgA compared with the amount of IgA found in
clear specimens of WGL fluid. Later on, studies in the same centre (Ferguson et
al, 1994) of paired samples of faeces and whole gut lavage fluids from ten patients
with a variety of gastrointestinal diseases showed that specimens of WGL fluids
contained much higher quantities of IgA than did the specimens of faecal extracts.
The use of whole gut lavage to study gut immunity
Elson and colleagues (1984) described the use of whole gut lavage (WGL) as a
non-invasive method for the quantitative measurement of immunoglobulins and
antigen-specific antibodies in mice. They carried out WGL using a solution
containing (162g/l) polyethylene glycol with an average molecular weight of 3350
plus traces of electrolytes such as sodium and potassium. Later on, Gaspari and
colleagues (1988) described a modified WGL technique using commercially
available polyethylene glycol (Golytely) in normal human volunteers. Golytely has
essentially been used clinically for cleansing the colon as a preparation for Barium
enema, colonoscopy and for surgical procedures in the colon. Golytely has been
found not to produce net absorption or secretion of fluids or electrolytes across the
mucosal barrier of the gut (Davis et al, 1980) and hence, can be used safely in
patients with liver, renal or cardiac diseases (unlike saline lavage).
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Human intestinal secretions contain large amount of protease enzymes which, if not
inhibited, significantly reduce the amount of immunoglobulins in WGL fluids
including SIgA despite the known resistance of SIgA to proteolytic enzymes
(Brown et al, 1970; Hohmann et al, 1983; Samson et al, 1973; O'Mahony et al,
1990). The loss of immunoglobulin contents of WGL fluids due to proteolysis can
be prevented by treating the lavage specimens with protease inhibitors such as
soybean trypsin inhibitor and phenylmethylsulfonyl fluoride (PMSF) as well as
chelating agents such as ethylene diamine tetracetic acid (EDTA) (Elson et al,
1984; Gaspari et al, 1988; O'Mahony et al, 1990). Calf serum is added as an
alternative substrate for any remaining proteases in WGL fluids (Elson et al, 1984;
Gaspari et al, 1988). Adding protease inhibitors was found not only to decrease the
loss of immunoglobulins in WGL fluids but also it to improve antigen stability and
to increase the sensitivity of the enzyme-linked immunosorbent assay (ELISA)
used to measure the amount of immunoglobulins and antigen-specific antibodies in
intestinal fluids (Hohmann et al, 1983). Storage of intestinal fluids at -70 °C has
been shown to maintain the immunoglobulin and specific antibodies content of
these fluids for up to one year (Forrest, 1992b). Azacol (a commercially available
reagent) has been used for the assessment of the activity of protease enzymes in the
intestinal secretion obtained by the WGL method (Elson et al, 1984).
Radial immunodiffusion has been used to estimate IgA concentration in exocrine
secretions, including intestinal secretions, but has been found to be relatively
insensitive and gives inaccurate estimates of immunoglobulin contents of these
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secretions due to the presence of different ratios of monomeric and polymeric
forms of immunoglobulins in the secretions (Brown et al, 1970; Tomasi and Grey,
1972).
ELISA has been used for quantitative study of immunoglobulins and antigen-
specific antibodies in the treated specimens of WGL fluids and has been shown to
be sensitive and reliable in the study of total immunoglobulins and specific
antibodies in exocrine secretions such as saliva, breast milk and intestinal fluids
(Elson et al, 1984; Hohmann et al, 1983; O'Mahony et al, 1990; Sack et al, 1980;
Svennerholm et al, 1977).
Applications ofWGL in clinical research
In the GI Unit of the Western General Hospital, WGL, in addition to its use for
cleansing the colon as a preparatory method for Barium enema and colonoscopy
and also as a treatment for intractable constipation, has been used to investigate gut
immunity in a variety of gastrointestinal diseases (O'Mahony et al, 1990;
O'Mahony et al, 1991b; Brydon et al, 1993; Brydon and Ferguson, 1992;
Choudari et al, 1993) as well as to investigate the relevance of host factors such as
age and nutrition and their effect on gut immunity (Hodges et al, 1993). Fluids
obtained by WGL technique normally contain traces of IgG, albumin, and alpha-1-
antitrypsin (Brydon et al, 1993). WGL fluids obtained from patients with
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inflammatory bowel diseases (IBD) were found to have higher concentrations of
IgG and albumin than did normal controls (O'Mahony et al, 1991b; Choudari et al,
1993). Therefore, WGL technique can be used as an objective means of grading
the loss of proteins and therefore disease activity in IBD patients.
Another use of WGL in clinical research is investigation of occult blood loss from
the gastrointestinal tract (Brydon and Ferguson, 1992). In the above study, it was
found that normal individuals may lose 0.1-1.1 ml of blood per day through their
gastrointestinal tract but higher concentrations of haemoglobin were found in WGL
fluids obtained from patients with colorectal cancer, rectal varices, severe
diverticular disease and in some patients with active IBD.
WGL has also been used in children (6-9 years old) from Sierra Leone to study the
relevance of age, infection, and malnutrition to intestinal immunity (Hodges et al,
1993). When compared with values for Scottish adults, WGL fluids from the Sierra
Leonean children had significantly higher concentrations of total IgA and IgM as
well as higher concentrations of IgA and IgM antibodies against dietary antigens
and Salmonella typhi lipopolysaccharide (LPS).
The use of WGL technique in obtaining material to study the intestinal immune
response to natural infection or to an orally administered vaccine is an important
application of WGL in clinical research. In an initial study in this centre, WGL
fluid was used to study the intestinal immune response to the live attenuated oral
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typhoid vaccine Ty21a (Sallam and Ferguson, 1992). An extension of that
preliminary work on the effect of the vaccine Ty21a on gut immunity forms an
important component of this thesis and will be discussed later.
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Section 3
BASIC STRUCTURE OF BACTERIA
Introduction
In 1866, Haeckel suggested that micro-organisms such as algae, protozoa, fungi
and bacteria should be placed in a separate kingdom called the protista. However,
in the middle of this century electron microscopy showed that bacteria have more
primitive cellular structure than the other three groups. Bacteria are classified as
prokaryotes, while algae, protozoa and fungi are classified as eukaryotes. The
eukaryotes also include plants and animals (Carlile and Skehl, 1974). The main
differences between prokaryotes and eukaryotes are summarised in Table 2.1.
features prokaryotes eukaryotes
Chromosome no. single multiple
Nuclear membrane absent present
Mitochondria absent present
Multiplication by binary fission by mitosis
Table 2.1. The main differences between prokaryotes and eukaryotes.
37
Prokaryotes are further classified into three main groups: Eubacteria,
Archaebacteria, and Cyanobacteria. Cyanobacteria, though a true prokaryote
(Laskin and Lechevalier, 1977; Laskin and Lechevalier, 1979), are chlorophyll-
containing and hence, previously were called the blue-green algae. Archaebacteria
have the most primitive cellular structure and include 3 groups of prokaryotes.
These are the Methanogens, extreme Halophiles and Thermoacidophiles. The
Eubacteria (all prokaryotes other than Archaebacteria and Cyanobacteria) can be
classified into Bacteria, Rickettsia, Chlamydia and Mycoplasma. Rickettsia and
Chlamydia differ from bacteria in being smaller and strictly intracellular parasites
(Woese and Wolfe, 1985).
General structural features of bacteria
The cell envelope
The cell envelope in the prokaryotes has 2 main components: an inner layer called
the cytoplasmic membrane and an outer layer called the cell wall. The structure
of the cell envelope is different in Gram-positive from that of Gram-negative
bacteria (Cheesbrough, 1984). The cell envelope in Gram-positive bacteria consists
of 2 layers; the cytoplasmic membrane and a thick peptidoglycan layer
(mucopeptide). An outer layer called the capsule is often present. The cell
envelope in Gram-negative bacteria is more complex than in Gram-positive
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bacteria. It consists of the cytoplasmic membrane (also called the inner membrane)
surrounded by a thin sheet of peptidoglycan attached to a complex layer called the
outer membrane, which contains the lipopolysaccharide (endotoxin) (Sleigh and
Timbury, 1981). The outer membrane is often surrounded by an outmost layer
called the capsule. The gel-filled region between the inner and outer membrane is
called the periplasm (Fig. 2.1).
The cytoplasmic membrane
The cytoplasmic membrane is the site of many major cellular functions (Jawetz et
al, 1987): (a) selective permeability and transport of solutions; (b) electron
transport and oxidative phosphorylation; (c) secretion of extracellular hydrolytic
enzymes (exoenzymes); (d) biosynthesis of phospholipids and proteins (e);
chemotactic function.
Bacterial cell wall
Bacterial cells contain high concentrations of inorganic ions and thus have high
osmotic pressure (5-20 atmospheres) (Hancock and Poxton, 1988). Therefore,
bacterial cells need strong cell wall to resist swelling due to fluid influx into the
cells causing their lysis. Furthermore, the cell wall maintains the shape of the cell
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and protects the mechanically fragile cytoplasmic membrane. Bacterial cell walls







Fig. 2.1 The cell envelope of a Gram-negative bacterium. LP= lipoprotein; LPS =






Many bacteria are surrounded with a large amount of extracellular polysaccharide.
This polysaccharide layer is also known as the 'Slime layer'. When the
polysaccharide layer is condensed and well-defined, it is called the capsule.
However, when this layer is a loose meshwork, it is called the glycocalyx. The
presence of the capsule is often correlated with the virulence of the pathogenic
bacteria. Encapsulated bacteria are protected from being phagocytosed. Anti-
capsular antibodies, however, can counteract the presence of the capsule (Jawetz et
al, 1987).
The nucleus
Bacteria lack true nuclei since there is no nuclear membrane or mitotic apparatus as
found in eukaryotic cells. Under electron microscopy, the cytoplasm can be seen to
be filled with DNA fibrils. The DNA of the bacterial nucleus is a single piece of
double stranded DNA and is thus regarded as a single chromosome of about 1 mm
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long and 2-3 X 10 molecular weight. The nuclear DNA is associated with small
amount of RNA and RNA polymerase. The DNA is folded around an RNA core




These are distributed throughout the cytoplasm and are the site of protein synthesis.
The cytoplasmic RNA of bacterial cells is of three types regarding function:
ribosomal (rRNA), amino acid transfer or transfer RNA (tRNA) and messenger
RNA (mRNA). Bacterial ribosomes have a sedimentation constant of 70S
(compared to the human and eukaryotic ribosomes which are composed of 80S)
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(Svedberg unit, i.e. S = 10~ cm/sec/unit field). The aggregates of the 70S particles
are attached to a common strand of mRNA to form polysomes where the mRNA
functions as the template for protein synthesis i.e. determines the order of amino
acids in the peptide chain. In spite of the presence of many similarities between
bacterial ribosomes and human cellular tissues, there are still some differences
which allow the use of antibacterial agents such as streptomycin which interfere
with bacterial metabolism at the ribosomal level without unduly affecting the
human ribosomal function.
Inclusion granules
In many species of bacteria, round granules may be seen in the cytoplasm. These
are known as inclusion granules. They are not essential structures and may be
absent under certain condition of growth. Inclusion granules include the following
(Shively, 1974). (a) Volutin granules (metachromatic granules): these are mainly
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composed of polymerised inorganic phosphate, stored in the cytoplasm as
polymetaphosphate which acts as an energy source for the cell metabolism, (b)
Lipid granules: these are mainly consist of polymerised (3-hydroxybutyric acid and
they may act as 'storehouse' for energy and carbon, (c) Polysaccharide granules:
these are either glycogen (red-brown) or starch (blue) which can be seen in the
cytoplasm of some bacteria when stained with iodine.
Flagella and pili (fimbria)
Flagella. Motile bacteria have thread-like appendages called flagella. A flagellum
is a hollow cylindrical structure composed of a protein subunit called flagellin
(Macnab and Aizawa, 1984; Doetsch and Sjoblad, 1980). Flagella are the organs
of locomotion and if they are mechanically removed, new flagella are formed and
the motility is restored within 3-6 minutes. Movement is brought about by the
rotation of the flagella. There are 3 patterns of flagella: (a) a single polar flagellum
(monotrichous); (b) a group of polar flagella (lophotrichous); (c) flagella
distributed over the whole cell (peritrichous). Bacteria respond to changes in the
environment by a mechanism called sensory transduction (Tayler, 1983). Sensory
transduction may occur due to chemotaxis, phototaxis (movement towards light) or
aerotaxis (movement towards optimum oxygen concentration) (Boyd and Siman,
1980).
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Pili (Fimbria). These are short filaments composed of a protein subunit called pilin
and are found in many gram negative bacteria e.g. enterotoxigenic E. coli. There
are 2 types of pili: (a) sex pili which are responsible for transfer of genes from a
donor to a recipient cell during bacterial conjugation; (b) ordinary pili which are
responsible for adherence of bacterial cells to host cells. These are, in certain
pathogenic bacteria such as enterotoxigenic E. coli, known as colonisation antigens
(Beachey, 1980).
Sporulation (spore formation)
When the vegetative forms of some bacteria such as Bacillus and Clostridium meet
adverse environmental conditions, especially nutritional depletion such as
unavailability of carbon and nitrogen, they form endospores. Spore formation
involves changes in the enzyme activity and morphology of the cells (Hurst and
Gould, 1984). Spores are resting cells which are highly resistant to dehydration,
disinfectant, and temperature extremes (Gould and Dring, 1974). Spores, however,
are unable to multiply. When favourable conditions return, the spores germinate to
form a single vegetative bacterial cell which is capable of reproduction (Keynan,
1973).
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Protoplast, Spheroplast and L-Form
Removal of the bacterial cell wall by lysozyme or by antibiotics, such as penicillin,
in osmotically suitable media, results in formation of protoplast in Gram-positive
bacteria and spheroplast in Gram-negative bacteria. When these cells are cultivated
in special culture media with a high osmotic pressure, they form mutant L-form
bacteria without cell walls. Some bacteria form the L-form spontaneously.
Spontaneously formed or antibiotic-induced L-forms in the host may lead to
chronic infection since some L-forms are able to resume normal cell wall synthesis
and reproduce if the environment becomes favourable (Clasener, 1972).
Basic structure of bacterial cell walls
Bacteria are classified as Gram-positive and Gram-negative according to their
response to the gram staining technique (Cheesbrough, 1984). Bacteria that retain
the stain crystal violet are called Gram-positive while bacteria decolorized by
washing with acetone or alcohol which then take up the red counterstain are called
Gram-negative. The difference in Gram staining of bacteria is, in fact, due to
differences in the structure of the cell walls which determine whether the Gram
stain is lost or retained. The three different types of bacterial cell walls found in
Eubacteria are described below.
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(A) Gram-positive bacteria. The cell wall is composed of a thick, cross-linked,
peptidoglycan layer and of teichoic acid which consists of polymers of ribitol
phosphate and/or glycerol phosphate (Schleifer and Kandler, 1972).
(B) Gram-negative bacteria. The cell wall is composed of a thin, cross-linked,
peptidoglycan layer and lipoprotein (Fig. 2.II). The outer layer of the cell wall
contains the lipopolysaccharide molecules which are referred to as endotoxins. The
lipid A part of the lipopolysaccharide is the site of the endotoxin activity i.e. it is
the toxic part of the lipopolysaccharide (Osborn, 1969).
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Fig.2.n Comparison between Gram-positive and Gram-negative cell wall
structures. (From Jawetz et al, 1987.)
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The peotidoglvcan layer
Bacterial cell wall is composed of the layers of the cell envelope lying between the
cytoplasmic membrane and the capsule. Bacterial cell wall acquires its strength
from the peptidoglycan layer (Henning, 1975). The peptidoglycan layer (known
also as mucopeptide or murein: all are synonyms) is composed of 3 parts; the
glycan backbone, the linear tetrapeptide side chains, and a set of identical cross-
linking peptide chains (X). The glycan backbone consists of alternating
disaccharide units (N-acetylglucosamine and N-acetylmuramic acid) polymerised
by (3-1,4 glycoside linkages. The basic structure of the glycan backbone is the same
in all bacterial species, but there is marked variations in the polymer length
according to numbers of repeating disaccharide units (e.g. E. coli has a length of
20-200 units of with an average of 35 units) (Hancock and Poxton, 1988).
The tetrapeptide side chains of the peptidoglycan of different bacterial species have
some features in common. These are the L-alanine at position 1, D-glutamic acid at
position 2 and D-alanine at position 4. Position 3 is a variable diamino acid and is
species specific. In most Gram-negative bacteria, diaminopimelic acid (DAP)
occupies position 3, while in Gram-positive bacteria L-lysine, diaminopimelic acid
or any L-amino acid may occupy position 3 (Jawetz et al, 1987).
The cross-linkages vary from species to species. In most Gram-negative bacteria
the cross-linkages form direct bridges between the amino group of diaminopimelic
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acid of one tetrapeptide side chain and the carboxyl group of the terminal D-
alanine. In many Gram-positive bacteria e.g. Staph, aureus, pentaglycine peptide
chains (5gly) cross-linkages connect the amino group of the L-lysine of one side
chain to the carboxyl group of the terminal D-alanine of the next chain .
Special features of Gram-negative cell walls
As cited above, the cell wall of Gram-negative bacteria contains lipoprotein, outer
membrane and lipopolysaccharide, in addition to the peptidoglycan layer.
The Lipoprotein
Lipoprotein is the most abundant protein of Gram-negative cells. The protein
component contains 57 amino acids, representing repeats of a 15-amino-acid
sequence (Inouye, 1979). Lipoprotein is covalently linked to the diaminopimelic
acid residues of the peptidoglycan through its C-terminal lysine residue and links
the peptidoglycan layer to the outer membrane. Lipoprotein stabilises the outer
membrane and anchors it to the peptidoglycan layer.
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The Outer membrane
This is a bilayer structure of which a phospholipid layer forms the inner layer
while the outer layer is formed by the lipopolysaccharide molecules (Inouye,
1980). Proteins of the outer membrane are individually named after the genes that
encode them. In E. coli and Salmonella typhimurium the porin proteins OmpC, D
and F penetrate both faces of the outer membrane and form relatively non-specific
pores that allow diffusion of small hydrophilic solutes through the membrane. In
addition to its function as a barrier preventing the leakage of the periplasmic
proteins, the outer membrane protects the bacterial cell (in enteric bacteria) from
bile salts and hydrolytic enzymes. The protein pores render the outer membrane
permeable to low-molecular weight solutes while higher molecular weight
molecules, such as antibiotics, pass relatively slowly. This may account for the
high antibiotic resistance of Gram-negative bacteria in which the outer membrane is
less permeable to large antibiotic molecules.
The Lipopolysaccharide (LPS)
The lipopolysaccharide of Gram-negative bacteria is usually composed of 3 main
parts: lipid A, core oligosaccharide and a series of repeating units (O antigen
polysaccharide or O-specific chain) (Fig. 2.III).
Lipid A is composed of phosphorylated P-l,6-linked D-glucosamine disaccharide
backbone to which are attached a number of long-chain fatty acids (Takayama et
al, 1983; Stewart-Tull and Davis, 1985). Lipid A has a unique fatty acid called P-
hydroxymyristic acid while other fatty acids vary according to the bacterial species.
Lipid A is often highly toxic and it is the biologically active part of the
lipopolysaccharide. It is usually referred to as endotoxin because it is firmly
attached to the cell surface and was thought to be released only when the cell is
lysed. However, it was found that a considerable amount of endotoxin may be
released by intact and actively growing bacteria (Galanos et al, 1977).
The core oligosaccharide is composed of a branched oligosaccharide containing a
unique sugar called 2-keto-3-deoxy-D-manno-octonate (KDO) in addition to
heptose, phosphoethanolamine and several hexoses. The structure of the core
oligosaccharide is present in all Gram-negative bacteria and is group-specific
(Luderitz et al, 1966).
The O-specific chain (O antigen) is a polymer of repeating units of oligosaccharide
(usually linear trisaccharides or branched tetra- or pentasaccharides) molecules and
represents a major surface antigen of bacterial cells. The O antigen polysaccharide
is serotype-specific and this character was used in the Kauffmann-White
classification of Salmonella spp. (Luderitz et al, 1966). LPS is highly
immunogenic inducing specific antibodies against the terminal repeating sugar units
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Fig. 2.Ill The 3 main components of the LPS of Gram-negative bacteria. (From
Jawetz et al, 1987.)
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The pathophysiological effects of LPS on the mammalian body
Fever. The thermoregulatory centre of the hypothalamus maintains the body
temperature within the normal limits due to balance between heat production and
heat loss. Endotoxins produced by Gram-negative bacteria such as Salmonella,
Shigella, E. coli etc. act on monocytes and macrophages resulting in the release of
interleukin-1 (endogenous pyrogen) which acts on the thermoregulatory centres of
the hypothalamus causing fever (Dinarella and Wolff, 1982). Repeated injection of
endotoxin, however, resulted in decreasing fever response may be due to tolerance.
Changes in leukocyte counts. Endotoxin results in an initial leucopenia due to the
sequestration of neutrophils in the capillary beds. This is followed by a
leucocytosis due to the release of granulocytes from bone marrow (Athens et al,
1961). Endotoxins increase the phagocytic and metabolic activities (glycolysis) of
many cells resulting in hypoglycaemia (Morrison and Ulevitch, 1978).
Vascular and circulatory changes. Infection with Gram-negative bacteria results
in an initial vasoconstriction of the arterioles and venules followed by peripheral
vascular dilatation. Endotoxins can activate the release of vasoactive substances
such as serotonin and kinins, resulting in the above vascular changes (Jawetz et al,
1987). Endotoxin can also activate both the intrinsic and extrinsic pathways of
coagulation (Morrison and Ulevitch, 1978). They activate Hageman Factor (Factor
XII) initiating the first step of the intrinsic pathway of coagulation. Endotoxins also
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act on the leukocytes (mostly the monocytes), for which process lipid A is
required, triggering the first step in the extrinsic pathway of coagulation (Rivers et
al, 1975). Intrinsic and extrinsic pathways lead to conversion of fibrinogen into
fibrin causing disseminated intravascular coagulation which is a frequent
complication of Gram-negative bacterial infection.
Shwartzman reaction. Animal experiments showed that when a rabbit was injected
intradermally with endotoxin followed 24 hours later by an intravenous injection of
another dose of endotoxin, this resulted in a necrosis at the site of intradermal
injection. This phenomenon is called the local Shwartzman reaction
(Shwartzman, 1937). When endotoxin was given intravenously on 2 successive
days, this resulted in the development of disseminated intravascular coagulation.
This is called the generalised Shwartzman reaction. It has been suggested that the
first dose of endotoxin blocks the reticuloendothelial system so that it is not able to
clear the second dose of endotoxin (Stewart-Tull and Davis, 1985).
Mechanism of action of LPS as an endotoxin
There is now much evidence that the endotoxic effect of LPS on target organs is
mediated by a variety of cytokines and other soluble factors. Macrophages have
been found to play an important role in the mechanism by which LPS produces its
endotoxic effect when stimulated by LPS (Manthey and Vogel, 1992). In
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experimental animals, purified LPS induced the production of tumour necrosis
factor (TNF), interleukin 6 (IL-6), interferon (IFN) and colony stimulating factor
(CSF) with the TNF peaked very early (about one hour after injection of LPS)
while CSF peaked few hours later (about 6 hours after injection of LPS)
(Henricson et al, 1990). In addition to TNF, IL-1 is an LPS-induced cytokine that
has been found to be produced by macrophages and appears early in the cascade of
events that results in manifestations of endotoxicity (Fong et al, 1989). The latter
study suggested that TNF may be an important factor that regulate the production
of LPS-induced IL-1.
Once macrophages are stimulated and produced TNF and IL-1, a co-ordination
between these two mediators appears to mediate the steps that follow in the cascade
of cytokines production. For instance, in vivo injection of animals with IL-1
stimulated the production of IL-6 (Neta et al, 1988) while pre-treatment of animals
with anti-TNF antibodies markedly inhibited the production of IL-6 (Fong et al,
1989).
The production of CSF as a response to stimulation by LPS seems to be markedly
induced by TNF and IL-1. Vogel and colleagues (Vogel et al, 1987) reported that
recombinant TNF or IL-la stimulated the production of CSF more rapidly than did
a dose of LPS of 25 pg. CSF may be produced by stromal cells rather than
macrophages. This is because nude mice, which lack T cells, have been found to
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respond normally and produces CSF as a response to LPS injection (Manthey and
Vogel, 1992).
The recent development in the techniques used for detection of cytokines and other
mediators has led to detection of more cytokines and other mediators that may be
involved in the cascade of events produced by LPS endotoxicity. For example, in
addition to the previously mentioned cytokines, IL-8 and IFN-y have recently been
found to be produced, in animals, as a response to LPS injection (Van Zee et al,
1991; Heinzel, 1990). Furthermore, LPS has been found to stimulate inflammatory
cells to express a variety of lipid autocoids such as leukotrienes, prostaglandins and
platelet activating factor (PAF) (Manthey and Vogel, 1992). PAF is thought to
enhance the production and expression of cytokines while prostaglandin E2 (PGE2)
is thought to have depressant effect.
Mechanism of action of LPS in septic shock and tissue injury. The lethal effect of
LPS on tissues has been found to be mainly due to neutrophils infiltration and
ischaemia. Manthey and Vogel (1992) have suggested that LPS produces
cardiovascular shock by stimulating the expression of the intercellular adhesion
molecule 1 (ICAM1) on the surface of the vascular endothelial cells which binds
CR3 and LFA-1 antigens expressed on the surface of neutrophils. Cytokines
stimulated by LPS induce endothelial and stromal cells to release chemotactic
factors that attract neutrophils to pass through the vascular endothelium and
infiltrate tissues. Locally produced prostaglandins and PAF induce vasodilatation
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resulting in hyperaemia and capillary leakage. Endothelial and macrophages are
stimulated to express procoagulant activity resulting in the formation of
intravascular fibrin clots, blocking the circulation and leading to local ischaemia.
Genetic resistance to LPS
Sultzer (1968) found that the mouse strain C3H/HeJ is resistant to some of the
endotoxic effects of LPS. Later, Watson et al (1974) found that a single locus on
chromosome 4 regulates a number of endotoxic reactions induced by lipid A. This
locus was called LPS responsiveness locus. The functions of the LPS
responsiveness locus were suggested by Watson et al (1980) as follows: the LPS
locus may control genes coding for the cellular receptor for lipid A or may control
genes coding for expression of cellular components required to convert the binding
process into biochemical signals. The macrophages and lymphocytes of the mouse
strain C3H/HeJ did not respond to LPS and this was found to be due to the absence
of specific receptors on these cells (Morrison and Ryan, 1979; Forui and Coutinho,
1978).
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Antigenic structure and antigenic properties of enteric Gram-negative bacilli
(Enterobacteriaceae)
Enterobacteriaceae have a complex antigenic structure. In addition to the somatic
(O), flagellar (H) and the capsular (K) (found on Salmonella typhi) antigens
mentioned before, fimbrial antigen (Type-1 fimbria) is formed by most strains of
salmonellae and leads to confusing cross-reaction in the agglutination test.
Likewise, M antigen (the slime or mucous antigen) prevents agglutination by anti-
O antigen antibodies (Sleigh and Duguid, 1989).
O antigen (somatic antigen). This antigen represents the side-chain of the
repeating units of the lipopolysaccharide. It is heat-stable and resistant to alcohol
(withstanding treatment with 96% ethanol for 4 hours at 37 °C). There are more
than 150 different O somatic antigens possessed by the different genera of the
Enterobacteriaceae and a single organism may possess more than one O antigen,
thus one (or more) O antigen could be common to various strains of Salmonella,
Shigella and E. coli leading to cross-reaction among these strains in the
agglutination reaction test. However, O antigen is used in subgrouping of the
different genera of Enterobacteriaceae. Although IgM antibodies are the
predominant antibodies against O antigen ( 10 ), yet IgG and not IgM antibodies
were associated with the decrease in morbidity and mortality due to Gram-negative
bacteraemia (McCabe et al, 1972) and although antibodies against antigen protected
animals in experimental infections with gram negative bacteria (Kaijser and Oiling,
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1973), yet until recently there was no practical evidence to confirm these findings
in humans.
R antigen. All cultures of Enterobacteriaceae contain variant and stable mutants
with respect to colonial morphology, antigenic characteristics and virus resistance.
Regarding their colonial morphology, these mutants could be in the smooth (S) or
in the rough (R) form. In S—»R mutation, the O-specific side-chain (O antigen) is
lost and the remaining core linked to the lipid A forms a new rough (R) antigen.
There are many types of R mutants (Fig. 2.IV): (1) Ra mutants: they lack the O
antigen but have the complete core attached to lipid A; (2) Rb to Re mutants: these
mutants have an incomplete core and they bear core fragments of varying length
according to the step at which the biosynthesis was blocked (Galanos et al, 1969).
It has been found that antibodies against O antigen are specific for individual LPS
(Galanos et al, 1977). Thus antibodies against the smooth (S) bacteria (parent
bacteria with complete LPS) are not effective in protecting from infection by
unrelated Gram-negative bacteria. On the other hand, anti-R and anti-lipid A
antibodies were found to be directed against a structure common to different LPS.
This common immunogenic character of R mutants was employed in developing a
cross-protective immunisation against a number of Gram-negative bacteria in
animals (Brande et al, 1977) and also in reducing the morbidity and mortality due
to Gram-negative bacteraemia in human volunteers compared to controls (Ziegler
et al, 1982).
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Gram-negative bacteria are present in large numbers as a commensal flora in man
e.g. in the oropharynx and in the urogenital tract, and colonise the gastrointestinal
tract from birth onwards. However, it is not yet known whether this continuous
presence of Gram-negative bacteria affects the response to LPS or not. In animals,
in vitro experiments showed that germ-free animals had stronger immunological
responses to LPS (Kiyono et al, 1980), and another study (Schaedler and Dubs,
1961) showed that they had higher resistance against the lethal effects of LPS, than
conventional animals. These observations suggest that the commensal flora
produces immunologic tolerance to endotoxin and hence, decreases the resistance
to pathogenic bacteria. Although LPS has been shown to be an important factor in
the virulence of the Gram-negative bacteria, yet possession of LPS in itself does
not confer pathogenicity on the bacteria. In fact, LPS is a component of the cell
envelopes of pathogenic, non-pathogenic and saprophytic (micro-organisms living
upon dead or decaying organic matter) Gram-negative bacteria. Furthermore, LPS
is not the only toxic factor in the pathogenicity of many Gram-negative bacteria,
especially those which produce exotoxin or those which have invasive capability.
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Fig. 2.IV: (a) Diagrammatic representation of LPS of Salmonella. When the 0-
polysaccharide is lost through mutation the LPS is termed "rough", compared to
the "smooth" wild-type parent, (b) Rough mutants of Salmonella. The Ra mutant
produces LPS with a complete core but no O-polysaccharide. Other R-mutants (Rb-
Re) produce only partial cores. The Re-mutant is the minimum LPS structure
which permits viability of the organism. KDO=keto-deoxy-octanic acid,
Hep=heptose, Glc=glucose, Gal=galactose and GlcNAc=N-acetyl glucosamine.
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H antigen (flagellar antigen). This antigen is heat and alcohol-labile and heating
for 30 minutes at 100 °C will remove all the flagella from the bacteria. The
unflagellated bacteria cannot be agglutinated by anti-H antibodies. Anti-H
antibodies are mainly IgG (Jawetz et al, 1987). H antigen on the bacterial surface
may interfere with agglutination by anti-0 antibodies. The amino acid sequences in
the flagellar protein (flagellin) are responsible for the production of H antigen
(Jawetz et al, 1987). Within a single serotype of a genus of Enterobacteriaceae,
flagellar antigens may be present in either or both of 2 forms, called phase 1 and
phase 2. In phase 1, known also as the 'specific phase', the bacterium has one or
more antigen from a set of 70 H antigens designated by small letter of the alphabet,
a to z then zl, z2, z3 etc. In phase 2, known as the 'group' or 'non-specific
phase', the bacterium has one or more antigens from another set of H antigens
designated by Arabic numerals. The strains vary spontaneously and reversibly
between these 2 phases. Thus the antigenic classification of Enterobacteriaceae
often indicates the presence of specific antigens e.g. in Salmonella paratyphi B it
is 01,4, 5,12:Hbl,2.
K antigen (capsular antigen). Some strains of Enterobacteriaceae produce a thick
capsule surrounding the bacterial cell formed of polysaccharide or proteins and
known as K antigen. In Salmonella typhi this antigen is called Vi antigen. K
antigen is a heat-labile antigen and can be removed from the bacteria by heating a
suspension for 1 hour at 100 °C. This antigen may be associated with the virulence
of the organism e.g. in E. coli attachment of the bacteria to the epithelial cells
64
before the invasion of the gastrointestinal or the urinary tract is facilitated by K
antigen, and in Salmonella typhi it was found that Vi antigen is associated with
invasiveness of the organism. K antigen may interfere with agglutination by anti-O
antibodies (Morrison and Ryan, 1979).
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Section 4
VACCINATION AGAINST TYPHOID FEVER
Introduction
Control of enteric infections can be achieved by improvement of primary health
care such as improvement of water supply, sanitation and health education.
However, because of the limitation of resources and other competing priorities
in many parts of the world, development of vaccines against enteric pathogens
may help in the control of the wide range of infectious diarrhoea and other
enteric infections.
Typhoid fever is not a diarrhoeal disease per se but vaccines against this enteric
infection are important for several reasons: (a) it is one of the most serious
health problems in many developing countries with an incidence rate of about
33 million cases per year world-wide (Simanjuntak et al, 1991); (b) in all
endemic areas, the highest incidence is concentrated among school-age children
(5-19 years old) (Levine et al, 1989); (c) appearance of multiple drug-resistant
strains of Salmonella typhi to the main clinically important antibiotics world¬
wide (Rowe et al, 1990); (d) the new vaccines against typhoid fever may serve
as a live carriers for vaccines against other infectious agents that cause
diarrhoea e.g. Shigella, V. Cholerae 01 and rotavirus (Levine and Noriega,
1993; Forrest etal, 1989).
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Parenteral typhoid vaccines
In 1896, Pfeiffer and Wright introduced the first parenteral vaccine for human
use against typhoid fever. They independently reported that a vaccine against
typhoid fever could be prepared by inactivating a culture of typhoid bacilli with
heat and preserving with phenol (Pfeiffer and Kolle, 1896; Wright, 1896;
Groschel and Hornick, 1981). However, a series of large-scale field trials in
several countries sponsored by the World Health Organisation (WHO) to assess
the efficacy of various types of parenteral killed whole-cell vaccines was only
carried out in the 1950s and 1960s (Yugoslav Typhoid Commission, 1957;
Yugoslav Typhoid Commission, 1964; Polish Typhoid Commission, 1966;
Hejfect et al, 1966; Aschcroft et al, 1967). Three types of parenteral killed
whole-cell vaccines were assessed: (a) alcohol-inactivated; (b) heat-inactivated
and phenol preserved; (c) acetone-inactivated vaccines. These vaccines
conferred 60%, 70-75% and 70-85% protection for 1-2 years, 3 years and 3-4
years respectively (World Health Organisation, 1979). Administration of the
parenteral killed whole-cell vaccines against typhoid and para typhoid fever A
and B (known as TAB vaccine) has been associated with systemic (mainly
fever) and local (pain) effects in 25-50% of the vaccinees (Levine et al, 1989).
Because TAB vaccines only provide partial protection and also because of the
high rate of adverse reactions associated with their administration, they rarely
have been used in any country, with the exception of Thailand, for systematic
typhoid fever control programs (Levine et al, 1989). Therefore, the search for
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a more acceptable and satisfactory vaccine continued and recently new vaccines
against typhoid fever, namely the oral typhoid vaccine Ty21a and the
parenteral vaccine, Typhim Vi, have been developed.
Oral typhoid vaccines
It is now almost axiomatic that vaccination against enteric infections such as
typhoid fever has to be at the portal of entry of the infectious agents. The aim
of oral administration of vaccines is to stimulate local intestinal immune
response, especially of the secretory immunoglobulin A (SIgA) class. Induction
of strong local immune responses is necessary for the efficacy of vaccines
against enteric infections (World Health Organisation, 1979; World Health
Organisation, 1982). SIgA may provide antibacterial protection by two
mechanisms: (a) direct action on bacteria, which may result in immobilisation,
agglutination, or prevention of adherence to the mucosa; and (b) combination
with bacterial products such as toxins or enzymes which cause inactivation and
help in their destruction by proteolytic enzymes (World Health Organisation,
1979). In addition to the fact that the route of antigen administration is
important in the development of an appropriate strong immune response, oral
vaccines are generally easier to produce and control for quality than parenteral
vaccines. Furthermore, oral vaccines are less reactogenic i.e. less side effects,
easier to administer and do not require medically trained personnel or sterile
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equipment. Based on the concept of the common mucosal immune system,
whereby a local presentation of an antigen at one mucosal surface can stimulate
an immune response at distant mucosal surfaces (Mestecky et al, 1978; Weisz-
Carrington et al, 1979; Mestecky, 1987; Weisz-Carrington et al, 1987) oral
vaccination has become an area of much interest because of the possibility of
development of oral vaccines not only against enteric infections but also against
other infections in other areas of the human body such as the respiratory system
(Ogra and Karzon, 1969; Forrest et al, 1990).
The oral typhoid vaccine Tv21a
The live attenuated oral typhoid vaccine Ty21a was developed by chemical
mutagenesis of the pathogenic strain of Salmonella typhi in the early 1970s
and proved to be safe (with mild, if any, adverse reactions) and genetically
stable (Germanier and Furer, 1975; Gilman et al, 1977). Large-scale field
trials carried out in Egypt, Chile and Indonesia measuring the protective
efficacy of the vaccine Ty21a have shown significant although variable levels
of protection against typhoid fever (Wahdan et al, 1980; Wahdan et al, 1982;
Levine et al, 1987; Simanjuntak et al, 1991). The protection rates were 96%,
67%, and 42% in Egypt, Chile and Indonesia respectively. The variation in the
rates of protection were attributed to the differences in the formulations,
vaccination schedules and the incidence rates of infection in these countries.
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The incidence rates of infection among children aged 5-19 years were 50/105,
150/105 and more than 1000/10 in Egypt, Chile and Indonesia respectively
(Simanjuntak et al, 1991).
Genetic characteristics of the vaccine Tv21a
In the early 1970s, Germanier and Furer reported the isolation and
characterisation of a Salmonella typhi strain as a possible candidate for a live
oral vaccine against typhoid fever (Germanier and Furer, 1975). In animals, an
avirulent mutant of Salmonella typhimurim called gal E mutant was found to be
suitable to be used as a live vaccine and provided mice with protection against
sublethal infection with a virulent strain of S. typhimurium (Germanier and
Furer, 1975). Gal E mutant is a rough-type strain that is unable to synthesise a
complete lipopolysaccharide in the absence of galactose in the medium
(Germanier and Furer, 1971). This defect is caused by the absence of an
enzyme called Uridine Diphosphate (UDP)-galactose-4-epimerase due to the
chemical mutagenesis (Nikaido, 1961; Germanier and Furer, 1975). The
protectivity of the vaccine is due to the fact that when galactose is supplied
exogenously (as occurs in vivo), the mutant regains its ability to synthesise
lipopolysaccharide, the immunologically important cell wall of smooth-type
strains, and to form the protective immunity (Germanier and Furer, 1975). The
avirulence of gal E mutant strains is mainly due to strong bacterial lysis
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following the uptake of galactose which when metabolised will result in
accumulation of galactose-1-phosphate and UDP-galactose (Fukasawa and
Nikaido, 1961). The avirulence of gal E mutant strains was also attributed to
the incomplete cell wall lipopolysaccharide (Germanier and Furer, 1975).
Based on the results obtained with S. typhimurium in mice, gal E mutant S.
typhi strains were isolated after chemical mutagenesis of the parent strain Ty2
of S. typhi (Germanier and Furer, 1975). Of several gal E mutants of S. typhi,
Ty21a was found to be genetically stable; reversion to the wild type (smooth
type) was not observed in vitro or in vivo. Furthermore, the vaccine strain of S.
typhi lacks the capsular antigen Vi which is known as the virulence factor in
the pathogenic strains of S. typhi (Silva et al, 1978). When given as an oral
typhoid vaccine (five to eight doses containing 3-10 x 10'° viable organisms) to
healthy volunteers from a non-endemic area, Ty21a provided 87% clinical
protection against experimental challenge with 105 virulent S. typhi (Gilman
and Hornick, 1977).
Determinants of mucosal immune response to vaccination
There are many factors that may influence the development of the mucosal
immune response to vaccines. As mentioned above, the route of administration
of a vaccine is an important factor that influences the outcome of vaccination.
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Studies have shown that oral rather than parenteral administration of the
vaccines, produces a strong mucosal immune responses (Ogra et al, 1968;
Heremans, 1974; Ogra et al, 1976; Lange and Holmgren, 1978; Svennerholm
et al, 1980; Mestecky et al, 1986). Furthermore, studies showed that parenteral
immunisation may actually suppress mucosal immune response and the SIgA
production (Pierce, 1980; Pierce, 1984). Oral vaccination followed by oral
boosting resulted in a good mucosal immune response and oral vaccination
followed by parenteral boosting gave rise to an intermediate results while
parenteral vaccination followed by parenteral boosting resulted in mucosal
tolerance rather than immunity (Svennerholm et al, 1984a; Holmgren and
Lycke, 1986).
Another important factor that may influence the outcome of immunisation is
the previous exposure to the same antigen or a cross-reacting antigen at the
mucosal site. It seems that previous exposure to the same antigen or cross-
reacting antigen by vaccination or natural infection primes the mucosal immune
system (Svennerholm et al, 1977; Svennerholm et al, 1980; Svennerholm et al,
1984a). For instance, Swedish women failed to produce specific mucosal
antibodies following parenteral cholera immunisation while such vaccine
stimulated a specific SIgA antibody response in breast milk of Pakistani women
(Svennerholm et al, 1980). Another example of the importance of previous
exposure to the challenging or cross-reacting antigen is the lack of the immune
response to an orally administered vaccine in young children. Studies in young
children (infants and toddlers 6-24 months of age) showed that administration
of oral S. typhi vaccine Ty21a did not produce any immune response while
administration of the same vaccine to school-age children produced significant
increase in the immune response (Murphy et al, 1991).
The nature of the challenging antigen is another important determinant of the
immune response to a vaccine. Antigens which are not degraded in the intestine
can bind to the apical surface of M cells of PPs and, with adjuvant activity,
such as cholera toxins, usually stimulate a good intestinal immune response
(Elson and Ealding, 1984; Lycke and Holmgren, 1986). Most food antigens,
on the other hand, are poor mucosal immunogens because they are rapidly
degraded in the intestine into non-immunogenic substances which do not bind
to M cells of PPs and may have tolerogenic rather than adjuvant characters
(Brandtzaeg et al, 1990; Lycke and Svennerholm, 1990). Live vaccines can
produce stronger mucosal immune response following a single oral vaccination
than can killed vaccines (Ogra et al, 1968; Levine, 1989). Following a single
antigenic challenge, primed cells may migrate into the lamina propria and only
limited cell proliferation and SIgA synthesis occurs (Brandtzaeg et al, 1990;
Lycke and Svennerholm, 1990). Therefore, it seems that live vaccines provide
sustained antigenic stimulation of the immune response over many years.
The frequency, doses, formulation and timing of immunisation may also have a
significant influence on the immune response. In field trials in Chile, three
doses of the oral typhoid vaccine Ty21a in the form of enteric-coated capsules
provided 67% protection for at least three years and four doses of the same
vaccine in the same formulation provided significantly greater protection than
did three doses (Levine, 1989). In contrast, in the above study one or two
doses of the vaccine Ty21a as enteric-coated capsules conferred lower level of
protection for only two years. Therefore, repeated and continuous antigenic
challenge of the gut mucosa by multiple doses of live vaccine seems to
stimulate a stronger immune response than a single exposure of an inactivated
antigen.
The dose of the vaccine required to stimulate an immune response may be a
key factor influencing the outcome of vaccination. While the oral typhoid
vaccine Ty21a at doses containing 109 viable S. typhi have been shown to
confer a significant protection against typhoid fever (Wahdan et al, 1980;
Wahdan et al, 1982), other studies showed that increasing the dose to contain
up to 1010 or 10U viable organisms will produce stronger immune response both
in intestinal mucosa and in serum (Forrest et al, 1991).
Different formulations of the same vaccine seem to produce different protective
efficacy when used at the same doses. Field trials showed that the vaccine
Ty21a in enteric-coated capsules gave a higher protective efficacy than did in
gelatine capsules/sodium bicarbonate formulation (Levine et al, 1987).
However, other field trials showed that the vaccine Ty21a in liquid formulation
was preferable to enteric-coated capsules and produced higher protection than
did the enteric coated capsules (Levine et al, 1990, Simanjuntak et al, 1991).
Optimal timing of the repeated antigen challenge is also an important factor
that may influence the outcome of the vaccination. Studies showed that
repeated doses of the vaccine at intervals consistent with the build-up of the
mucosal immunological memory may optimise the immune response
(Lycke and Svennerholm, 1990). Based on the results obtained by Forrest et al
(1991) regarding the optimal timing for administering the oral typhoid vaccine
Ty21a and studying the intestinal immune responses to the vaccine, I designed




SMOKING AND THE INTESTINAL IMMUNE SYSTEM
Introduction
The association of tobacco smoking with the prevalence of a variety of diseases
in the respiratory tract and in distant organs of the human body is well known
(World Health Organisation, 1975; US. Department of Health and Education
Welfare, 1979; US. Department of Health and Human Services, 1983). The
effects of tobacco smoking on the gastrointestinal tract have been the subject of
several studies (Packard, 1960; Bennett, 1972; Kikendall et al, 1984).
However, most of these studies only addressed the effects of tobacco smoking
on the upper part of the gastrointestinal tract but not the intestine.
The effects of tobacco smoking on immunity in animals and humans have been
extensively studied by Holt and Keast (1977) and later comprehensively
reviewed by Holt (1987). However, these studies only investigated the effects
of smoking on the systemic immune system. Other studies investigated the
effects of smoking on the concentration of immunoglobulins in the salivary
specimens of a group of healthy control and in patients with head and neck
tumours (Barton et al, 1990). However, it is now axiomatic that the systemic
immune system is separate from the mucosal immune system and the findings
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in saliva do not necessarily represent the immune response status at the
intestinal mucosal level (O'Mahony, etal, 1991a).
The appearance of reports suggesting the presence of a relationship between
cigarette smoking and inflammatory bowel disease (Harries et al, 1982; Benoni
and Nilsson, 1984; Motley et al, 1988; Jick and Walker, 1983; Tobin et al,
1987) has increased the interest on the effects of smoking on the intestinal
mucosal immune system. Some workers resorted to in vitro study of
immunoglobulin production in the colonic mucosa of two groups of controls
(smokers and non-smokers) and patients with inflammatory bowel disease
(Cope et al, 1989).
Apart from the study carried out by Srivastava and colleagues (1991), there
have been no in vivo studies investigating the relationship between smoking and
the intestinal mucosal immune system. However, the smoker group in the
above study were not heavy smokers and used to smoke only an average of 15
cigarette per day for one year.
Tobacco smoking has been shown to influence a variety of factors that may
directly or indirectly affect the integrity of the immune system and
subsequently its capability to protect the human body against a wide spectrum
of infectious agents. Furthermore, the presence of an integrated immune system
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has also been found to be important for the reaction against and removal of new
antigenic cells that may develop to malignant cells.
Green (1954) suggested the presence of a specific immune mechanism that may
be involved in the control of cancer. This mechanism was called
"immunosurveillance mechanism". Later on, Keast (1970) reviewed studies
that provided evidence for the possibility of presence of an immunosurveil lance
mechanism and supported the suggestion by Green (1954) regarding the
presence of such mechanism in the normal immune system.
Therefore, factors that may influence the integrity of the immune system such
as immunosuppressive drugs, infections, congenital and acquired immune
deficiency diseases and cigarette smoking may contribute to the
immunosenescence of the immune system.
Studies in animals
Effect of cigarette smoke on humoral immunity
Cigarette smoke has been shown to modify the humoral immune response of
the local as well as the systemic immune system of animals. In mice, exposure
to heavy cigarette smoke (30 cigarettes/day for 26 weeks) resulted in
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suppression of both primary and secondary immune responses against
intratracheally injected sheep red blood cells (SRBC) (Thomas et al, 1973). In
this study, suppression of the immune responses was not limited to the local
immune response in the bronchopulmonary system but extended into distant
organs such as the regional lymph nodes and spleen. The degree of
immunosuppression was found to be related to the distance of the organ
involved from the site of entry of cigarette smoke (Thomas et al, 1973; Holt
and Keast, 1977).
Cigarette smoke was shown to produce biphasic changes in the primary
immune responses of the regional lymph nodes and spleen of mice with an
initial enhancement followed by depression of the immune responses against
SRBC. Thomas et al (1974) examined the effect of cigarette smoke on mice for
varying periods up to 42 weeks. After 9 days exposure to cigarette smoke
(mixture of smoke/air (1:7) at a puff volume of 35 ml) the number of direct
and indirect plaque-forming cells (pfc) detectable in the lungs of mice as a
response to intratracheally injected SRBC fell to 30% of that in the control
animals. After 182 days exposure, the number of pfc in the lungs of mice fell
to less than 5% of the normal control. The primary immune response in the
lungs was virtually abrogated and the secondary immune response was delayed.
Furthermore, the immune response in the lungs was found to be different from
the immune responses in distal organs. For instance, the immune response in
the lungs exhibited an immediate depression after commencement of exposure
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to cigarette smoke and enhancement was never observed. In contrast, the
immune responses in the regional lymph nodes and spleen after exposure to
cigarette smoke showed biphasic changes with an initial enhancement followed
by depression with long-term exposure. In another study (Thomas et al, 1975),
similar biphasic changes in the primary immune responses were observed. In
that study, however, the secondary immune responses were not significantly
changed.
The effect of high tar (HT) and low tar (LT) cigarette on the primary and
secondary immune responses of animals were studied by Holt et al (Holt et al,
1976). In mice, exposure to LT cigarette smoke for a period of 26 weeks
resulted in enhanced primary followed by normal secondary immune responses
against intraperitoneally injected SRBC whereas exposure of mice to HT
cigarette smoke for the same period exhibited marked depression of primary
and delay in secondary immune responses.
Various contents of tobacco smoke were studied in an attempt to elucidate the
effect of exposure to cigarette smoke. In mice, daily intraperitoneal injection of
0.1 ml of water soluble fraction (WSF) of cigarette smoke for 8 weeks resulted
in significant decrease in the number of serum pfc and serum concentration of
IgG against SRBC compared to the control animals (Yamakido et al, 1984). In
another study (Onari et al, 1980), daily subcutaneous injection of 0.1 ml of
WSF of cigarette smoke for 6 weeks before being antigenically challenged with
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SRBC resulted in a significant inhibition in the increase of serum IgG levels
and decrease in the number of IgM-forming cells in the spleen of the injected
mice.
Adding concentrations of either nicotine or WSF of cigarette smoke ranging
from 1 to 100 pg per ml to a rabbit lymphoid cell culture resulted in a
significant suppression of IgG and IgM pfc responses against SRBC (Roszman
and Rogers, 1973). In this study, suppression of immune responses was found
to be dependent on the concentration of nicotine or WSF and complete
suppression of IgG and IgM antibody responses was obtained when the
concentrations of nicotine or WSF ranged from 200 to 1000 pg per ml.
Suppression of humoral immune responses, however, was found, in one study,
to be reversible and recovery of the immune responses occurred after cessation
of exposure to cigarette smoke (Esber et al, 1973).
The above studies have clearly demonstrated the effect of exposure to cigarette
smoke and other tobacco extracts such as nicotine and WSF of cigarette smoke
on humoral immune responses in animals and shown that the degree of this
effect depends upon the duration of exposure and the dose of cigarette smoke
or tobacco extracts.
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Effect of cigarette smoke on cell-mediated immunity
The effect of exposure to cigarette smoke on cell-mediated immunity (CMI) has
been studied in mice and rabbit. CMI was studied in vitro by measuring the
responsiveness of lymphocytes, from various organs of mice daily exposed to
cigarette smoke for up to 35 weeks, to phytohaemagglutinin (PHA) (Thomas et
al, 1973). After five weeks, the responsiveness of lymphocytes from the
regional lymph nodes showed an initial enhancement. After 35 weeks exposure
to cigarette smoke, however, the responsiveness to PHA of lymphocytes from
these nodes was found to be markedly depressed. In contrast, the
responsiveness to PHA of lymphocytes from blood and spleen was found to be
depressed after 5 weeks. After 35 weeks exposure, the lymphocytes from blood
showed significant decrease in the responses while lymphocytes from spleen
showed no significant difference in the responses to PHA. Responsiveness was
compared between mice exposed to cigarette smoke and control animals.
Similar results were obtained when the reactivity of tumour-antigen specific T
lymphocytes were studied in smoke-exposed mice after inoculation with viable
tumour cells (Chalmer et al, 1975).
In another study (Yamakido et al, 1984), the responsiveness of lymphocytes
from spleen of mice intraperitoneally injected daily with WSF of cigarette
smoke to PHA and Concanavalin A (Con A) was found to be significantly
depressed 8 weeks after injection. In this study, the activity of natural killer
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(NK) cells was determined in another group of mice intraperitoneally injected
with 5 mg of tobacco tar twice a week and was found to be decreased.
The effects of nicotine and WSF of cigarette smoke on CMI were studied in
vitro using peripheral lymphocytes from rabbit, Con A as a T cell stimulant and
goat anti-rabbit Fab (anti-Fab) as a B cells stimulant (Roszman et al, 1975). In
this study, nicotine and WSF were found to suppress the mitogen-induced
responses of both T cells and B cells.
Although HT and LT cigarettes have been shown to have different effects on
humoral immune responses, they have been found to produce similar effects on
CMI (Holt et al, 1976). In the above study, CMI against bacteria and tumour-
specific antigens showed similar depression in animals exposed to HT or LT.
Effect of cigarette smoke on alveolar macrophages
In vitro studies on the effect of short-term exposure to cigarette smoke on
pulmonary alveolar macrophages (PAMs) showed that exposure to cigarette
smoke resulted in an immediate decrease in the viability of PAMs associated
with an increase in the rate of production of (radiolabeled) RNA in the
surviving cells (Holt and Keast, 1973). In this study, a significant number of
PAMs lavaged from murine lungs were found to be dead and the rate of
83
synthesis of tritriated RNA was found to be increased 30 minutes after
exposure to cigarette smoke.
In guinea pig, short-term exposure to cigarette smoke resulted in reduction of
the number of PAMs (Rylander, 1971). In another experiment, short-term
exposure of guinea pigs to cigarette smoke resulted in a decrease in the number
of PAMs as well as in the number of leukocytes (Rylander, 1973).
Long-term exposure of mice to cigarette smoke, on the other hand, was shown
to produce biphasic changes in the number of PAMs. In one study in vivo, the
number of PAMs recovered from endobronchial lavage of mice exposed to
cigarette smoke daily for up to 34 weeks showed an initial decrease in the first
two weeks followed by a significant increase within 2-4 weeks (Holt and
Keast, 1973).
In guinea pig, long-term exposure to cigarette smoke resulted in similar
findings (Rylander, 1971). In another study, the number of PAMs and
polymorphonuclear leukocytes, lavaged from the lungs of guinea pig exposed
to cigarette smoke daily for up to 8 weeks, were found to be increased
(Rylander, 1974).
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Effect of cigarette smoke on the animal resistance to a challenge
The defence of the lungs against inhaled bacteria is achieved by the mucociliary
apparatus of the upper respiratory tract and the alveolar macrophages of the
lower respiratory tract (Thomas, 1967). In mice, studies indicated that
clearance of bacteria from bronchopulmonary tree is an active process
involving primarily the phagocytic activity of the alveolar macrophages and
assisted by the mucociliary system and is not due to natural death of the
organisms (Laurenzi et al, 1963; Green and Kass, 1964). In the former study,
cigarette smoke was found to be one of the most pulmonary irritants of various
substances tested and caused most interference with the antibacterial
mechanisms of the bronchopulmonary tree.
Studies on the effect of exposure to cigarette smoke for various periods of time
on the ability of the bronchopulmonary system to dispose of foreign bodies
showed that both short- and long-term exposure to cigarette smoke reduce the
antibacterial capacity of the lungs of animals (Rylander, 1969; Rylander,
1971). In one study, a single exposure of mice to cigarette smoke for 1, 3, or 6
hours decreased the resistance of mice to respiratory infection by Klebsiella
pneumoniae as demonstrated by the increased mortality and decreased survival
time (Spurgash et al, 1968). In this study, increasing the time interval between
exposure and challenge from 1 to 48 hours resulted in decrease in the mortality
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and increase in the survival time indicating that the debilitating effect of
cigarette smoke is reversible.
In vitro, the phagocytic activity of rabbit alveolar macrophages against
Staphylococcus albus was studied and found to be inhibited after exposure to
cigarette smoke. This inhibition was found to vary according to the dose of
cigarette smoke (Green and Carol in, 1967). In this experiment, PAMs exposed
to cigarette smoke failed to adhere to the surface of the flask used in the
experiment suggesting that paralysis of PAMs might be one of the mechanisms
by which cigarette smoke produce its harmful effect on the respiratory system.
Indeed, one study by Dalham (1966) indicated that the decrease in the bacterial
clearance of the respiratory system after exposure of animals to cigarette smoke
is due to paralysis of the muco-ciliary apparatus. The paralysis of the muco¬
ciliary apparatus in this study, however, was found to be reversible.
Cigarette smoke and tumour growth in animals
Tobacco has been shown to contain many carcinogenic substances (US.
Department of Health Education and Welfare, 1971). When tobacco is burnt,
tar is released and many other carcinogenic substances such as
methylchlanthrene, benzopyrene and benzanthracene can be isolated
(Kleinsasser, 1983). These carcinogenic substances are known as polycyclic
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aromatic hydrocarbons (PAH). Inhalation of cigarette smoke in the
experimental animals enhanced the growth of an established malignant cells
(Thomas and Holt, 1974). In this study, only mice chronically exposed to
cigarette smoke died with tumour cells in the lungs whereas short-term
exposure of mice to cigarette smoke resulted in no significant difference in the
tumour cell growth from that in the control group.
Therefore, the above studies in experimental animals have indicated that
exposure to cigarette smoke may result in characteristic pattern of
immunological and inflammatory changes. Bacterial clearance from the
respiratory system and resistance to bacterial infection have been shown to be
affected. Furthermore, chronic exposure to cigarette smoke have been shown to
enhance growth of malignant tumours. The above findings in experimental
animals have provided the impetus for further studies in humans with the




Studies on peripheral blood
Cellular components of the blood. In vitro studies on human leukocytes
showed that nicotine, at levels comparable to that encountered in the blood of
smokers, caused a slight, although significant, depression of
phytohaemagglutinin (PHA)-stimulated deoxyribonucleic acid synthesis in
human leukocytes (Neher, 1974). In vivo studies showed that smoking results
in "smokers leukocytosis" with an increase in all major classes of peripheral
blood leukocytes (Core et al, 1971). Polymorphonuclear leukocytes were found
to be increased up to 44% in the circulation of smokers (Bridges et al, 1985).
However, the chemotactic and bactericidal activity of the polymorphonuclear
leukocytes were found to be normal (Noble and Penny, 1975).
The number of monocytes in the peripheral blood of smokers was also found to
be increased (Bridges et al, 1985). However, the intracellular capacity of these
monocytes to kill Candida fungi was found to be partially defective (Nielsen,
1985). Likewise, the number of circulating basophils in the peripheral blood of
smokers was found to be decreased significantly during smoking and, after
abstinence for 12 hours, to rise to higher numbers than in non-smokers
(Walter, 1982). The level of activity of NK cells in the circulation of smokers
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was examined in two different studies (Ferson et al, 1979; Hughes et al, 1985)
and was found to be depressed .
Not surprisingly, the effects of smoking on T cells populations, as one of the
most important components of the immune system, has attracted much interest.
Studies showed that the total number of T cells in the peripheral blood of
smokers is increased (Burton et al, 1983; Robertson et al, 1983). Both total
(CD3+) and T helper (CD4+) T cells were found to be increased in light and
moderate smokers (Hughes et al, 1985). However, in heavy smokers, T
suppressor/cytotoxic (CD8+) T cells were found to be increased with a relative
decrease in CD4+ T cells (Ginns et al, 1982).
Non-cellular components of the blood. The concentrations of IgA, IgM, and
IgG in the serum of smokers were reported to be reduced by up to 10-20%
compared to non-smokers (Gulsvik and Fagerhole, 1979; Gerrard et al, 1980;
Anderson et al, 1982). Smoking seems to produce biphasic changes in the
concentration of IgE and IgD in the serum of smokers. The levels of IgE and
IgD in light smokers were found to be significantly increased, whereas in
heavy smokers these levels were found to be below the levels of non-smokers
(Bonini, 1982; Bahna et al, 1980; Bahnaetal, 1983a; Bahnaetal, 1983b).
Smokers also exhibit a number of non-specific serological abnormalities
compared to non-smokers. For instance, serum of smokers has been found to
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contain an increased levels of C-reactive protein compared to non-smokers
(Heiskell et al, 1962). Furthermore, autoantibodies such as antinuclear and
rheumatoid factors were reported to be higher in smokers compared to non-
smokers (Mathews et al, 1973).
Studies on the lungs
Cellular components of the bronchoalveolar lavage. Bronchoalveolar lavage
fluids obtained from smokers showed characteristic features regarding alveolar
macrophages. Smoking produces marked increase in the number of alveolar
macrophages together with an increase in the number of neutrophils
(Hunninghake et al, 1979; Harris et al, 1970; Weinberger et al, 1978).
Furthermore, it seems that smoking results in activation of the alveolar
macrophages and produces an increase in the metabolic activity (Harris et al,
1970), adherence (Mann et al, 1971), activity of the lysosome enzymes
(Martin, 1973), and the responsiveness to chemotactic stimulants (Warr and
Martin, 1974; Richards et al, 1984). However, antigen presentation and
activation of T lymphocytes by alveolar macrophages was found to be
depressed by smoking (Clerici et al, 1984; Lawrence et al, 1983).
The effect of smoking on the phagocytic activity of the alveolar macrophages is
controversial and the various studies carried out in this respect have shown
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discrepant results. While some studies showed that the phagocytic activity of
alveolar macrophages of smokers is normal (Harris et al, 1970; Cohen and
Cline, 1971). Other studies showed that it is deficient (Martin and Warr, 1977;
Fisher et al, 1982). Presence of large numbers of alveolar macrophages was
suggested to be the reason behind the depressed phagocytic activity and the
suppressive effect on proliferation of T cells in the lungs of smokers (Holt,
1986).
Immunoglobulins in bronchoalveolar lavage. Generally, the IgA
concentration in the bronchoalveolar lavage from smokers was found to be
normal (Warr et al, 1977). The concentration of IgG was also found to be
normal in some studies (Warr et al, 1977; Low et al, 1978), but was found to
be increased in other studies (Reynolds and Newball, 1974; Bell et al, 1981).
Studies on saliva
The few studies which have been carried out on the effect of smoking on the
immunoglobulin concentration in saliva showed discrepant results. In one
study, the use of whole saliva to study the immunoglobulin concentration in
smokers and non-smokers showed no difference between IgA concentration of
smokers and non-smokers (Olson et al, 1985). In another study, salivary IgA
concentration was found to be higher in the smokers than in non-smokers
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(Watanabe et al, 1983). Other studies, however, showed that salivary IgA
levels are lower in smokers than in non-smokers (Bennet and Reade, 1982;
Jedrychowski et al, 1980). When pure parotid saliva from groups of healthy
smokers and non-smokers was used, the concentration of IgA was found to be
reduced among the smokers compared to non-smokers (Barton et al, 1990).
Since whole saliva is mixed with crevicular fluids and similar in its
immunoglobulin contents to serum, its use, rather than pure saliva, may
produce inaccurate results and contribute to the discrepancy in the results of
various studies on salivary IgA in smokers and non-smokers.
Studies on the IgG concentration in the saliva of smokers and non-smokers also
produced conflicting results. In one study, IgG levels of smokers were found to
be lower than in non-smokers (Jedrychowski et al, 1980). In another study,
however, there was no difference in concentration of IgG of smokers and non-
smokers (Barton et al, 1990). In the above study, the concentration of salivary
IgM was reported to be increased in the smokers as compared to non-smokers.
Studies on cervical mucosa
The effect of cigarette smoking on the local immunity of the cervix was
examined and it was found that cigarette smoking is associated with a
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significant decrease in the number of Langerhan's cells, the most important
antigen presenting cells in the normal cervical epithelium (Barton et al, 1988).
It was postulated that smoking is a cofactor that interact with the sexually-
transmitted human papilloma virus (HPV) that results in an increase in the
likelihood of developing a virally induced neoplastic changes in the cervix (Lur
Hansen, 1982; Pfister, 1987). Neoplastic transformation in the cervical
epithelium was found to be associated with prolonged infection with HPV
(Singer and McCane, 1986). Therefore, the reduction in the number of
Langerhan's cells may impair presentation of the viral antigen to T
lymphocytes resulting in suppression of the local immunity of the cervical
epithelium, allowing establishment and persistence of a local viral infection
with likelihood of development of cervical carcinoma.
Smoking and inflammatory bowel disease
Cigarette smoking has received considerable attention in recent years as a
possible factor in the pathogenesis of inflammatory bowel disease (IBD). There
is increasing evidence that patients with ulcerative colitis tend to be non-
smokers or ex-smokers whereas patients with Crohn's disease tend to be
smokers (Bures et al, 1982; De Castella, 1982; Somerville et al, 1984).
Furthermore, ex-smokers were found to be at a greater risk of ulcerative colitis
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than either those who have never smoked or current smokers (Boyko et al,
1987). The above findings have led to the suggestion that smoking has a
protective effect in ulcerative colitis and may be a causal factor regarding
Crohn's disease.
In spite of the increasing number of epidemiological studies investigating the
relationship between smoking and IBD, there have been few studies
investigating this relationship in terms of the mucosal immune system.
Although the exact mechanism (or mechanisms) by which smoking may
influence the IBD is (are) still unknown, studies carried out in this field have
postulated some possible mechanism(s) which are discussed below.
The colonic mucus, an essential component of the intestinal mucosal barrier,
has been shown to be quantitatively and qualitatively abnormal in ulcerative
colitis patients (Podolsky and Isselbacher, 1984). Cigarette smoking has been
found to produce hypersecretion and modification of respiratory mucus by
systemic and local effects (Kollerstrom et al, 1977). In vitro study of colonic
mucus production has shown that patients with ulcerative colitis have reduced
mucus production compared with controls, and that ulcerative colitis patients
who did not smoke showed reduced mucus production compared with non-
smokers control (Cope et al, 1986). Therefore, the increased production of
colonic mucus found in smokers may improve the quality of the mucosal
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barrier and may explain how cigarette smoking may protect against ulcerative
colitis.
The lining epithelium of the intestinal mucosa is another important factor
involved in the intestinal mucosal defence system. The integrity and
effectiveness of this barrier could be assessed by measuring the urinary
recovery of orally administered 'probe' molecules such as Cr-EDTA (which
does not cross through intact epithelium). It has been found that 24 hour
urinary recovery of 'Cr-EDTA is significantly lower in healthy smokers
compared to healthy non-smokers suggesting that smoking may tighten the
intestinal epithelium by reducing the paracellular junctions or by decreasing the
permeability of the intestinal epithelium (Prytz et al, 1989).
Smoking may also influence the blood flow in the rectum. When rectal blood
flow was measured using laser Doppler flowmetry, patients with ulcerative
colitis in remission (all non-smokers) were found to have increased rectal blood
flow compared with healthy smokers and non-smokers controls (Srivastava et
al, 1990). In this study, acute cigarette smoking resulted in a pronounced
decrease in the rectal blood flow in all subjects but patients with colitis had
significantly higher values compared with smokers. The mechanism which has
been suggested to be involved in the reduction of rectal blood flow during
smoking is nicotine-induced vasoconstriction and the reduction in blood flow
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may decrease the amount of inflammatory mediators reaching the mucosal
surface decreasing the likelihood of developing ulcerative colitis.
Inflammatory mediators such as prostaglandin E2 (PGE2) and leukotriene B4 are
known to be increased in IBD. These mediators are also known as eicosanoids.
In the gut, cigarette smoking was found to reduce both luminal and tissue PGE2
in the gastric mucosa (McCready et al, 1985; Quimby et al, 1986). In one in
vitro study, the production of eicosanoids by the colonic mucosa of cigarette
smokers was found to be lower than that of non-smokers (Motley et al, 1990).
In another in vitro study, the colonic production of PGE2 in patients with
ulcerative colitis was found to be significantly decreased in heavy smokers
compared to those who have never smoked (Cope et al, 1991).
Therefore, the above findings suggest that smoking may have an inhibitory
effect on the release of the inflammatory mediators rendering the colonic
mucosa less liable to the inflammatory process and development of ulcerative
colitis.
Immunoglobulin production in the gut may also be affected by smoking. IBD is
known to be associated with altered immunoglobulin production. In vitro
studies on the immunoglobulin production by the colonic mucosa in IBD
patients and controls showed that smoking decreases the production of IgA in
both IBD patients and controls, markedly decreases the production of IgM in
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IBD patients and increases the production of IgG in the smokers (Cope et al,
1989). This study suggests that smoking may be involved in the pathogenesis of
IBD by suppressing the local intestinal immunity. However, one in vivo study,
using whole gut lavage as a material for the investigation, found that there was
no significant difference between the concentration of intestinal IgA, IgM and
IgG in healthy smokers and non-smokers (Srivastava et al, 1991). This study
also showed that there was no significant difference between smokers and non-
smokers with ulcerative colitis. Therefore, the results of the latter study cast
doubts on the suggestion that smoking may influence the pathogenesis of IBD
by interfering with the normal humoral mucosal immune system.
Finally, the mechanism (or mechanisms) by which smoking may interfere in
pathogenesis of IBD (and may be other immune disorders in the gut) is/are
still, as yet, not well understood. Obviously, laboratory investigations,
particularly in terms of intestinal mucosal immunity, are required to support the
findings of the epidemiological studies to answer the question: does smoking
have any role in the pathogenesis of the immune disorders of the gut ?
Therefore, WGL, as a non-invasive, safe and useful method to obtain intestinal
secretions can be used to investigate the effect of smoking on the immunity.
The use of reliable method which provides a direct access into the intestinal
secretions may help in explanation not only the inflammatory changes
associated with cigarette smoking but may also help in explaining some of the
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neoplastic complications related to smoking. Furthermore, the use of reliable
methods to investigate the effect of smoking on the intestinal immune system
may help in moving from the stage of reporting immunological changes
associated with smoking to the stage where such immunological changes can be






WHOLE GUT LAVAGE: PERSPECTIVE VIEW
AND TECHNICAL DEVELOPMENT
Introduction
In humans, a non-invasive technique that can provide a direct access into
intestinal secretions has always been the aim of many investigators. Elson and
colleagues (1984) reported a "relatively easy" method by which a lavage
solution could be exploited to obtain repeated samples of intestinal secretions
from mice, and the possibility of measuring both total IgA and antigen-specific
antibodies in these secretions. A modification of the above method was
reported by Gaspari et al (1988) who described a whole gut lavage technique in
humans for obtaining intestinal secretions using a commercially available
lavage solution (Golytely). The process of collecting, processing and analysing
human intestinal secretions was proved to be feasible and whole gut lavage
fluids were found to be useful material for a variety of investigations on gut
immunity. O'Mahony and colleagues (1990) published their preliminary study
on the use of whole gut lavage technique in patients with coeliac disease or
Crohn's disease. In the above study, total immunoglobulins and antigen-
specific antibodies in intestinal secretions of the patients studied were readily
measured by ELISA and whole gut lavage technique was found to be safe and
well-tolerated by most of the patients involved in the study.
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I have further evaluated the use of whole gut lavage for obtaining intestinal
secretions to study gut immunity in healthy British volunteers, patients with a
variety of gastrointestinal diseases as well as patients who had had salmonella
infection. A sequential lavage study was carried out in another group of
patients to validate the use of any clear specimen passed per rectum, during the
whole gut lavage process, as a representative of the rest of whole gut lavage
effluent.
The lavage solution
The commercial lavage solution used in whole gut lavage has essentially been
used for cleansing the colon as a preparation for Barium enema (Skucas et al,
1976), colonoscopy (Rhode et al, 1977), colon surgery (Hewitt et al, 1973) as
well as for the treatment of intractable constipation (Puxty and Fox, 1986). The
main constituent of the lavage solution is polyethylene glycol (PEG) which has
a molecular weight of 3350 and used at a concentration of 59 g/litre tap water.
PEG is a non-absorbable material that produces an osmotic diarrhoea and does
not cause net absorption or secretion of fluids or electrolytes across the wall of
the intestine (Davis et al, 1980; Malawer and Powell, 1976). Other contents of
the lavage solution include sodium chloride (BP 1.45g), sodium bicarbonate
(BP 1.63g), sodium bisulphate (BP 5.68g) and potassium chloride (BP 0.75g).
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The lavage solution has now been marketed as "Golytely" or "Klean.prep" and
is available in small sachets to be made up to one litre by adding tap water
resulting in an osmolality of 260 mosm/litre.
Lavage protocol
The approval of the Medicine and Clinical Oncology Ethics of Medical
Research Subcommittee of Lothian Health Board was obtained before
commencing the study of whole gut lavage (WGL) and written consent was
obtained from every participant. Subjects involved in the study were asked to
fast overnight and to come next morning to the G.I.Unit to start drinking the
lavage solution at about 08.30. Before subjects started drinking the lavage
solution, a brief medical history was recorded and 10-20 mis of venous blood
samples were taken from every participant. Because lavage solution was found
to be more palatable if consumed chilled, it was made up and kept in the fridge
for a few minutes before it was consumed. Subjects were asked to drink the
lavage solution at a rate of 200 mis every 10-15 minutes for a period of 3-4
hours till the total volume consumed was 3-4 litres i.e. at a rate of one litre
per hour. Subjects were also asked to record the time at which they started and
completed each glass of the lavage solution and to stop drinking at any time
should they find the procedure intolerable.
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Within 2 hours, the bowel of the subjects started to move. Solid and semi-
liquid stools were discarded and only clear fluid stools passed per rectum were
collected. Once the subjects started to pass clear fluid stools per rectum, they
were allowed to have a cup of tea or coffee with some biscuits and to leave.
Clear fluid stools were collected in 2-3 20 mis universal containers and sent to
the gastrointestinal (GI) laboratory within 10 minutes of collection where
protease enzyme inhibitors were added to the lavage specimens, to minimise
degradation of proteins by protease enzymes present in large amount in the
intestinal secretions i.e. to be processed (see below), and stored. For the
purpose of measuring the PEG contents in the stool samples, a specimen of the
lavage solution consumed by the subjects was collected in one to two 20 mis
universal containers before or during the experiment.
Blood samples were divided into two small 10 mis tubes, one of them was sent
to the Department of Clinical Biochemistry for the assay of total
immunoglobulin concentration whereas the other tube was sent to the G.I
laboratory for serum extraction and storage.
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Processing of specimens
Once clear fluid stools were obtained from subjects involved in the WGL
study, specimens were transported immediately to the G.I laboratory for
processing and storage. This is because a previous study (O'Mahony et al,
1990) has shown that a delay of 1-2 hours in processing lavage stools may
result in up to 92% loss in IgA contents of the specimens.
Specimens were filtered through glass filter papers (Whatmann Glass
Microfibre Filters 12.5 cm) into 50 mis test tubes. Before adding protease
inhibitors, approximately 3 mis of the filtered fluid was dispensed into 2 x 1.5
mis tubes and 20 pi of sodium azide solution (20 g/litre distilled water) was
added to each tube to be used for the measurement of protease enzymes activity
in the processed and unprocessed lavage specimens (see below).
To a 20 ml universal container, 10 mis of the filtered lavage fluid was
transferred and 1 ml of Soybean trypsin inhibitor (SBTI) (Sigma), at a
concentration of 1 mg/ml in phosphate buffer solution (PBS), was added. After
mixing, 0.56 ml of 0.1M ethylenediaminetetracetic acid (EDTA) (as a
chelating agent for calcium and magnesium ions which are required for the
activation of protease enzymes) was added. After mixing, 0.24 ml of 0.1M in
95% alcohol phenylmethylsulphonyl fluoride (PMSF) was added and mixed.
Thereafter, 0.12 ml of sodium azide (bactericidal agent) (20 g/litre distilled
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water) was added. After leaving the mixture to stand for two minutes to allow
protease enzyme inhibitors to work, 0.6 ml of heat-inactivated new born calf
serum (NBCS) was added to the mixture to provide an alternative substrate for
any remaining protease enzymes. The final volume of the mixture in the
universal container was 12.5 mis. The mixture was then divided into 8 aliquots
dispensed in 8 x 1.5 tubes and stored at -70 °C for analysis later in various
experiments.
Assays performed on WGL fluid
The following assays were performed on processed WGL fluids. Details of the
methodology will be described later in this chapter.
Total and antigen-specific immunoglobulin concentration assay: Enzyme-linked
immunosorbent assay (ELISA) was performed to measure total
immunoglobulins (Ig) A, M and G, secretory IgA, anti-Salmonella typhi
lipopolysaccharide (LPS) antibodies and anti-Salmonella typhimurium RC-
mutant antibodies in processed WGL fluid.
Polyethylene glycol (PEG) assay: The concentration of PEG was measured in
processed lavage samples to examine the degree of dilution of the intestinal
secretions by the lavage solution. In a sequential lavage study, PEG
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concentration (in addition to many other indices in the lavage fluid effluent)
was measured in 5-6 serial lavage specimens obtained from every subject
involved in the study to investigate the validity of taking one clear specimen of
the lavage effluent as a representative of the rest of the effluent.
Protease enzymes activity assay: The effect of adding protease enzymes
inhibitors and the degree of inhibition was studied in both processed and
unprocessed lavage fluid.
Albumin concentration in WGL fluid assay: Excessive amounts of albumin in
WGL fluid may indicate the presence of an abnormal section of the gut, e.g. an
ulcer, that allows leakage of albumin molecules from the systemic circulation
into the gut lumen.
Alpha-1-antitrvpsin in WGL fluid assay: The amount of alpha-1-antitrypsin in
WGL fluid may be another indication of the amount of the protein loss across
the gut due to an inflammatory process in the mucosa of the gut.
Subjects studied
Twenty-two healthy British volunteers were recruited for the study of the effect
of the newly licensed oral typhoid vaccine Ty21a on the intestinal immune
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status of individuals from areas which are known to be non-endemic with
typhoid fever such as the United Kingdom (UK). This group of volunteers was
further divided into 14 heavy smokers and 8 non-smokers to investigate the
influence of heavy smoking on gut immunity and the effect of boosting the
immune status of these smokers/non-smokers subjects with a mitogenic
substance such as the oral typhoid vaccine Ty21a.
For the sequential lavage study, 11 patients were recruited from the out-patient
clinic as well as from the in-patient department of the gastrointestinal unit
(GIU) of the Western General Hospital. These are patients who were attending
the GIU to be treated from a variety of G.I diseases or patients who were
admitted to be prepared for lower endoscopy (flexible sigmoidoscopy and/or
colonoscopy).
To study the effect of naturally acquired salmonella infection on the gut
immunity, a group of 8 patients were recruited from the City Hospital after
treatment for salmonella infection. These were mostly patients who had
returned from holidays abroad and were referred to Dr. Gray of the City
Hospital with manifestations of salmonella infection.
To investigate the phenomenon of intestinal IgA deficiency in subjects with
normal concentration of serum IgA I observed while investigating the
immunoglobulin contents in WGL fluid of patients with a variety of
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gastrointestinal diseases, 1 retrospectively studied WGL specimens obtained
from normal individuals as well as from patients attending the GIU for a
variety of gastrointestinal diseases during 1991 and 1992. These specimens
were stored at -70 °C.
WGL specimens of patients with inflammatory bowel diseases (IBD) obtained
during 1991 and 1992 were studied with respect to the total immunoglobulins
and antigen-specific antibody concentrations in these specimens, comparing
them with the findings in lavage specimens obtained from healthy volunteers.
Further details of all subjects (healthy volunteers and patients) involved in the
different studies cited in this thesis will be described in the relevant chapters.
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Section 2
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
Introduction
During the last three decades there has been a prominent increase in the number
and variety of methods available for immunodiagnostic tests. This is because
there has been marked development in the methods which use labelled antigens
or antibodies resulting in more sensitive and specific tests.
Radioimmunoassay (RIA) was regarded as the method of choice for assays of
both large and small molecular weight substances (Sonksen, 1974) and
immunofluorescence was found to be a useful method for the measurement of
antibody levels in infectious and auto-immune diseases (Nairn, 1976).
However, both tests have their limitation. RIA requires rather sophisticated and
expensive equipment, the reagents utilised in have short shelf-life and the strict
regulatory controls on the use of isotopes have tended to exclude RIA from
many small laboratories. Immunofluorescence was found to be tedious, time-
consuming and can be used for only small batches of tests (Voller et al, 1978).
Old tests based on haemagglutination and complement fixation were found to
be less accurate than modern assays such as RIA. Therefore, the search for
alternative methods which use other labels for antigens and antibodies has
continued and ELISA was found to be the most promising method which uses
enzymes that can be linked to antigens and antibodies and the complexes
produced have both immunological and enzymatic activity.
ELISA was first described in the early seventies (Engvall and Perlmann, 1971)
and is nowadays regarded as at least one of the most sensitive and specific
methods for detecting both antibodies and antigens and has rapidly superseded
other methods for the quantitative measurement of antigen-specific antibodies
as it can be used for large-scale tests and it is relatively economical in the use
of reagents required for the tests. Furthermore, reagents used in ELISA have
long shelf-life and there are no radioactivity hazards.
There are two main types of ELISA techniques, homogeneous and
heterogeneous. Homogeneous method involves the simultaneous use of all
reagents in one step. It is particularly useful for rapid assays of low molecular
weight compounds such as drugs (e.g. morphine, digoxin and gentamjcin )
and some hormones (e.g. T3, T4 and Cortisol). However, homogeneous
methods are generally not suitable for detecting larger molecules such as
microbial antigens and their antibodies.
The heterogeneous type of ELISA can be further classified into competitive and
non-competitive ELISA. The latter technique was the main type of ELISAs
used in the research work described in this thesis where it was used for
detection of total immunoglobulins, using Double Antibody Sandwich
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technique, and antigen-specific antibodies, using the indirect method of the
non-competitive ELISA.
Measurement of total immunoglobulins bv ELISA
The method most commonly used for antigen detection and quantitation is the
double antibody sandwich (non-competitive) ELISA. Double antibody
sandwich involves the following steps:
1. ELISA plates, a 96-well microtitration plastic plates (the solid phase) is
coated with specific antibodies (usually animal derived antibodies) and
incubated overnight. For the measurement of TIgA, 96-well Immulonl
129A (Dynatech) ELISA plates were coated with 200 ng/ml affinity-
purified goat anti-human IgA antibodies in 0.05M carbonate buffer, pH
9.6, (Northeast Biomedicals). Coating antibody and all reactants in the
following steps were added in volumes of 0.125 mis per well. Coated plates
were incubated overnight at 4 °C.
2. Following overnight incubation, free antibodies are washed away. Plates
were then blocked with low molecular protein such as bovine serum
albumin (BSA) or adult bovine serum to minimise any non-specific
binding. For the assay of TIgA, wash solution was composed of 0.05%
ill
Tween 20 (Sigma) added to 1 litre normal saline. Tween 20, a detergent,
was added to minimise non-specific reactions. Plates were washed three
times either manually using multi-channel pipette or automatically using
ELISA-wash machine (Wellwash). The solution used for blocking was
composed of 0.05% Tween 20, 1% adult bovine serum (Span) added to 1
litre normal saline.
3. Standard and test samples are added to the coated plates at two-fold serial
dilutions and at an appropriate initial dilution of the standard and test
samples and then incubated. Human colostrum with an initial dilution of
1.25 pg/ml of IgA was used as a standard in the assay performed for the
measurement of TigA concentration in WGL fluid, saliva and jejunal
aspirate. The initial dilution of the test samples was 1/100. The solution
used for dilution of the standard and test samples (ELISA diluent) was
composed of 0.05% Tween 20, 1% adult bovine serum in 1 litre normal
saline. Plates were then incubated overnight at 4 °C.
4. Unbound proteins are washed away and an enzyme-labelled specific
antibodies (conjugate) is added at an appropriate concentration to every
well. The two most commonly used enzyme labels are alkaline phosphatase
and horseradish peroxidase. Goat anti-human IgA labelled with alkaline
phosphatase (Northeast Biomedicals or Sigma) at a concentration of 1/5000
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in ELISA diluent was used as a conjugate for the measurement of TIgA in
WGL fluid. Plates were then incubated for 3 hours at room temperature.
5. Free conjugate is washed away while the bound conjugate is visualised by
the addition of the substrate. The substrate is a chromogen substance which
is degraded by the enzyme of the conjugate to produce a stable, soluble,
and coloured end-product (Voller et al, 1978). There are many types of
substrates and the choice of the appropriate one is governed by the enzyme
used. Para-nitrophenyl phosphate (PNP) is the only colorometric substrate
that is used with alkaline phosphatase conjugate and found to be safe and
available in tablet form that produces a stable yellow end-product. The
quantity of the test antigen is assessed by the change in the colour of the
end-product i.e. optical density of the test solution using a
spectrophotometer. For the TIgA assay, PNP (Sigma) 1 mg/ml in 10%
Diethanolamine (DEA) buffer at pH 9.8 was added to every well and the
plates were read using ELISA reader (MR 5000, Dynatech) at wavelength
of 405 nm. When the optical density of the standard was 1.000 and at least
3 of the test samples dilutions were within the range of the standard, the
test was technically completed.
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Interpretation of the results
The concentration of the antigen in the sample is measured by reference to a
standard curve prepared by plotting the optical density (OD) values of serial
dilutions of a standard containing known concentration of the antigen being
measured. This involves plotting a curve of the OD on Y-axis against the
concentration of the standard on X-axis. Immunoglobulin concentration in the
test samples are then measured by comparing the OD of the test sample with
that of the standard, i.e. extrapolating the immunoglobulin levels of the test
samples from the standard curve.
For TIgA measurement, a standard curve was constructed by plotting the OD
of the standard dilutions on the Y-axis against the log-transformed values of the
concentration of the standard on the X-axis resulting in a straight line. The
standard solution (human colostrum) contained known amount of the TIgA
(mostly secretory IgA) starting from 1250 ng/ml decreasing to 19.350 ng/ml.
The correlation coefficient (r) of the standard curve was obtained and the
technique was regarded a satisfactory one only when r value of 0.99 could be
obtained. The concentration of TIgA in the test samples was determined by
taking the mean value of 2-3 test samples calculated from the OD values of
these samples when they fell within the range of the standard curve (Fig 3.1).
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ELISA used for the measurement of TIgM and TlgG levels in lavage samples
were basically similar to the above described method. Human reference serum
(Protein Reference Unit PRU, Sheffield) was used as a standard with an initial
dilution of 1000 ng/ml. The initial dilution of the test samples was 1/25 for
IgM and 1/10 for IgG. Results were read and interpreted as described for IgA.
Measurement of secretory IgA concentrations in WGL fluid
The ELISA technique used for the measurement of secretory IgA (SIgA) levels
in WGL fluid was basically similar to the ELISA performed for the
measurement of TigA concentration, with the exception that the conjugate used
for TIgA assay (goat anti-human IgA alkaline phosphatase) was replaced by
conjugate that is specific for SIgA. This conjugate is called anti-human IgA
secretory piece alkaline phosphatase (The Binding Site Ltd.). The conjugate
used for SIgA assay was added to the well at a dilution of 1/2000 in ELISA
diluent. The same standard, human colostrum IgA, of which SIgA is almost
100%, was used for SIgA assay.
115
Measurement of antigen-specific antibodies in WGL fluid
ELISA has been used with enthusiasm by workers on infectious diseases where
the need is often for the measurement of antibodies against a variety of
infectious agents. Investigators have found that the indirect method of ELISA is
particularly suitable for the measurement of antigen-specific antibodies titres
(Engvall and Perlmann, 1972).
The indirect method of ELISA involves immobilisation of the antigen by
passive adsorption on to the solid phase. Test samples are then incubated with
the solid phase and any antibodies in the test samples become attached to the
antigen. After washing to remove unreacted components of the test samples, an
anti-globulin enzyme conjugate is added and incubated. This will become
attached to any antibodies bound to the antigen. Washing again will remove
unbound reactants and finally the substrate is added. The colour change of the
substrate will be a measure of the conjugate fixed which itself is proportional to
the antibody levels in the test samples.
The actual concentration of the specific antibodies in the substance being tested
is rather difficult to measure because the initial concentration of the standard is
not known and it is somewhat difficult to determine, in absolute weight, the
precise amount of the antigen-specific antibodies in the standard solution.
Investigators, therefore, used to express the results obtained by the indirect
method as the percentage of OD of the test samples and the standard solution.
An alternative way of expressing the results is the designation of an arbitrary
value for the standard "X units" then a standard curve is constructed from the
serial dilution of the standard. The antibody contents of the test samples is then
extrapolated from the standard curve.
Measurement of anti-Salmonella typhi LPS antibodies
The following technique was used for the quantitative measurement of anti-
Salmonella typhi lipopolysaccharide (LPS) antibodies in WGL fluid and
serum.
1. ELISA plates (Immulon2 129B, Dynatech) were used for the measurement
of anti-Salmonella typhi LPS antibodies in lavage specimens and serum.
These plates allow the coating antigen to be adsorbed more strongly to the
solid phase than Immulonl plates. Five to ten mgs of Salmonella typhosa
LPS (Sigma L-6386) were dissolved 1:1 (w/v) in distilled water then a
calculated volume of the solution was added to carbonate buffer solution
(Sigma) to give a final concentration of 1 pg/ml. Wells were coated with
100 f-il of the coating antigen and incubated overnight at 4 °C. Plates were
washed three times as described for TIgA then blocked for 45 minutes. The
blocking buffer (as well as the diluent) was composed of 0.05% Tween 20,
0.05% (w/v) bovine serum albumin (Sigma A-7906) added to one litre
normal saline. Adult bovine serum (used for ELISA block and diluent in
TigA assay) was excluded because it produced high non-specific reaction
and gave inaccurate results in this assay.
2. Serum from a colleague found to have a high titre of anti-TAB vaccine
(typhoid vaccine) antibodies was collected and aliquoted into small tubes
which were stored at -70 °C to be used as a reference standard for this
assay. The initial dilutions of the standard used for the quantitative
measurement of anti-Salmonella typhi LPS antibodies in WGL fluid and
serum were 1/100, 1/200 and 1/2000 for the measurement of IgA, IgM and
IgG antibodies respectively whereas the initial dilution of the test samples
were 1/2 for WGL fluid and 1/100 for serum samples. The standard
solution and test samples were added in duplicate into the ELISA plates and
a series of doubling dilutions were made as for the TIgA assay. Plates were
then incubated overnight at 4 °C.
3. After washing, goat anti-human IgA, IgM or IgG alkaline phosphatase
conjugate (Sigma Immuno Chemicals) was added at the appropriate
concentration and incubated for 3-4 hours at 22 °C. The rest of the
technical procedure and reading the plates was carried out as for TIgA
assay.
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4. Antibody titres in the test samples were extrapolated from the standard
curve. An arbitrary value of 1000 units/ml anti-Salmonella typhi LPS
antibodies were designated for the standard and the results of the test
samples were expressed as units/ml. However, after obtaining the TIgA
results (|ig/ml) of the same samples, results were expressed as units/mg
TIgA. (Fig 3.II).
Specificity of anti-Salmonella typhi LPS antibodies assay
Because other Salmonella spp, other than Salmonella typhi, as well as other
members of Enterobacteriaceae may share some of the Salmonella typhi
antigens, the specificity of the anti-Salmonella LPS antibodies assay was
further investigated. LPS of a Salmonella typhimurium mutant (Rc-mutant) was
used as a coating antigen. This antigen was prepared by Dr. McLoughlin
(department of Medical Microbiology, University of Edinburgh) and the
standard was prepared by collecting blood samples from 6 patients with active
inflammatory bowel diseases and the serum obtained was stored at -70 °C to be
used as a standard. This work was carried out by Dr. McLintock of the G.I.
laboratory, Western General Hospital.
Generally, the following conditions were necessary to meet while performing
all types of ELISA in order to obtain satisfactory results:
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1. Optimum concentration of antibodies or antigens used for coating of the
solid phase.
2. Optimum incubation time and the temperature at which ELISA plates to be
incubated.
3. Optimum composition of the solution used for ELISA wash, block and
diluent.
4. Optimum choice of the conjugate and substrate as well as the time required
by the substrate to produce the optimum OD.
120
Section 3
DETERMINATION OF POLYETHYLENE GLYCOL
LEVELS IN WGL FLUID
Introduction
Hyden (Hyden, 1955) described a turbidimetric analysis of polyethylene glycol
(PEG) in biological material based on the development of an oil-in-water
emulsion of PEG when exposed to trichloroacetic acid (TCA) in the presence
of barium ions. This method was, however, found to be adversely affected by
various factors which affect colloidal solutions in general e.g. temperature, pH,
vibration, method of mixing, interfering ions etc.
Later on, Malawer and Powell (1967) reported the development of an improved
method for PEG assay in which they introduce an emulsifying agent (gum
Arabic) to stabilise the oil-in-water emulsion. In the above study, the
introduction of an emulsifying agent into the PEG assay was reported to
produce more accurate and reproducible results.
Procedure
The method described below is mainly based on the method reported by
Malawer and Powell (1967). This method involves the use of PEG 3350 (BDH
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Biochemicals) at a concentration of 1 g/100 ml in distilled water as a standard
solution. Standard solution was added to four test tubes at 0.2, 0.4, 0.6, and
0.8 ml to which distilled water was added to make up 1 ml solution. This
would give a solution (standard) of PEG which varies in its concentration from
200 to 800 mg/ml. One ml of distilled water was added to a fifth tube to be
used as a blank.
Lavage samples and PEG solution used as standard were diluted 1/10 in
distilled water and added in duplicate into 20 ml test tubes. To all tubes, the
following were added (all reagents were supplied by BDH Biochemicals): 10
mis distilled water, 1 ml of 10% (w/v) BaCl2.2H20, 2 mis Ba(OH)2, and 2 mis
of 5% (w/v) ZnS04.7H20. The tubes were then mixed vigorously for one
minute and left to stand for 10 minutes. The fluids were then filtered through
double thickness (Whatmann no. 42) ashless filter papers. One ml of the filtrate
was added to 3 mis gum Arabic solution (10 mg per litre distilled water),
mixed and then 4 mis of 30 % (w/v) trichloroacetic acid (TCA) containing 5 %
(w/v) BaCl2.2H20 solution was added. Tubes were then sealed with parafilm
and left to stand for 75 minutes at room temperature. The optical density of the
test samples and standard were read by a spectrophotometer (Pye Unicam PU
8610, Philips) at a wave length of 650 nm. A standard curve was constructed




DETERMINATION OF ALBUMIN CONCENTRATION
IN WGL FLUID
Introduction
Determination of albumin concentration in WGL fluid was based on the fact
that human albumin reacts with its specific antibody forming
immunocomplexes which precipitate quickly in the presence of PEG. The
precipitate produces turbidity the density of which is related to the
concentration of albumin in the lavage samples (immunoturbidimetric assay).
The turbidity is then measured photometrically at a wave length of 340 nm and
the optical density obtained is used to construct a standard curve from which
the concentration of the albumin in the test samples can be extrapolated.
Reagents used in albumin assay
The reagents used were as follows.
PEG reagent. This is composed of 40g PEG 6000 (BDH Biochemicals), 6g
tris buffer, 2g Tween 20 (Sigma) and lg sodium azide dissolved in 1 litre
distilled water and adjusted to pH 7.0 with HC1.
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Antibody reagent. Composed of sheep anti-human albumin serum (SAPU
code S034-205) diluted 1/50 in PEG reagent (to be prepared fresh on day of
assay).
Diluent. Composed of 9g sodium chloride, 60g PEG 3350 and lg sodium
azide in 1 litre distilled water.
Calibration standard. Human serum SPS-01 (PRU-Sheffield) diluted to give
albumin concentrations of 10, 20, 50, 100, and 200 pg/ml in diluent.
Procedure
The procedure involves diluting 50 pi of the standard solution or test samples
with 0.95 ml PEG reagent into 3 ml test tubes to be used as blanks. Another 50
pi of the standard solution or test samples were added into 0.95 ml antibody
reagent in 3 ml test tubes. After leaving to stand for 15-20 minutes, standard
solution, test samples and blanks were read by spectrophotometer (Pye Unicam
PU 8610, Philips) at a wave length of 340 nm. A standard curve based on the
optical density obtained was constructed and the test samples were extrapolated
from the standard curve.
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Determination of alpha-l-antitrypsin in WGL fluid
The methodology used for determination of alpha-l-antitrypsin concentration in
WGL fluid was based on the same principle, reagents, and procedure described
above for the determination of albumin concentration in WGL.
Determination of protease enzymes activity in WGL fluid
Processed and unprocessed lavage specimens were required for this assay. A
suspension of Azacol (Sigma A 9404) in 10 mg/ml phosphate buffer solution
(PBS) was prepared. Half a ml of this suspension was transferred into 3 ml
polystyrene test tubes which were then put in a water bath at 37 °C. The
reaction was started by the addition of 50 pi lavage specimens (processed or
unprocessed). The reaction was stopped after 30 minutes by transferring the
test tubes to iced water for 5 minutes. Tubes were then centrifuged (using
Mistral 3000i, MSE centrifuge) at 2000 rpm at 4 °C for 5 minutes and 0.1 ml
of the supernatant was added to 0.9 ml PBS before mixing the tubes. The
solution was then read by spectrophotometer (Pye Unicam PU 8610, Philips) at
a wave length of 530 nm. The percentage of inhibition of protease activity in
the processed samples were determined by calculating the optical density of the
processed and unprocessed specimens.
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Section 5
QUANTITATION OF IMMUNOGLOBULIN-PRODUCING CELLS
IN THE LAMINA PROPRIA OF SMALL BOWEL BIOPSIES USING
IMAGE ANALYSIS
Background
Image analysis may be used to identify various parameters such as size,
number, shape, position, and optical density of identifiable parts of an image.
Image analysis requires a microscope, video camera, visual display monitor,
computer with double-disc drive and a printer. An image from the microscope
is transferred by the video camera to the monitor. The image on the screen is
modified to give an image suitable for measuring (the image is converted into a
binary image) where different grey intensities can be detected. Detectable areas
can be measured and the values can be recorded.
Procedure
The image analyser used was manufactured by Leitz (TAS plus, Bosch).
Sections of intestinal biopsies were prepared and stained
immunohistochemically (by Mr. Bode, MLSO technician in the G.I laboratory,
WGH) using either IgA or IgM polyclonal antibodies. Sections that contained
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high interstitial immunoglobulins were excluded because they attract large
quantities of the stain making the section rather difficult to count. The
microscope was set to Kholer illumination to obtain optimum resolution and the
slides were adjusted to be examined under xlOO objective. The appropriate
software programme was loaded into the computer of the analyser. IgA- or
IgM-containing plasma cells were counted in the lamina propria of every field
examined and the area of lamina propria in which these cells were counted was
measured excluding the areas of the intestinal glands such as crypts of
Lieberktihn. Up to 50 different fields were examined systematically per slide.
When counting was completed, a print out of the final measurements including
the total number of cells counted, the total size of the area of lamina propria
measured and the mean number of cells per square millimetre was obtained.




MISCELLANEOUS METHODS AND MATERIALS
Oral typhoid vaccine Tv21a
This is a live attenuated mutant strain of Salmonella typhi Ty21a (Vivotif
Berna, and Vivotif Evans, Switzerland) which is contained in enteric-coated
9
capsules. Each capsule of the vaccine contains at least 10 live Salmonella typhi
Ty21a organisms in a lyophilised form. The live organisms in the capsules have
lost their pathogenicity due to irreversible change in the cell wall. The vaccine
is unstable at normal room temperature and therefore the vaccine should always
be stored at 4 °C. More detail about this vaccine has been described earlier in
chapter 2.
Statistical methods
A data analysis software programme (Minitab, versions 7 and 8) was used to
perform statistical tests on results of the various studies described in this thesis.
Whenever data were found to be normally distributed, levels were expressed as
means. Student "t" test was used to compare matched pairs of observations
(Paired sample t-test) or independent samples (Two-sample test). Pearson
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correlation coefficient (r) was used to examine the relationship between two
variables.
For non-parametric data, on the other hand, levels were expressed as median
and ranges. Wilcoxon signed-rank test was used for paired data whereas Mann-
Whitney U-test was used for independent set of data. Spearman's rank
correlation coefficient was used to study the relationship between two variables.
Computer work
IBM and IBM compatible computers were used during the research work for
handling, storage and presenting data and a variety of computer software
packages were employed for this purposes. For data storage, dbase III plus
(Ashton-Tate Corporation) was used. Graphical representation of the results
were performed using GraphPad Inplot (GraphPad software Inc. version 4)
software. Word processing of the text was done using Word for Windows
(Microsoft Corporation, version 6.0) and references were organised using
Reference Manager (Research Information Systems, Inc. version 5.01).
Statistical analysis of the data were performed using Minitab (Minitab statistical
software, release 7 and 8).
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Fig 3.1. Standard curve of total IgA in WGL fluid.
130
concentration (units/ml)







As mentioned before, obtaining intestinal fluids as a material to investigate
the intestinal mucosal immune system is regarded as the "gold standard" by
which other methods may be compared. Elson et al (1984) reported the use
of WGL technique for quantitative measurements of intestinal
immunoglobulins and antigen-specific antibodies in mice followed by Gaspari
et al (1988), who described the use of WGL in man. The technique was first
introduced into the gastrointestinal unit of the Western General Hospital in
1988. Since then, WGL has been used to collect material to investigate the
intestinal mucosal immunity in patients with a variety of gastrointestinal
diseases, as well as in volunteers for various immunological studies.
Since the introduction of WGL technique, a great deal of technical
modification and development have been made to the process of collecting,
processing and storing the fluids obtained by WGL method. Obtaining
intestinal fluids by WGL method is non-invasive and has been found to be a
safe and reliable method for collection of intestinal secretions to study the
local intestinal immunity.
In practice, the first clear sample of the lavage effluent is taken as
representative of the rest of the lavage fluid. However, an important
question has always been asked: how representative is the first clear sample
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of the rest of the lavage fluid ? Although O'Mahony et al (1990) addressed
this point, they only studied up to two clear serial lavage samples from
every patient (n=14) and only the concentration of total IgA was measured
in these serial lavage samples. Further study, using more than two clear
samples from every subject and measuring other substances (such as the
various immunoglobulins, antigen-specific antibodies, alpha-1-antitrypsin
and other proteins and proteases activity) is obviously important to validate
the use the first clear sample as a representative of the rest of the lavage
fluid.
Therefore, the study of O'Mahony et al (1990) may not be sufficient to
establish whether gut lavage effluent is a perfusate, in which case any clear
sample can be taken as a representative of the rest of the lavage fluid, or
whether the first clear sample of gut lavage effluent is just a bolus of
material to study gut immunity. In the latter case, careful interpretation of
the significance of the quantitative measurements of immunoglobulins and
other components ofWGL fluid would be required.
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Aims of the study
1. To obtain at least 5 or 6 sequential clear specimens from every patient.
2. To examine the time at which these clear specimens can be obtained.
3. Whether or not sufficient volumes of clear lavage effluent are
obtainable to be used for a variety of investigations.
4. To study various indices such as immunoglobulin contents, antigen-
specific antibodies titres, alpha-l-antitrypsin, albumin etc. in the serial
lavage specimens.
5. Finally and most importantly, to examine whether the first clear sample
is representative of the rest of the lavage effluent or not i.e. whether gut
lavage effluent is a perfusate or a bolus of material from the gut.
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Patients studied
WGL was carried out in eleven patients (7 females and 4 males) were
recruited from the out-patient clinic and from wards of the gastrointestinal
unit (GIU). The age of patients ranged between 22 and 82 years (median
age 61 years). Further details of patients involved in this study are
described in table 4.1.
patient age sex out-patient/
in-patient
diagnosis remarks
1 28 M out-patient ulcerative colitis
2 22 M out-patient ulcerative colitis
3 61 M out-patient Crohn's disease ileostomy
4 76 F in-patient colonic polyp
5 82 F in-patient Crohn's disease constipation
6 36 F out-patient Crohn's disease ileostomy
7 64 F in-patient diarrhoea for inv.
8 73 M out-patient ca rectum constipation
9 61 F in-patient Crohn's disease
10 23 F in-patient ulcerative colitis
11 34 F in-patient Crohn's disease
Table 4.1. Patients involved in the serial lavage study.
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Approach
Patients attending the out-patient clinics of the GIU for a variety of GI
diseases as well as patients in ward D1 and D2 who were admitted to the
GIU either for treatment or for preparation for lower endoscopy were
recruited after explaining the aims and the nature of the study. Written
consents were obtained from all participants.
Methodology
1. After overnight fasting, patients started to drink the lavage solution at
about 08.30 next morning. The nature of the lavage solution was
described in the materials and methods chapter (chapter 3). Drinking of
the lavage solution was at a regular rate of 200 mis (one glass) every
10-15 minutes over a period of 2-3 hours. The patients recorded the
time when each glass was completed. A specimen of the lavage solution
were taken into two universals to be used in the PEG assay later.
2. Within one to two hours the bowel of the subjects started to move.
Solid and semi-liquid stools were discarded.
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3. When the subjects passed clear fluid stools per rectum, the clear
specimens were filtered and processed as described in chapter 3. Two
unprocessed samples were also taken. Processed and unprocessed
samples were put in a small box containing ice to reduce the activity of
the proteolytic enzymes in the specimens till all 5 to 6 clear specimens
were obtained then they were put at -70 °C as described in chapter 3.
4. Patients continued to drink the lavage solution till they passed at least 5
to 6 clear stool specimens.
5. The time at which every clear fluid stool specimen obtained was
recorded and the volume of each clear specimen was measured.
Assays performed
The following assays were performed in 5 to 6 sequential lavage specimens
obtained from the subjects. The methodology of these assays were
described in chapter 3.
1. Standard ELISA was carried out for the quantitative measurements of
TIgA, TIgM and TIgG. A modified ELISA was performed for the
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6. Proteases contents in the processed and unprocessed samples.
Since the data obtained in this study were found to be non-parametrically
distributed and paired, the Wilcoxon signed-rank test was used for the
statistical analysis of the results.
Results
Three patients were excluded from the final analysis. These are patients
number 4, 5 and 10. Patient number 4 was excluded because she only
passed four small volume clear lavage specimens and failed to pass further
specimens. At least 2 lavage specimens obtained from patient number 5, an
82-year old lady, were found to be contaminated by urine. Patient number
10, a 23-year old lady with ulcerative colitis, had excessive bleeding per
rectum during the experiment and the lavage specimens obtained from this
lady were found to contain large amounts of haemoglobin. Graphical
representation of total IgA, IgM and IgG in serial lavage samples of these
three patients are shown in Figs. 4.XIII, 4.XIV and XV.
The first five sequential lavage specimens from each of the eight
participants who continued the experiment successfully were used in the
study.
Output of whole gut lavage
Generally, WGL technique was well-tolerated by all participants in this
study. Once the patients started to pass clear lavage fluid per rectum, up to
5 to 6 good volumes of sequential clear fluid specimens could be obtained
from every subject. The intake and output of lavage fluids obtained from 8
patients are shown in table 4.II and represented graphically in Figs. 4.1 to
4.VIII.
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Levels of various indices in five sequential lavage samples
1. TIgA concentrations. The levels of TIgA in five sequential lavage
specimens obtained from every individual out of 8 patients showed no
significant differences between samples number 1 and numbers 2, 3, 4,
or 5 (p = 1.000, 1.000, 0.529, and 0.834 for the differences between
sample number 1 and numbers 2, 3, 4, and 5 respectively). Fig. 4.IX.
2. Anti-Salmonella typhi (LPS) IgA antibody titres. No significant
differences were found between samples number 1 and numbers 2, 3, 4,
or 5 (p=0.624, 0.441, 0.726, and 0.441 for the differences between
samples number 1 and numbers 2, 3, 4, and 5 respectively). Fig. 4.X.
3. TIgM concentrations. No significant differences were found between
samples number 1 and numbers 2, 3, 4, or 5 (p =0.161, 0.272, 0.076,
and 0.080 for the differences between samples number 1 and numbers
2, 3, 4, and 5 respectively). Fig. 4.XI.
4. TIgG concentrations. No significant differences were found between
samples number 1 and numbers 2 or 3 (p=0.529 and 0.363 for the
differences between samples number 1 and numbers 2 and 3
respectively). However, the differences between samples number 1 and
numbers 4 or 5 were found to be significant (p= 0.025 and 0.021 for
the differences between samples number 1 and numbers 4 and 5
respectively). Fig. 4.XII.
5. Albumin concentrations. No significant differences were found
between samples number 1 and numbers 2, 3, 4, or 5 (p =0.933, 0.612,
0.402, 0.612 for the differences between samples number 1 and
numbers 2, 3, 4, and 5 respectively).
6. Alpha-l-antitrypsin concentrations. No significant differences were
found between samples number 1 and numbers 2, 3, 4, or 5 (p = 1.000,
1.000, 0.529, and 0.447 for the differences between samples number 1
and numbers 2, 3, 4, and 5 respectively).
7. Proteases inhibition. No significant differences were found in the
percentage of inhibition of proteases activity between samples number 1
and numbers 2, 3, 4, or 5 (p= 1.000, 0.201, 1.000, and 0.138 for the
differences between samples number 1 and numbers 2, 3, 4, and 5
respectively).
8. Total protein concentrations. No significant differences were found
between samples number 1 and numbers 2, 3, or 4 (p =0.363, 0.834,
and 0.080 for the differences between samples number 1 and numbers
2, 3, and 4 respectively). However, the difference between samples
number 1 and number 5 was found to be significant (p=0.022) (table
4.III).
Conclusion
WGL has been shown to be a tolerable, non-invasive, and safe method that
provides direct access to the intestinal secretions and a reliable method to
investigate the gut immunity. Sufficient volumes of the lavage effluent were
obtainable to allow various investigations of on the lavage output This
experiment has shown that there are no significant differences between the
concentrations of the various indices studied in the first clear sample passed per
rectum in the WGL technique and the four succeeding sequential clear samples.
Therefore, I concluded that the first clear sample obtained from WGL effluent is











































Table 4.II. Intake and output of lavage fluids of 8 patients involved in the
serial lavage study (continued below). Patients 4, 5 and 10 were excluded
(see text).
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Table 4.II. (continued) Intake and output of lavage fluids of 8 patients
involved in the serial lavage study.
patient sample 1 sample 2 sample 3 sample 4 sample 5
1 1850 1620 1500 1200 1400
2 1700 1940 1400 1000 1000
3 500 600 400 420 420
4 540 553 560 560 460
5 330 480 420 370 330
6 450 500 710 440 410
7 830 880 1190 680 670
8 560 470 460 420 440
Table 4.IEL Values of total proteins in the serial lavage study (fig/ml). No
significant differences were found between samples number 1 and numbers
2, 3 or 4 (p values were 0.363, 0.834 and 0.080 respectively), but the
difference between samples number 1 and number 5 was found to be
significant (p value was 0.022).
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Fig. 4.1. Intake and output of lavage fluid of patient 1 involved in the serial
lavage study.













Fig. 4.HI. Intake and output of lavage fluid of patient 3 involved in the












Fig. 4.IV. Intake and output of lavage fluid of patient 4 involved in the
serial lavage study. This patient had an ileostomy.
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time of day
Fig. 4.V. Intake and output of lavage fluid of patient 5 involved in the
serial lavage study.
Fig. 4.VI. Intake and output of lavage fluid of patient 6 involved in the
serial lavage study. This patient had intractable constipation.
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Fig. 4.VII. Intake and output of lavage fluid of patient 7 involved in the
serial lavage study.
Fig. 4.VIII. Intake and output of lavage fluid of patient 8 involved in the
serial lavage study.
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Fig. 4.IX. Concentrations of total IgA (TIgA) in 5 sequential lavage
samples of 8 patients involved in the serial lavage study. S=sample
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Fig. 4.X. Concentrations of anti-Salmonella typhi LPS IgA antibodies in 5


















Fig. 4.XI. Concentrations of total IgM (TIgM) in 5 sequential lavage









Fig. 4.XII. Concentrations of total IgG (TIgG) in 5 sequential lavage
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Fig. 4.XIII. Concentrations of TIgA in sequential lavage samples of 3










0 —, 1 1 1 1—
si s2 s3 s4 s5
Fig. 4.XIV. Concentrations of TIgM in sequential lavage samples of 3
patients excluded from the final analysis of the results in the serial lavage
study.
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Fig. 4.XV. Concentrations of TIgG in sequential lavage samples of 3




INTESTINAL IeA. IsM AND IsG IN INFLAMMATORY BOWEL
DISEASE AS COMPARED TO HEALTHY VOLUNTEERS
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Background
Inflammatory bowel disease (IBD) consists of two major illnesses, ulcerative colitis
(UC) and Crohn's disease (CD), and is characterised by chronic inflammation of
the intestine. Both diseases, UC and CD, have been described as chronic
inflammatory diseases because of the prolonged clinical course and due to the fact
that inflammatory infiltrate contains lymphocytes and macrophages, a histological
picture of chronic inflammation. During acute exacerbation (active stage of IBD),
the inflamed mucosa contains large numbers of acute inflammatory cells such as
neutrophils and monocytes which then pass to the intestinal lumen (Schreiber et al,
1992).
The aetiological agent(s) for UC and CD is/are, as yet, unknown. A large number
of microbial and dietary agents have been suggested as candidates for the aetiology
of UC and CD. However, none of those agents has been proved to be the causative
agent of either UC or CD. UC is characterised by mucosal ulcers and the
infiltration of the mucosa and submucosa with neutrophils, macrophages and
lymphocytes while the histopathological lesion of CD is characterised by




Peripheral blood lymphocyte function. The total number of the peripheral blood
lymphocytes (PBLs) of patients with IBD has been found not to significantly differ
from normal controls (Selby and Jewell, 1983). However, the functional state and
the degree of activation of PBLs may be changed. Using the T9 antigen, which is
the transferrin receptor and is expressed during early lymphocyte activation,
Raedler and colleagues (1985) have demonstrated that 24% of PBLs of patients
with active CD expressed early activation markers and only 10% of PBLs
expressed the T9 antigen in inactive CD. In another study, Pallone et al (1987)
demonstrated that, in CD, T9 antigen was expressed in increased proportions on
both peripheral blood mononuclear cells (MNCs) and isolated intestinal lamina
propria MNCs. Mueller and co-workers (1990) showed that levels of soluble
interleukin-2 receptors (IL-2R) in sera of patients with CD were increased. Soluble
IL-2R appear on the surface of T cells and macrophages during cellular activation
(Schreiber et al, 1992). However, activation of PBLs was found to be not specific
for IBD and was observed also in a variety of autoimmune diseases such as
systemic lupus erythematosus, rheumatoid arthritis and Behcet's disease, but not in
bacterial or viral colitis (Raedler et al, 1985).
Intestinal lymphocyte function. IBD is characterised by a mixed cellular infiltrate
consisting mainly of B cells and T cells. B cells are found in the mucosa close to
IBD ulcers while T cells are found around granulomas and in the submucosa of CD
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lesions (Schreiber et al, 1992). In addition, neutrophils, eosinophils, mast cells and
macrophages are also encountered in IBD lesions. Immunohistological studies have
shown that IBD is associated with increased expression, on intestinal B cells and T
cells, of lymphocyte activation antigens such as 4F2, transferrin receptors, IL-2
receptors and HLA-DR (Pallone et al, 1987; Allison et al, 1984; MacDonald et al,
1990). Allison et al (1984) demonstrated also the appearance of CD7 as a marker
for the increased T cell activation in IBD. Furthermore, CD4+ and CD8+ T
lymphocyte subpopulations were found to be increased in both active UC and CD
(Schreiber et al, 1991). Generally, the above studies have shown that IBD is
associated with increased activity of B cells and T cells in the intestine as well as in
the peripheral blood of patients with UC and CD.
Intestinal immunoglobulins synthesis and secretion in IBD
In the normal mucosa, IgA-producing B cells are the predominant type of
immunoglobulin-producing cells, being 20 times as numerous as IgG-producing
cells (Crabbe et al, 1970). They represent 70-90% of the total immunoglobulin-
producing cells in the intestine (Brandtzaeg and Baklien, 1976). Intestinal MNCs
isolated from normal mucosa have been shown to secrete large amounts of IgA
spontaneously (MacDermott et al, 1983; MacDermott et al, 1986) and to have
different functional characteristics from peripheral blood MNCs which have been
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found to produce little IgA, IgG and IgM spontaneously (MacDermott et al, 1983;
MacDermott et al, 1981; MacDermott, 1988).
In IBD, the mucosal immune system shows an altered immuno-regulation with a
marked increase in IgG-containing cells. In vitro studies have shown that the total
numbers of lymphocytes in intestinal specimens from IBD patients were four times
greater than in normal mucosa with the major increase occurring in IgG-containing
cells (Brandtzaeg et al, 1974; Baklien and Brandtzaeg, 1975; Rosedrans et al,
1980; Scott et al, 1983; Van Spreeuwel et al, 1985). Compared with normal
control specimens, numbers of IgG-containing cells were found to be 30 times
greater while numbers of IgA-containing cells were found to be 2 times greater and
those of IgM-containing cells were 5 times greater than in normal control
specimens (Brandtzaeg et al, 1974; Baklien and Brandtzaeg, 1975).
Studies on total IgG (TIgG) and IgG subclasses in the mucosa of IBD patients,
showed that there was an increase in IgG 1-containing cells in the mucosa of UC
patients while the mucosa of patients with CD contained an increased number of
IgG2-containing cells (Kett et al, 1987). Compared to intestinal MNCs of normal
controls, MNCs of IBD patients exhibited a marked increase in spontaneous
secretion of TIgG with increased proportions of IgGl in MNCs from UC patients
and IgG2 in MNCs from CD patients (Scott et al, 1986).
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The differences in the IgG subclasses expression between the 2 diseases suggest
that there may be different antigenic stimuli since IgGl (and IgG3) are the
dominant antibodies in the immune response to proteins and T cell-dependent
antigens (Skakib and Stanworth, 1980; Heiner, 1984; Oxelius, 1984) whereas the
production of IgG2 antibody is mainly stimulated by carbohydrate and bacterial
antigens (Schreiber et al, 1992). This may account for the recurrent bacterial
infections such as otitis media, pneumococcal respiratory infections, pericarditis
and meningococcal infections reported to be associated with IgG2 and IgG4
deficiencies (Skakib and Stanworth, 1980; Heiner, 1984; Oxelius, 1984). Whether
the increased production of IgG and IgG subclasses represents defined responses
against specific antigens or merely up-regulation of non-specific responses to
common luminal antigens remains not well-understood.
In contrast to IgG, there have been conflicting reports regarding IgA synthesis and
secretion by the intestinal mucosa of IBD patients. MacDermott et al (1981; 1983)
reported decreased spontaneous IgA secretion by the isolated MNCs of intestinal
mucosa from IBD patients compared to normal controls. Furthermore, MNCs of
intestinal mucosa from IBD patients were found to produce more IgAl (up to 71-
74% of the total IgA) than IgA2 while the MNCs of intestinal mucosa from normal
controls produced more IgA2 (up to 61% of the total IgA) (MacDermott et al,
1986). Conversely, in one in vitro study, Badr El-Din et al (1988) reported a
significant increase in the number of IgA-plasma cells and in the production of
total IgA (TIgA) by colonic mucosa from patients with quiescent UC as compared
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to normal controls, but no concomitant increase in the amount of secretory IgA
(SIgA) was observed in the culture.
In a pilot study of the immunoglobulin concentrations in WGL fluid, O'Mahony et
al (1990) reported that no significant differences were found between levels of
TIgA in WGL fluid of patients with CD and the normal controls while levels of
IgG and IgM were found to be significantly higher in the patients group compared
to the normal control group. Similar results were reported by Mwantembe (1992)
who found that, regardless of disease activity, there were no significant differences
between levels of TIgA in WGL fluid of patients with IBD and normal controls.
However, the individuals used as a control group in the study of O'Mahony and
colleagues (1990) were patients who underwent WGL as a preparation for barium
enema or colonoscopy after presenting with one or more gastrointestinal problem(s)
such as irritable bowel syndrome (IBS) or constipation. Although these individuals
were reported to be "immunologically normal", this does not exclude the fact that
they were not healthy and using them as a normal control may produce confusing
results. The number of patients with CD involved in the study of O'Mahony et al
was relatively small (10 patients). Furthermore, the technique of WGL was at its
early stages and further improvements have been introduced into the methods of
administering the lavage solution (supervised by special nurse) and processing of
the lavage effluent. Results obtained by Mwantembe were widely scattered and the
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control group used for the comparative study was similar to that used by
O'Mahony.
Therefore, further research into the intestinal immune status of patients with IBD
by investigating levels of intestinal immunoglobulins, particularly IgA, has become
necessary. Furthermore, levels of intestinal immunoglobulins of patients with
active and quiescent IBD should be compared with levels of immunoglobulins in
the intestinal fluid of well characterised healthy individuals.
Aims of the study
In the light of the above studies reporting conflicting results on the intestinal
immunoglobulins, particularly IgA, of patients with IBD, one aim of the study was
to investigate the intestinal immune status of patients with active and inactive IBD
by studying levels of immunoglobulins in their WGL fluid and comparing them
with British adult healthy volunteers. The other aim of the study was to investigate
levels of intestinal immunoglobulins in WGL fluid of healthy individuals since
personal communication with Professor Svennerholm (University of Goteborg,
Sweden) indicated that levels of intestinal TIgA in healthy Swedish individuals
were much lower than those levels in the so called "normal patients" previously
reported from this centre.
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Therefore, for all the above reasons it was important to re-examine TIgA, TIgM
and TIgG in healthy individuals. I did not intend to carry out an extensive analysis
of IBD cases since such work is being carried out by other researchers in this
centre who are investigating the immunoregulatory mechanisms in IBD.
Patients and methods
Specimens of WGL fluid obtained from a group of 22 British adult healthy
volunteers (2 females and 20 males) with a median age of 27 years (ranged
between 22 and 44) were used as a normal control. This group is described in
more detail in chapter 6. WGL specimens obtained from patients who underwent
WGL during the year 1992 were reviewed and lavage samples found to be from
patients confirmed to have IBD (CD or UC) were selected. Most of these patients
underwent WGL as a bowel preparation for barium enema, colonoscopy and/or
bowel surgery. WGL specimens were stored at -70 °C after being collected and
processed as described in chapter 3. A total of 59 specimens were found to be of
IBD patients (32 females and 27 males) with a median age of 40 years, ranged
between 12 and 79. IBD patients were divided into 40 patients (23 females and 17
males) with CD and 19 patients (9 females and 10 males) with UC. Patients with
CD were further divided into subgroups of 16 patients (9 females and 7 males)
with active CD and 24 patients (14 females and 10 males) with inactive CD.
Likewise, patients with UC were further divided into subgroups of 9 patients (4
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females and 5 males) with active UC and 10 patients (5 females and 5 males) with
inactive UC.
Assessment of disease activity was based on the concentrations of TIgG in WGL
fluid of IBD patients. Previous work in this centre (Choudari et al, 1993; Ferguson
et al, 1994; Brydon et al, 1993; O'Mahony et al, 1991b) found that a level of >
10 pg/ml TIgG in WGL fluid was almost always consistent with clinical
assessment of active IBD while WGL fluid obtained from patients with inactive
IBD and normal individuals contained lower levels of TIgG.
Quantitative measurement of the concentrations of total IgA, IgM and IgG in WGL
specimens obtained during the year 1992 and specimens of the healthy volunteers
were carried out using ELISA. The technical details were as described in chapter 3.
Since all results obtained in this study were found to be non-parametrically
distributed, the Mann-Whitney U-test was used for the statistical analysis of the
data.
Results
The numerical data in sections 1-4 below are also shown in table 5.1.
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1. Concentrations of total IgA, IgM and IgG in WGL fluid of healthy
volunteers. The medians of the concentrations of total immunoglobulins in
WGL fluid were 73.25 pg/ml with a range of 10.00-173.20, 2.2 pg/ml with a
range of 0.1-9.5 and 1.0 ng/ml with a range of 1.0-2.0 for TIgA, TIgM and
TIgG respectively.
2. Concentrations of total IgA, IgM and IgG in WGL fluid of IBD patients as
a whole. When all 59 CD and UC patients were studied together as one group,
the medians of the concentrations of total immunoglobulins in WGL fluid were
146.0 pg/ml with a range of 31.0-520.0, 5.1 pg/ml with a range of 1.1-80.9
and 7.1 pg/ml with a range of 0.4-280.3 for TIgA, TIgM and TIgG
respectively.
3. Concentrations of total IgA, IgM and IgG in WGL fluid of patients with
Crohn's disease. As one group, patients with CD had the following medians
(and ranges): 137.0 pg/ml (49.0-520.0), 6.0 pg/ml (1.1-80.9) and 7.05 pg/ml
(0.5-280.0) for TIgA, TIgM and TIgG respectively. When patients with CD
were further divided into subgroups of active or inactive CD patients, they
were found to have the following medians (and ranges): (a) active CD patients
had medians of 154.0 pg/ml (65.0-413.0), 6.95 pg/ml (2.30-28.50) and 30.3
pg/ml (11.4-280.3) for TIgA, TIgM and TIgG respectively; (b) inactive CD
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patients had medians of 105.0 pg/ml (49.0-520.0), 4.5 pg/ml (1.1-80.9) and
3.35 pg/ml (0.50-9.00) for TIgA, TlgM and TIgG respectively.
4. Concentrations of total IgA, IgM and IgG in WGL fluid of patients with
ulcerative colitis. As one group, patients with UC were found to have the
following medians (and ranges): 236.0 pg/ml (31.0-453.0), 4.60 pg/ml (2.30-
43.70) and 7.30 pg/ml (0.40-236.40) for TIgA, TlgM and TIgG respectively.
When patients with UC were further divided into subgroups of active or
inactive UC patients, they were found to have the following medians (and
ranges): (a) active UC patients had medians of 294.0 pg/ml (68.0-453.0), 8.90
pg/ml (2.50-43.70) and 52.5 pg/ml (17.0-236.4) for TIgA, TlgM and TIgG
respectively; (b) inactive UC patients had medians of 92.0 pg/ml (31.0-365.0),
3.90 pg/ml (2.30-16.50) and 1.90 pg/ml (0.40-7.30) for TIgA, TlgM and
TIgG respectively.
5. Comparison between levels of total IgA in WGL fluid of healthy volunteers
and patients with Crohn's disease. When levels of TIgA in WGL fluid of
healthy volunteers were compared with levels of TIgA in WGL fluid of patients
with CD regardless of disease activity, patients with CD were found to have
significantly higher levels of TIgA than had healthy volunteers (p =0.0003)
(table 5.1 and Fig. 5.1). When patients with CD were divided into patients with
active or inactive CD, patients with either active or inactive CD were found to
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have significantly higher levels of TIgA than had healthy volunteers (p values
were 0.0003 and 0.006 for active and inactive CD versus healthy volunteers
respectively) (table 5.1 and Fig. 5.IV).
6. Comparison between levels of total IgA in WGL fluid of healthy volunteers
and patients with ulcerative colitis. When levels of TIgA in WGL fluid of
healthy volunteers were compared with levels of TIgA in WGL fluid of patients
with UC regardless of disease activity, patients with UC were found to have
significantly higher levels of TIgA than had healthy volunteers (p =0.003)
(table 5.1 and Fig. 5.1). When patients with UC were further divided into
patients with active or inactive UC, levels of TIgA were found to be
significantly higher in WGL fluid of patients with active UC than in healthy
volunteers (p =0.0003) but no significant differences were found between levels
of TIgA in WGL fluid of patients with inactive UC and those of healthy
volunteers (p =0.208) (table 5.1 and Fig. 5.IV).
7. Comparison between levels of total IgM in WGL fluid of healthy
volunteers and patients with Crohn's disease. As one group, patients with
CD were found to have significantly higher levels of TIgM than did healthy
volunteers (p=0.0001) (table 5.1 and Fig. 5.II). Likewise, when patients with
CD were divided into patients with active or inactive CD, levels of TIgM in
patients with CD, regardless of disease activity, were found to be significantly
higher than those of healthy volunteers (p values were 0.0001 and 0.001 for
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active and inactive CD versus healthy volunteers respectively) (table 5.1 and
Fig. 5.V).
8. Comparison between levels of total IgM in WGL fluid of healthy
volunteers and patients with ulcerative colitis. As one group, patients with
UC were found to have significantly higher levels of TIgM than had healthy
volunteers (p=0.0002) (table 5.1 and Fig. 5.11). When patients were divideJinto
patients with active or inactive UC, patients with UC, regardless of disease
activity, were found to have significantly higher levels of TIgM than had
healthy volunteers (p values were 0.0006 and 0.010 for active and inactive UC
versus healthy volunteers respectively) (table 5.1 and Fig. 5.V).
9. Comparison between levels of total IgG in WGL fluid of healthy volunteers
and patients with Crohn's disease. As one group, patients with CD were
found to have significantly higher levels of TIgG than had healthy volunteers
(p=0.0001) (table 5.1 and Fig 5.III). Regardless of disease activity, levels of
TIgG in WGL fluid of patients with CD were found to be significantly higher
than in healthy volunteers (p values were 0.0001 and 0.0003 for active and
inactive CD versus healthy volunteers respectively) (table 5.1 and Fig 5.VI).
10. Comparison between levels of total IgG in WGL fluid of healthy volunteers
and patients with ulcerative colitis. As one group, patients with UC were
found to have higher levels of TIgG than had healthy volunteers (p=0.0001)
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(table 5.1 and Fig. 5.III). Likewise, regardless of disease activity, patients with
UC were found to have higher levels of TIgG than had healthy volunteers (p
values were 0.0001 and 0.034 for active and inactive UC versus healthy
volunteers respectively) (table 5.1 and Fig. 5.VI).
11. Comparison between levels of total IgA and IgM in WGL fluid of patients
with active and inactive Crohn's disease. When levels of TIgA in WGL fluid
of patients with active CD were compared with those of patients with inactive
CD, no significant differences were found between the 2 subgroups
(p =0.1633). Likewise, no significant differences were found between levels of
TIgM in WGL fluid of patients with active and inactive CD (p=0.1633) (table
5.II).
12. Comparison between levels of total IgA and IgM in WGL fluid of patients
with active and inactive ulcerative colitis. No significant differences were
found between levels of TIgA in WGL fluid of patients with active and inactive
UC (p =0.094). Likewise, no significant differences were found between levels




Immunoglobulin A (IgA) was found to be the predominant immunoglobulin in
WGL fluid of both healthy volunteers and IBD patients. While WGL fluid of the
healthy volunteers contained only traces of TIgM and TIgG, WGL fluid of patients
with IBD contained large amounts of TIgM and, in particular, TIgG. Compared to
healthy volunteers, and regardless disease activity, WGL fluid of patients with CD
and UC contained significantly higher levels of TIgA, TIgM and TIgG. Patients
with active CD or UC had significantly higher levels of TIgA, TIgM and TIgG in
WGL fluid than had healthy volunteers. While patients with inactive CD had
significantly higher levels of TIgA, TIgM and TIgG than did healthy volunteers,
patients with inactive UC had significantly higher levels of TIgM and IgG than did
healthy volunteers but no significant differences were found between levels of
TIgA in WGL fluid of healthy volunteers and patients with inactive UC.
Within the subgroups of CD and UC patients, no significant differences were found
between levels of TIgA or IgM in WGL fluid of patients with active CD and
patients with inactive CD. Likewise, no significant differences were found between
levels of TIgA or TIgM in WGL fluid of patients with active UC and patients with
inactive UC.
The above findings indicated that IBD is associated with major alteration in levels
of intestinal immunoglobulins, particularly TIgG. The intestinal secretions of
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patients with IBD exhibited a marked polyclonal up-regulation of IgA, IgM and
IgG. Whether the increase in polyclonal immunoglobulins in IBD patients was due
to leakage from the systemic circulation or due to increase in local production is, as
yet, unknown. Since levels of TIgA and TIgM in WGL fluid of patients with active
IBD overlapped with those of inactive IBD, these levels can not be used as indices
for disease activity in IBD.
Accurate and reliable analysis of intestinal immunoglobulins in IBD patients may
provide an important clue(s) into the pathophysiology and immunopathology of
IBD.
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Fig. 5.1. Concentrations of TIgA in WGL fluid of healthy volunteers compared to
patients with Crohn's disease (CD) and ulcerative colitis (UC). * =Median. Bars










Fig. 5.H. Concentrations of TIgM in WGL fluid of healthy volunteers compared to
patients with Crohn's disease (CD) and ulcerative colitis (UC). *=Median. Bars




















Fig. 5.HI. Concentrations of TIgG in WGL fluid of healthy volunteers compared

























Fig. 5.IV. Concentrations of TIgA in WGL fluid of healthy volunteers compared
to active & inactive Crohn's disease (CD) and active & inactive ulcerative colitis
(UC). • =median. * = levels are significantly higher than healthy volunteers. Bars























Fig. 5.V. Concentrations of TIgM in WGL fluid of healthy volunteers compared to
active & inactive Crohn's disease (CD) and active & inactive ulcerative colitis
(UC). *=median. *= levels are significantly higher than in healthy volunteers.





























Fig. 5.VI. Concentrations of TIgG in WGL fluid of healthy volunteers compared
to active & inactive Crohn's disease (CD) and ulcerative colitis (UC).
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Chapter VI
THE INTESTINAL IMMUNE RESPONSES TO THE
ORAL TYPHOID VACCINE Tv21a
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Introduction
Humans are the only host for Salmonella typhi and infection may follow
ingestion of contaminated food or water with clinical illness (typhoid fever)
developing after an incubation period of 7-14 days. It has been estimated that
about 33 million cases of typhoid fever occur annually world-wide (Institute of
Medicine, 1986) and although patients with typhoid (as well as paratyphoid)
fever are encountered in all parts of the world, they are now primarily found in
those countries of the developing world where sanitary conditions and the
standards of personal and food hygiene are poor.
In developed countries with good sewerage and water supply systems, most
cases of typhoid fever are sporadic and either imported (by travellers or
imported food) or can be traced to contact with a chronic carrier
(approximately 3% of patients with typhoid fever become chronic carriers)
(Hoffman, 1991). In the tropics and subtropics, epidemics occur, with the peak
of incidence in the hot and dry months of the year when the concentration of
the organisms in the water is higher (not diluted by rain) (Hoffman, 1991).
However, the majority of cases of typhoid fever are found in endemic areas
where the annual blood culture-positive attack rate may be more than
1000/100,000 population per year (Simanjuntak et al, 1991).
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In most endemic areas the incidence of typhoid fever is higher among children
who are 5-19 years old (Edelman and Levine, 1986; Ashcroft, 1962) i.e.
schoolchildren. This is of potential relevance in the control of typhoid fever
since schoolchildren represent an important group in which typhoid fever can
be controlled by school-based immunisation programmes.
Vaccination against typhoid fever is particularly important since, as mentioned
above, it is an important enteric infection among school-age children in the
developing countries. Furthermore, there are increasing numbers of reports
about the appearance of multiple drug-resistant Salmonella spp. world-wide.
Particularly problematic are species resistant to the three main antibiotics which
are traditionally used for the treatment of enteric infection; chloramphenicol,
ampicillin, and co-trimoxazol (Rowe et al, 1990). The increase in the number
of travellers who lack natural immunity against typhoid fever from
industrialised countries to areas known to be endemic for typhoid fever has
increased the need to develop a vaccine against this enteric infection.
Until recently, protection against typhoid fever could only be provided by
parenteral vaccines of heat-killed, phenol- or acetone-preserved whole-cell
Salmonella typhi organisms. Parenteral killed whole-cell typhoid vaccines have
been available since 1896 (Groschel and Hornick, 1981) and have been used
throughout this century. Two doses of these vaccines, 4-6 weeks apart,
provides significant protection against typhoid fever in endemic areas (varied
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from 51 to 88%) among children and adults for around 3 years (Levine et al,
1989). However, local and systemic side effects associated with the
administration of these vaccines are common and it has been estimated that
between 25 and 50% of the vaccinees will have an adverse reaction following
the administration of the vaccine (Hoffman, 1991) in addition to the fact that
the above vaccines must be given parenterally. More details about the
disadvantages of parenterally-administered vaccines were described in chapter
2.
The above drawbacks of the parenterally-administered killed whole-cell
vaccines stimulated intensive research seeking oral vaccines with minimal side
effects. As a result, a live attenuated oral typhoid vaccine was developed in the
early 1970s by chemical mutagenesis of a pathogenic strain of Salmonella typhi
with the production of the vaccine strain Ty21a (gal-E mutant strain)
(Germanier and Fiirer, 1975). The appearance of the vaccine Ty21a offered
new hope of an effective oral vaccine without significant side effects. Details of
the development of this vaccine were cited in chapters 2 and 3 of this thesis.
The vaccine Ty21a has been demonstrated to be genetically stable, safe and
provided a significant protection against experimentally challenged Salmonella
typhi at a dose of 10 , a dose that caused typhoid fever in 53% of unimmunised
control volunteers (Germanier and Fiirer, 1975; Gilman et al, 1977). Field
studies into the protective efficacy of the vaccine Ty21a have shown various
182
degrees of protection against typhoid fever between 42 and 96% (Simanjuntak
etal, 1991; Wahdanetal, 1980).
Based on the results of the protective efficacy obtained from the field trials, the
vaccine Ty21a has been licensed in USA, Australia and many European
countries, including UK, for the prophylaxis against typhoid fever. The
recommended dosages, schedules and formulation of the vaccine have varied
from country to another. For instance, in the USA four doses of the vaccine
Ty21a has been recommended to be taken every other day (Wolfe, 1990) while
in the UK only three doses of the vaccine has been recommended to be taken
on three alternate days in the form of enteric-coated capsules (Department of
Health, 1992).
In spite of the fact that the aim of administering an oral live vaccine, such as
Ty21a, is to stimulate specific intestinal antibodies, in particular secretory IgA
(SIgA), yet an extensive research work has been directed to field trials
measuring the protective efficacy of the vaccine (Wahdan et al, 1980; Levine et
al, 1987; Simanjuntak et al, 1991) or the immune response in the serum of the
vaccinees (Black et al, 1983). Field trials have assessed the protective efficacy
of the vaccine in different areas with different rates of incidence of infection.
However, there is no evidence that the vaccine Ty21a provides protection
against naturally-acquired infection with typhoid fever in healthy adults from
non-endemic areas. Furthermore, as was mentioned in chapter 2, it is now
widely accepted that systemic immunity is quite separate from mucosal
immunity and thus the findings in serum cannot be extrapolated to the gut.
Forrest et al (1991) investigated the effect of a variety of formulations, dosages
and the timing of administration of the vaccine Ty21a in a group of healthy
Australian soldiers using jejunal aspirate as a material for the study. However,
in another study Forrest (1992a) accepted that obtaining jejunal fluids is an
invasive, labour-intensive procedure, which is inconvenient for the patient and
the investigator. In addition, the findings in the jejunal aspirate may only
reflect the state of the immune response at the level of the jejunum and not the
whole gut.
Therefore, investigation of the effect of the oral live typhoid vaccine Ty21a in
British healthy volunteers by using WGL technique may provide a better
understanding of the kinetics of the immune response against this vaccine in the
complex micro-environment of the gut.
Subjects and methods
A total of 25 adult healthy British volunteers (2 females and 23 males) were
recruited for this study. Of these volunteers, 22 (2 females and 20 males)
completed the experiment successfully. Three volunteers were excluded for a
variety of reasons (see below). The median age of the 22 volunteers was 27
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with a range of 22-44 years. The volunteers recruited for this study were
selected from the records of the Clinical Research Centre of the Department of
Medicine, University of Edinburgh. Selection of the volunteers was based on
the following criteria: the age, alcohol drinking, and smoking habit. Subjects
aged less than 20 or more than 60 years and subjects who drink more than 20
units of alcohol per week were excluded. Only subjects who are either heavy
smokers (smoke more than 20 cigarettes per day for the last 3 years or more) or
absolutely non-smokers were selected. The reason for selection of heavy
smokers and non-smokers in this study was to investigate the effect of smoking
on the gut immunity and whether a mitogen such as the oral typhoid vaccine
Ty21a would boost an antigen-specific intestinal immune response in this group
(see chapter 8).
Volunteers were sent an information sheet explaining the aim of the study,
WGL procedure and the preparatory procedures to be followed should the
candidate wish to take part in the study. Written consent was obtained in
advance from every volunteer. Subjects were asked to attend two sessions of
WGL with an interval of 3 weeks between the first and the second session.
Before subjects started drinking the lavage solution on their first visit, 10-20
mis of venous blood samples were taken and an information sheet for every
participant was completed. The information sheets contained information about
previous vaccination, particularly typhoid vaccine, history of travelling abroad
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highlighting visits to third world countries where typhoid fever is known to be
endemic, and history of infection especially with Salmonella typhi or
Salmonella paratyphi A, B or C. The information sheet also included records
about drug intake, smoking and alcohol drinking habits. In addition, history of
previous surgical and/or medical illness, other than infection, was recorded. A
copy of the above mentioned information sheet is included in the appendix of
this thesis. The procedure of WGL technique proceeded as described in chapter
3.
Three subjects were excluded from the study (all males) due to the following
reasons. One volunteer was found, during completion of the information sheet,
to be diabetic and on oral hypoglycaemic tablets. Another volunteer was
excluded from the study because he failed to complete the first session of WGL
because he had nausea one hour after he started drinking the lavage solution.
Although the third volunteer had successfully completed the first session of
WGL, he had to leave Edinburgh and was not able to attend the second session
of the WGL and therefore he was excluded from the study.
After subjects completed the first session of WGL, they were given 3 enteric-
coated capsules of the oral typhoid vaccine Ty21a, with each capsule containing
9
2 x 10 live Salmonella typhi organisms, to be taken on days 1, 3 and 5 (day 0
was day of the first WGL session) one hour before or after meal.
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Volunteers returned 3 weeks later for the second session of WGL. Another
blood sample was taken from every volunteer and further information about
any side effect(s) observed following ingestion of the capsules containing the
vaccine were recorded before subjects start drinking the lavage solution as
described before.
Since results obtained in this study were found to be non-parametric and
paired, the Wilcoxon signed-rank test was used for the statistical analysis of the
data.
Assays performed
1. ELISA: for the quantitative measurement of total immunoglobulins in
processed WGL specimens. Measurement of total immunoglobulins in
serum was carried out in the Department of Clinical Biochemistry, WGH.
2. ELISA: for the quantitative measurement of antigen-specific antibodies
(anti-Salmonella typhi LPS antibodies) both in processed lavage specimens
and in serum. The technical details of the above assays have already been
described in chapter 3.
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3. ELISA: for the quantitative measurement of anti-Rc mutant of Salmonella
typhimurium antibodies in processed lavage samples. Salmonella is a
member of the Enterobacteriaceae family which is a large heterogeneous
group of Gram-negative bacilli whose natural habitat is the intestinal tract
of humans and animals. Therefore, antigens of Salmonella typhi may be
shared not only by other strains of Salmonella species but also by other
members of family. Thus, whether the intestinal immune responses
stimulated after administration of the oral typhoid vaccine Ty21a were
specific to Salmonella typhi antigens, or due to cross-reaction with antigens
of Salmonella species other than Salmonella typhi, or antigens of other
members of the Enterobacteriaceae family, had to be further investigated.
Rc mutant antigen of Salmonella typhimurium is a common antigen shared
with at least 3 members of the Enterobacteriaceae family (E. coli, Shigella
and Salmonella). Therefore, Rc mutant antigen was exploited to confirm
that the anti-Salmonella typhi LPS immune response induced after
administration of the vaccine Ty21a was specific for the Salmonella typhi
organisms and not due to non-specific immune up-regulation i.e. to exclude
the possibility that the increase in the post-vaccination anti-Salmonella typhi




1. The oral typhoid vaccine Ty21a: apart from mild abdominal discomfort
reported by one volunteer, the oral live typhoid vaccine Ty21a was well-
tolerated by all other subjects involved in this study and there were no side
effects or complaints about this vaccine.
2. Total IgA: the median value of the pre-vaccination total IgA (TIgA) in
WGL fluid of 22 volunteers was 73.25 pg/ml with a range of 10.00-173.20
whereas the median of the post-vaccination TIgA was 69.60 pg/ml with a
range of 20.00-225.30. There was no significant difference between pre-
and post-vaccination TIgA (p=0.63). (Fig 6.1)
3. Total IgM: the median value of the pre-vaccination total IgM (TIgM) in
lavage specimens was 2.20 pg/ml with a range of 0.10-9.50 whereas the
median of the post-vaccination TIgM was 1.75 pg/ml with a range of 0.10-
5.10. There was no significant difference between pre- and post-vaccination
TIgM (p=0.16). (Fig. 6.II).
4. Anti-Salmonella typhi LPS IgA antibodies in WGL fluid: the median of
the pre-vaccination IgA in WGL fluid was 57.30 units/mg of TIgA with a
range of 12.00-265.10 whereas the median of the post-vaccination IgA was
120.20 units/mg of TIgA with a range of 6.90-1518.60. There was an
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overall significant increase in the post-vaccination specific IgA in WGL
specimens (p=0.018). (Fig. 6.III).
There was a significant increase in specific IgA in lavage specimens of 14 out
of 22 volunteers (63.6%) after vaccination with the oral typhoid vaccine
Ty21a. However, there was a significant decrease in specific IgA in the lavage
specimens of 4 out of 22 volunteers (18.2%). Four volunteers out of 22 were
found to have no significant change in specific IgA in their lavage samples.
Results were considered to be significantly increased or decreased if the
changes were found to be more than 20% greater or less than the basic values.
This is because the inter-assay coefficient of variation of the ELISA used in this
assay was about 15-20%.
5. \nti-Salmonella typhi LPS IgM antibodies in WGL fluids: the median of
the pre-vaccination specific IgM in WGL specimens was 0.10 units/ml with
a range of 0.10-1.60 whereas the median of the post-vaccination specific
IgM was 0.65 with a range of 0.10-12.10 units/ml. There was an overall
significant increase in the post-vaccination specific IgM (p =0.006). (Fig.
6.IV).
6. Anti-Salmonella typhi LPS IgA antibodies in serum: the median of the
pre-vaccination specific IgA in the serum of 22 volunteers was 407.00
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units/ml with a range of 46.00-7150.00 whereas the median of the post-
vaccination specific IgA was 727.00 units/ml with a range of 42.00-
7274.00. There was an overall significant increase in post-vaccination
specific IgA in the serum of 22 healthy volunteers (p=0.004). (Fig.
6.V).
7. Anti-Salmonella typhi LPS IgM antibodies in serum: the median of the
pre-vaccination specific IgM in serum was 791.00 units/ml with a range of
277-5540 whereas the median of the post-vaccination specific IgM was
920.00 units/ml with a range of 373.00-6446.00. There was an overall
significant increase in the post vaccination specific IgM in the serum of 22
healthy volunteers (p =0.014).
8. Anti-Salmonella typhi LPS IgG antibodies in serum: the median of the
pre-vaccination specific IgG in the serum was 511.0 units/ml with a range
of 167.0-4499.0 whereas the median of the post-vaccination specific IgG
was 720.0 units/ml with a range of 169.0-46267.0. There was an overall
significant increase in the post-vaccination specific IgG in the serum of 22
healthy volunteers (p =0.009). (Fig. 6.VI).
9. The correlation between specific antibodies in lavage fluid and serum:
The correlation between anti-S. typhi LPS IgA antibodies in WGL fluid and
serum before and after vaccination was studied in order to investigate the
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relationship, if any, between systemic (serum) and local (WGL fluid)
humoral immune responses. There was no association between anti-S. typhi
LPS IgA antibodies in WGL fluid and serum before or after vaccination
(r=0.077, p=0.732 for the correlation before vaccination; r=0.255,
p=0.252 for the correlation after vaccination) (Fig. 6.VII). The correlation
between the increase in specific IgA antibodies in lavage fluid and the
increase in specific IgA antibodies in serum after vaccination was also
investigated and it was found that there was no association between the
changes in serum and those in WGL specimens (r=0.25, p=0.252).
Likewise, it was found that there was no association between the increase in
specific IgM antibodies in lavage fluid and serum (r=0.36, p=0.10).
The correlation between levels of anti-S. typhi LPS IgA in WGL fluid and anti-
S. typhi IgG antibodies in serum before and after vaccination was also
investigated and it was found that there was no correlation between the above
antibodies (r=142, p=0.527 for the correlation before vaccination; r=0175,
p=0.437 for the correlation after vaccination) (Fig. 6.VIII). Likewise, the
correlation between the increase in specific IgA antibodies in lavage fluid and
the increase in specific IgG antibodies in serum was also investigated and it was
found that there was no association between changes of specific IgA in lavage
fluid specimens and specific IgG antibodies in serum (r=0.28, p=0.20).
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10. Anti-Rc mutant of Salmonella typhimurium IgA antibodies in WGL
fluids: the median of the pre-vaccination anti-Rc mutant IgA antibodies was
found to be 166.30 units/ml with a range of 2.00-1324.60 whereas the
median of post-vaccination anti-Rc mutant IgA antibodies was 242.30
units/ml with a range of 38.10-1206.20. There was no significant increase
in the post vaccination anti-Rc mutant IgA antibodies (p =0.127). (Fig.
6.IX).
Conclusion
The live oral typhoid vaccine Ty21a was well-tolerated, safe and produced
minimal, if any, side effects. This vaccine, given at 3 doses (each dose contains
9
2 x 10 live Salmonella typhi organisms) over 3 alternate days in the form of
enteric-coated capsules, significantly increased specific intestinal IgA antibodies
in 14 out of 22 (63.6%) adult healthy British volunteers. Although there was an
overall increase in the anti-Salmonella typhi LPS antibodies in the serum of the
volunteers involved in this study, yet the statistical tests carried out to
investigate the relationship between the increase in the quantity of specific
antibodies in serum and those in lavage fluid have clearly demonstrated that
there is no association between systemic and intestinal humoral immune
responses to the oral typhoid vaccine Ty21a.
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The indirect ELISA method used for the quantitative measurement of anti-
Salmonella typhi LPS antibodies to investigate the effect of the oral typhoid
vaccine on gut immunity was shown to be specific. The anti-Salmonella
typhi LPS antibodies due to a cross-reacting antigen(s) were not significantly
increased.
I also concluded that the technique of WGL is non-invasive, safe and well-
tolerated by most of the volunteers. Furthermore, WGL is a reliable method for
obtaining material to study gut immunity.
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Fig. 6.1. Pre- & post-vaccination TlgA in WGL fluid of 22 British healthy
volunteers involved in the study of the effect of the oral typhoid vaccine Ty21a
on gut immunity. Bars show the upper and lower quartiles of the ranges.
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Fig. 6.H. Pre- & post-vaccination TlgM in WGL fluid of 22 British healthy
volunteers involved in the study of the effect of the oral typhoid vaccine Ty21a
on gut immunity. Bars show the upper and lower quartiles of the ranges.
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Pre & Post Vaccination Anti-Ty21a IgA in Lavage Fluids
Fig. 6.III. Pre- & post-vaccination anti-S. typhi LPS IgA antibodies in WGL
fluid of 22 British healthy volunteers involved in the study of the effect of the
oral typhoid vaccine Ty21a on gut immunity.
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Fig. 6.IV. Pre & post-vaccination anti-S typhi LPS IgM antibodies in WGL
fluid of 22 British healthy volunteers involved in the study of the effect of the
oral typhoid vaccine Ty21a on gut immunity.
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Fig. 6.V. Pre- & post-vaccination anti-S. typhi LPS IgA antibodies in serum of
22 British healthy volunteers involved in the study of the effect of the oral
typhoid vaccine Ty21a on gut immunity.
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Fig. 6.VI. Pre- & post-vaccination anti-S. typhi LPS IgG antibodies in serum
of 22 British healthy volunteers involved in the study of the effect of the oral
typhoid vaccine Ty21a on gut immunity.
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Fig. 6.VII. The correlation between concentrations of anti-S. typhi LPS IgA
antibodies in WGL fluid and serum, before and after vaccination, of 22 British
healthy volunteers involved in the study of the effect of the oral typhoid
vaccine Ty21a on gut immunity.
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Fig. 6.Vni. The correlation between concentrations of anti-S. typhi LPS IgA
antibodies in WGL fluid and anti-S. typhi LPS IgG antibodies in serum, before
and after vaccination, of 22 British healthy volunteers involved in the study of
the effect of the oral typhoid vaccine Ty21a on gut immunity.
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Fig. 6.IX. Pre- & post-vaccination anti-S1. typhimurium Rc-mutant IgA
antibodies in WGL fluid of 22 British healthy volunteers involved in the
study of the effect of the oral typhoid vaccine Ty21a on gut immunity.
Bars show the upper and lower quartiles of the ranges.
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Chapter VII




The genus Salmonella was so named in honour of Daniel Elmer Salmon, a
veterinary pathologist who was the director of the Bureau of Animal Industry in
Washington DC, where the organism Salmonella cholerae-suis was discovered by
his assistant Theobald Smith in 1885 (Grady and Keusch, 1971). Salmonella
cholerae-suis was thought, incorrectly, by Smith, to be the causative organism of
the swine cholera (a viral disease).
Microbiology
Salmonella is a genus of the family Enterobacteriaceae, a large heterogeneous
group of Gram-negative bacilli. Salmonella spp. are non-capsulated, non-
sporulating aerobic bacilli that usually ferment glucose, mannitol and maltose, but
not lactose, producing acid and gas (with the exception of Salmonella typhi which
produces acid but not gas). With the exception of Salmonella gallinarum and
Salmonella pullorum, all Salmonella spp. are almost always motile by peritrichous
flagella which may be expressed in two or more antigenic forms (H antigens).
In addition to the flagellar (H) antigens, Salmonella spp., like other members of
the family Enterobacteriaceae, possess one or more somatic (O) antigens on which
the Kauffmann-White classification of Salmonella spp. is based (Kauffmann,
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1969). These are due to lipopolysaccharide (LPS) structure and have been grouped
A to Z with additional numbered categories. An additional somatic, heat-labile
antigen known as Vi (virulence) antigen (also known as the capsular or K antigen)
is found in Salmonella typhi and Salmonella paratyphi C and prevents agglutination
with anti-0 antisera. Virulence of particular strain of Salmonella in mice was found
to be positively correlated with the amount of Vi antigen possibly due to the fact
that the capsule provides additional protection from phagocytosis (see chapter 2).
However, some strains of Salmonella typhi that lack the Vi antigens can cause
disease in man (Griffiths and Gorbach, 1993).
The Kauffmann-White classification of Salmonella spp. includes more than 2000
combinations of O and H antigens and although pathogenic Salmonella organisms
are grouped A to Z, more than 90% of the human pathogenic salmonellae fall into
groups A to E which contain 40 serotypes.
An alternative approach to the Kauffmann-White classification of Salmonella spp.,
is the classification based on the host specificity (Candy and Stephen, 1988).
According to this classification, Salmonella spp. are divided into 3 main
categories: Salmonella typhi (one serotype) infecting only man; Salmonella
cholerae-suis (one serotype) infecting swine; and Salmonella enteritidis
(approximately 1700 serotypes) which may infect humans or animals.
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Salmonella spp. are found in the intestinal tract of many vertebrates and in the
internal organs and bloodstream of some invertebrates. Salmonella organisms have
been found in whales, tortoises, house flies, sheep, rats, chicken, buffalo etc.
(Griffiths and Gorbach, 1993). They are also found in rivers, sea water and sewage
(Snydman and Gorbach, 1991). Salmonellae cause major food-born diseases on a
global basis of both personal and economic importance world-wide (Rodrigue et al,
1990). Although the incidence of typhoid fever has declined in many developed
countries, the incidence of non-typhoidal salmonellosis may actually be rising
(Longfield, 1991). In the USA, it has been estimated that there are approximately
0.8-3.7 million cases of food poisoning due to Salmonella each year (Chalker and
Blaser, 1988).
Contaminated food is understandably the most frequent vehicle for transmission of
Salmonella organisms. Outbreaks are often traced to commercially processed meat
and meat products, inadequately cooked poultry and unpasteurized milk or dairy
products. In the USA, pets have been implicated in about 3% of outbreaks of
salmonellosis (Centres for Disease Control, 1986). Other routes of transmission
include flies and other insects. Recently, gastrointestinal endoscopy has also been
found to be responsible for transmission of Salmonella organisms (Longfield,
1991).
There are many factors which make understanding of the pathogenesis and
immunopathology of salmonella infection an extremely difficult task. In
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addition to the fact that a large number of Salmonella serotypes are responsible for
human diseases, there appear to be a variety of potential virulence factors among
the various serotypes. Vi antigen and the outer membrane LPS are two independent
virulence factors and it has been found that different strains of Salmonella
organisms are virulent at different infective doses (Carter et al, 1987). For
instance, Salmonella pullorum, a chicken pathogen, was found to be unable to
9 5
produce diseases in humans at a dose of 10 while only 10 Salmonella newport
were found to cause overt diseases in some volunteers.
In humans, salmonellae produce a wide range of diseases which varies from
asymptomatic carrier through a self-limited enteritis to typhoid fever (see below).
The important pathogenic event associated with salmonella infection is the invasion
of the epithelium of the terminal ileum and colon (Keusch, 1991) which has been
suggested to occur through M cells (Sneller and Strober, 1986). The possible
relationship between gut pathogens and M cells was described in chapter 2.
Clinical syndromes associated with salmonella infection include the following, (a)
Gastroenteritis: this accounts for about 75% of documented salmonella infection
and is characterised by nausea, vomiting, abdominal pain followed by diarrhoea
which may last from 3 to 5 days. Diarrhoea varies from minimal to dysenteric with
purulent and bloody stools and even cholera-like diarrhoea (Black et al, 1960). The
latter type of diarrhoea is most frequently seen in individuals with achlorhydria
(Gray and Trueman, 1971). (b) Bacteraemia: this is found in about 10% of cases.
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It varies from transient bacteraemia accompanying some cases of gastroenteritis to
bacteraemia which may result in lethal shock (Griffiths and Gorbach, 1993). (c)
Localised Infection: this accounts for about 5% of salmonella infection and may
occur in any organ following bacteraemia resulting in endocarditis, meningitis,
arteritis, osteomyelitis etc. (Black et al, 1960). There is a well-known association
between sickle cell anaemia and salmonella osteomyelitis, (d) Enteric fever: this is
caused by Salmonella typhi (causes typhoid fever) and Salmonella paratyphi A,
Salmonella paratyphi B and Salmonella paratyphi C (cause paratyphoid fever).
Typhoidal salmonella infection differs from non-typhoidal infection in being
primarily a systemic and not intestinal illness. Typhoid and paratyphoid fever
remain a serious health problem in the developing countries. Typhoid fever has
been described in chapter 6. (e) Chronic asymptomatic carrier state: if Salmonella
organisms continue to persist for more than one year, the patient is regarded as a
chronic carrier. The carrier state may follow both typhoidal or non-typhoidal
infection, after either symptomatic or asymptomatic infection. It has been estimated
that about 0.2-0.6% of non-typhoidal and 1-3% of typhoidal Salmonella cases will
become chronic carriers (Musher and Rubenstein, 1973; Kaye, 1991).
Mechanisms of diarrhoea due to salmonella infection
The precise mechanism(s) of diarrhoea associated with salmonella infection is (are)
not yet well-understood. However, three mechanisms have been suggested for the
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diarrhoea due to salmonella infection, (a) Salmonella organisms may produce
toxins (enterotoxins) which stimulate fluid secretion into the gut lumen.
Enterotoxins produced by Shigella organisms (Shiga toxins) are known to cause
secretion of fluid into gut lumen resulting in accumulation of large amount of fluid
and causing diarrhoea (Keusch et al, 1972). (b) Invasion of the gut epithelium by
Salmonella organisms results in interaction with polymorphonuclear cells that then
release prostaglandins at the site of invasion thereby causing diarrhoea (Gorbach,
1988). (c) Damaged epithelium may be unable to reabsorb fluids from the gut
lumen resulting in accumulation of fluid in the gut lumen and diarrhoea (Griffiths
and Gorbach, 1993).
The intestinal immune responses against bacterial infection of the gut
In addition to a number of non-specific defence mechanisms by which the intestine
is protected from colonisation by bacteria (see chapter 2), there are specific
immune mechanisms that provide additional protection of the gut. These are the
humoral immune responses and cell-mediated immunity.
Intestinal humoral immune responses. Bacterial infection of the gastrointestinal
tract normally produces an intestinal secretory antigen-specific immune responses,
usually SIgA (Chan et al, 1981). The unique structure of SIgA renders this
antibody well-suited to protect the intestinal mucosal surface (see chapter 2 for the
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structure and function of SIgA). SIgA antibodies have been reported to appear
within one week of the onset of bacterial infection and within as little as 3 days
after re-immunisation (Svennerholm et al, 1984a). In addition to the function of
immune exclusion known to be performed by SIgA, it has recently been shown that
SIgA mediates antibody-dependent T cell-mediated cytotoxicity (Tagliabue et al,
1984) and interferes with the utilisation, by bacteria, of necessary growth factors
such as iron in the intestinal environment (Holmgren and Svennerholm, 1992).
Furthermore, it has been suggested that SIgA may play a role in the inductive stage
of the mucosal immune responses by facilitating antigen uptake by Peyer's patches
(Holmgren and Svennerholm, 1992).
Cell-mediated immune responses. Cell mediated mucosal immune reactions
through major histocompatibility complex (MHC)-restricted cellular cytotoxicity,
natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity have
been shown to play an important role in the intestinal mucosal immunity against
invasive enteric infection caused by Salmonella organisms (Tagliabue et al, 1984).
Interferon gamma (IFN-y)-producing T cells have been reported to be significantly
increased in number in the human duodenal mucosa after intestinal antigenic
challenge and it has been suggested that these cells may play an important role in
the intestinal mucosal immune defence (Tagliabue et al, 1992). IFN-y has been
shown to increase IgA production, MHC antigen expression and the expression of
the secretory-component receptors on the enterocytes surfaces (Brandtzaeg et al,
1990). Furthermore, IFN-y has been found to interfere with the tight junctions
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between intestinal epithelial cells, in vitro, such that permeability is increased. It
also interfere with the receptivity of epithelial cells to invasive enteric pathogens
(Holmgren et al, 1989).
Generally, intestinal infections with Salmonella seem to prime the intestinal
immune system. Responses elicited by salmonella infection (as well as other enteric
pathogens) vary and depend, to a large extent, on the virulence factors of the
pathogen, mode of the reaction by the host, and the degree of the invasiveness of
the pathogen. Although serum antibodies are commonly detected even after non¬
invasive intestinal infections (Levine and Nataro, 1994), they are not believed to
play an important role in the protection against gut infections.
Aim of the study
The aim of this study was to investigate the intestinal humoral immune responses to
naturally-acquired salmonella infection, both typhoidal and non-typhoidal. Patients
who had had salmonella infection in the preceding 12 months were recruited for
the study. Concentrations of total immunoglobulins and antigen-specific antibodies
in WGL fluid of those patients were measured and compared with the levels of
immunoglobulins and antibodies in WGL fluid of healthy British volunteers and
IBD patients. Levels of immunoglobulins and antigen-specific antibodies in the sera
of the above patients and volunteers were also studied and compared.
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The British healthy volunteers (or at least some of them) may have had salmonella
infection in the form of salmonella food poisoning, gastroenteritis and/or
enterocolitis, particularly those who had a history of travelling abroad. Therefore,
it was important to examine levels of antibodies in the gut of these volunteers as an
indicator of probable previous exposure to salmonella infection.
Patients with IBD are known to have general up-regulation of the intestinal
mucosal immunity with increased production of intestinal IgG, IgM and IgA
(Schreiber et al, 1992). Therefore, investigating levels of anti-Salmonella typhi
LPS antibodies in WGL fluid of patients with IBD and comparing them with other
immunologically normal subjects may provide valuable information regarding the
intestinal antigen-specific immune responses.
Patients and Methods
Eight patients (4 females and 4 males) who had had naturally acquired salmonella
infection were recruited for this study. The mean age of these patients was 41.25
(±12.34 SD). Six out of 8 patients had the manifestations of salmonella infection
during or soon after returning from holidays abroad. The rest of the patients had
the infection while in the UK. Patients were recruited from the out-patient
department of the City Hospital as well as from the Day Bed Area of the
Endoscopy Theatre of the Western General Hospital. Patients who had had
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salmonella infection (either typhoidal or non-typhoidal), treated and discharged
from the City hospital within the preceding 12 months were recruited. Likewise,
patients who were referred to Endoscopy Theatre for a variety of gastrointestinal
diseases and had recovered from salmonella infection within the preceding 12
months were also recruited for this study. During their illness, patients were treated
with ciprofloxacin (4-quinolone) or had had only supportive therapy. At the time of
the study, none of the recruits was taking antibiotics and all patients' stools were
culture-negative for salmonella organisms. The serotypes of salmonella organisms
involved in the infection and other details are given in table 7.1. Apart from the
history of salmonella infection, all patients were fit and well and had no history of
immunological disorders.
patient age sex date of infection date of lavage Salmonella serotypes
1 23 F 21/08/91 21/03/92 S. paratyphi A
2 23 M 21/06/92 03/09/92 S. typhi
3 39 M 17/04/92 23/11/92 S. typhi
4 57 M 10/10/90 22/09/91 S. enteritidis
5 47 F 19/07/91 17/10/91 S. enteritidis
6 49 F 15/10/91 09/01/92 S. enteritidis
7 44 F 23/07/91 24/02/92 S. enteritidis
8 48 M 26/07/92 08/12/92 S. enteritidis
Table 7.1. Patients involved in the study of intestinal immunity following
naturally-acquired salmonella infection.
All recruits underwent WGL. The protocol and methodology of WGL were as
described in chapter 3. Blood samples were also obtained from all patients at the
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time of the study. ELISA was used to measure levels of TIgA and TIgM in WGL
fluids and also for quantitative measurement of anti-Salmonella typhi LPS specific
IgA, IgM and IgG antibodies in WGL fluids and in the sera of all patients. The
technical details of ELISA methodology were as described in chapter 3. The
concentrations of total IgA, IgM and IgG in the sera of patients were measured by
the Department of Clinical Biochemistry.
Since IgA is the predominant immunoglobulin in the intestinal secretions, anti-
Salmonella typhi LPS IgA in WGL fluid were expressed in two different ways: (a)
units/ml (an arbitrary value of 1000 units of ax\l\-Salmonella typhi LPS antibodies
per ml was designated to the concentration of the standard reference serum, see
chapter 3); (b) units/mg of TIgA. The results obtained in (a) were further
calculated considering the concentration of TIgA in WGL fluid expressed as p.g/ml.
The results of anti-Salmonella typhi LPS IgA antibodies expressed as units/mg of
TIgA were used in the comparison between patients who had had salmonella
infection, healthy volunteers and IBD patients.
Results of the concentration of anti-Salmonella typhi LPS IgM antibodies in WGL
fluid, however, were found to be too low to be expressed as units/mg of TIgM and
therefore, they were expressed as units/ml.
Levels of immunoglobulins and antigen-specific antibodies in WGL fluid and sera
of the patients involved in this study were compared with immunoglobulins and
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antibodies in WGL fluid and sera obtained from the 22 healthy British volunteers
described in chapter 6. The data of the healthy volunteers mentioned in this chapter
were the pre-vaccination data. The concentrations of immunoglobulins and
antibodies of the above patients were also compared with immunoglobulins and
antigen specific antibodies in WGL fluid and sera of 30 patients with inflammatory
bowel disease selected from the records of the G.I laboratory, Western General
Hospital. These patients were studied during 1990 and 1991 by a colleague who
investigated the profiles of immunoglobulins and antibodies in WGL fluid and sera
of patients with inflammatory bowel diseases as part of his Ph.D degree
(Mwantembe, 1992).
Since all data were found to be non-parametrically distributed, the Mann-Whitney
U-test was used for the statistical analysis of the results.
Results
Sections 1-5 below are the results of measurements carried out for samples
obtained from the group of 8 patients who had had naturally-acquired salmonella
infections. The results are also summarised in table 7.II.
1. Concentration of TIgA and TIgM in WGL fluid: the median value of the
concentrations of TIgA of patients who had had Salmonella infection (typhoidal
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and non-typhoidal) was 101.6 pg/ml with a range of 24.5-175.6. The median
value of the concentrations of TlgM of those patients was 5.4 pg/ml with a
range of 2.3-16.8. Surprisingly, one patient who had had typhoid fever (patient
3) was found to have a concentration of TIgA of 24.5 pg/ml i.e. less than half
of the minimum value of the range of the concentrations of TIgA of the rest of
the patients (the range of TIgA values of the rest of patients was 57.6-175.6
pg/ml).
2. Concentration of anti-Salmonella typhi LPS antibodies in WGL fluid: the
median value of the concentrations of anti-Salmonella typhi LPS IgA antibodies
was found to be 5.45 units/ml with a range of 2.10-25.40. When the results
were expressed as units/mg of TIgA, the median was found to be 81.2 units/mg
of TIgA with a range of 30.1-176.0. The median value of the concentrations of
anti-Salmonella typhi LPS IgM antibodies was 0.55 units/ml with a range of
0.1-4.0.
3. Concentration of total IgA, IgM, and IgG immunoglobulins in serum: the
median values of the levels of IgA, IgM, and IgG in the sera of the patients
involved in the study were 1741.0, 1166.0 and 12180.0 pg/ml with ranges of
1200.0-4174.0, 887.0-2166.0 and 5829.0-18096.0 for IgA, IgM and IgG
respectively.
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4. Concentration of anti-Salmonella typhi LPS IgA, IgM, and IgG antibodies
in serum: the median value of the concentrations of IgA, IgM, and IgG
antibodies in the sera of the patients were 732.0, 3286.0, and 4708.0 units/ml
with ranges of 118.0-3794.0, 631.0-7792.0, and 1270.0-14065.0 for IgA,
IgM, and IgG antibodies respectively.
5. The correlation between anti-Salmonella typhi LPS antibodies in WGL
fluid and serum: the correlation co-efficient (r) of the relationship between
levels of anti-Salmonella typhi LPS IgA antibodies in WGL fluid and serum
was found to be 0.51 (p=0.29) and r value for the relationship between IgM
antibodies in WGL fluid and serum was found to be 0.39 (p=0.35). The
correlation co-efficient of the relationship between anti-Salmonella typhi LPS
IgA in WGL fluid and IgG antibodies in the serum was found to be zero.
Sections 6-10 are the results of the comparative study between patients who had
had salmonella infection, the British healthy volunteers and IBD patients.
6. Levels of TIgA in WGL fluid of patients who had had salmonella infection
compared to TIgA levels in WGL fluid of healthy volunteers and IBD
patients: there was no significant difference between levels of TIgA in WGL
fluid of patients who had had salmonella infection and TIgA levels in WGL
fluid of healthy volunteers (p =0.336). However, levels of TIgA in WGL fluid
from patients who had had salmonella infection were found to be significantly
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lower than levels of TlgA in WGL fluid of 1BD patients (p =0.0003). (Fig.
7.1).
7. Levels of TIgM in WGL fluid of patients who had had salmonella infection
compared to levels of TIgM in WGL fluid of healthy volunteers and IBD
patients: levels of TIgM in WGL fluid from patients who had had salmonella
infection were found to be significantly higher than levels of TIgM in WGL
obtained from the healthy British volunteers (p =0.029). On the other hand,
there were no significant differences between levels of TIgM of the patients
who had had salmonella infection and levels of TIgM of the or IBD patients
(p=0.986). (Fig. 7.II).
8. Levels of anti-Salmonella typhi LPS IgA and IgM antibodies in WGL fluid
of patients who had had salmonella infection compared to levels of IgA and
IgM antibodies in WGL fluid of healthy volunteers and IBD patients: there
were no significant differences between levels of anti-Salmonella typhi LPS IgA
antibodies (expressed as units/mg of TlgA or as units/ml) in WGL fluid of the
patients who had had salmonella infection and these antibodies in WGL fluid of
healthy volunteers or IBD patients (p values when results were expressed as
units/mg of TlgA were 0.523 and 0.06 respectively; p value when results were
expressed as units/ml were 0.223 and 0.163 respectively). Likewise, there were
no significant differences between the concentrations of IgM antibodies in
WGL fluid of the patients who had had salmonella infection and these
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antibodies in WGL fluid of healthy volunteers and 1BD patients (p values were
0.153 and 0.567 respectively). (Fig. 7.Ill and Fig. 7.IV).
9. Comparison between levels of IgA, IgM, and IgG in serum of patients
who had had salmonella infection and healthy volunteers: levels of IgM in
the sera of patients who had had salmonella infections were found to be
significantly higher than levels of IgM in the sera of the healthy volunteers
(p =0.037) (Fig. 7.V). However, there were no significant differences between
levels of IgA or IgG in the sera of patients who had had salmonella infection
and levels of the same immunoglobulins in the sera of the healthy volunteers (p
values were 0.869 and 0.250 respectively).
10. Levels of anti-Salmonella typhi LPS IgA, IgM, and IgG antibodies in serum
of patients who had had salmonella infection compared to levels of those
antibodies in serum of healthy volunteers and IBD patients: levels of IgG
antibodies in the sera of patients who had had salmonella infection were found
to be significantly higher than levels of IgG antibodies in the sera of both
healthy volunteers and IBD patients (p values were 0.0001 and 0.0002
respectively) (Fig. 7.VI). Levels of IgM antibodies in the sera of patients who
had had salmonella infection were found to be significantly higher than levels
of IgM antibodies in the sera of the healthy volunteers (p =0.010) but not
significantly different from levels of IgM antibodies in the sera of IBD patients
(p=0.400) (Fig. 7.VII). Levels of IgA antibodies in the sera of patients who
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had had salmonella infection were not significantly different from levels of IgA
antibodies in the sera of both healthy volunteers or IBD patients (p values were
0.181 and 0.245 respectively).
After the results of the 8 patients who had had salmonella infection, as one group,
were analysed and compared with results of healthy volunteers and IBD patients,
the results of the patients who had had salmonella infection were analysed
according to the serotype of Salmonella spp. and date of infection. Table 7.IV
contains a description of the results of the patients who had had salmonella
infection analysed according to the serotype of Salmonella spp., antibiotics, if any,
prescribed at the time of infection, time since infection (period between time of
infection and time of lavage study), anti-Salmonella typhi LPS IgA antibodies in
WGL fluid (expressed both as units/ml and units/mg of TIgA), ani\-Salmonella
typhi LPS IgM antibodies in WGL fluid and anti-Salmonella typhi IgG antibodies
in serum.
Tables 7.II and 7.Ill summarise the results of the immunoglobulins and anti-
Salmonella typhi LPS antibodies in WGL fluid and in sera respectively, of patients
who had had salmonella infection, healthy volunteers and IBD patients.
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Conclusion
Levels of TIgA as well as anti-Salmonella typhi LPS IgA in WGL fluid of patients
who had had naturally-acquired salmonella infection (typhoidal and non-typhoidal)
within the preceding 12 months did not significantly differ from levels of those
immunoglobulins and antibodies in WGL fluid of the British healthy volunteers
while levels of TIgA in WGL fluid of the above patients were found to be
significantly lower than levels of TIgA in WGL fluid of IBD patients. However,
levels of TIgM in WGL fluid of the Salmonella-infected patients were found to be
significantly higher than levels of TIgM in WGL fluid of the healthy volunteers
while no significant differences were found between levels of a.nt\-Salmonella typhi
LPS IgM in WGL fluid of patients who had had salmonella infection and the other
groups.
Surprisingly, one patient who had had Salmonella typhi infection had the lowest
concentration of TIgA and anti-Salmonella typhi LPS IgA antibodies (expressed as
units/ml) in WGL fluid and had low anti-Salmonella typhi LPS IgG antibodies in
serum.
In serum, only the level of TIgM of patients who had had salmonella infection
showed a significant difference (higher) from the level of TIgM of the healthy
volunteers. Both IgM and IgG anti-Salmonella typhi LPS antibodies in sera of
patients who had had salmonella infection were found to be significantly higher
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than levels of these antibodies in the sera of the healthy volunteers while levels of
IgA antibodies in the sera of the salmonella patients and the healthy volunteers did
not show significant differences. No correlation was found between antigen-
specific intestinal and systemic immune responses among the patients who had had
salmonella infection.
The above results indicate that interpretation of the intestinal (as well as the
systemic) immune responses against enteric infection is considerably a difficult task
and should be taken into consideration while interpreting the immune responses to
oral vaccines against these pathogens. The role of intestinal immune responses
produced by various enteric pathogens in protection against subsequent infection is

























































































































































Fig. 7.1. Concentrations of TIgA in WGL fluid of patients who had had salmonella
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Fig. 7.II. Concentrations of TIgM in WGL fluid of patients who had had




















Fig. 7.ffl. Concentrations of anti-Salmonella typhi LPS IgA antibodies in WGL
fluid of patients who had had salmonella infection as compared to healthy














Fig. 7.IV. Concentrations of anti-Salmonella typhi LPS IgM antibodies in WGL
fluid of patients who had had salmonella infection as compared to healthy



















Fig. 7.Y. Concentrations of TIgM in sera of patients who had had salmonella





























Fig. 7.VI. Concentrations of anti-Salmonella typhi LPS IgG antibodies in sera of



































Fig. 7.VII. Concentrations of anti-Salmonella typhi LPS IgM antibodies in sera of




EFFECT OF CIGARETTE SMOKING ON GUT IMMUNITY:
DOES SMOKING SUPPRESS INTESTINAL IMMUNE RESPONSES ?
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Introduction
Cigarette smoking has been shown to modify the systemic immune responses in
animals as well as in humans (see chapter 2). Both the cellular and the humoral
aspects of the immune system have been shown to be affected by cigarette
smoking.
In spite of the extensive research work into the influence of cigarette smoking
on the systemic immune system, there have been few studies, in vivo,
investigating the effect of smoking on the mucosal immune system. The
discovery, in the last few years, of an epidemiological relationship between
cigarette smoking and inflammatory bowel diseases (IBD) (see chapter 2) has
markedly increased the interest in the immunological changes associated with
cigarette smoking, and of particular interest is the effect on the intestinal
mucosal immune system.
Barton and colleagues (1990) investigated the effect of cigarette smoking on the
concentration of immunoglobulins in pure parotid saliva obtained from healthy
smokers, non-smokers and ex-smokers and found that the concentration of
salivary IgA in the smokers group was significantly reduced compared to the
non-smokers control. The concentration of salivary IgM, on the other hand,
was found to be significantly increased in the smokers group. In the above
study, the decrease in the salivary IgA in the smokers group was found to be
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dose-related and reversible after cessation of smoking. However, further
studies on saliva showed that the immunological changes in the saliva do not
necessarily represent the profile of the immune responses at the intestinal
mucosa (O'Mahony et al, 1991).
Srivastava et al (1991) investigated the effect of smoking on the humoral
immune responses of the gut using the WGL technique in healthy subjects and
patients with ulcerative colitis including both smokers and non-smokers. This
study found no difference between immune responses in the intestinal mucosa
of smokers and non-smokers and they concluded that smoking does not
suppress the intestinal immune system. However, smokers in the above study
were not heavy smokers (smoked as little as 10 cigarettes per day) and the
period of smoking was relatively short (one year).
Therefore, in this study the WGL technique was exploited to investigate further
the influence of heavy smoking (20 cigarette per day or more) for a long period
(at least 3 years). Alteration of the mucosal immunoglobulins and antigen
specific antibodies may be important, not so much in their own right, but as
markers of underlying alteration in the intestinal immune function. If further
work confirms the presence of mucosal IgA deficiency among heavy smokers,
the implications are considerable, not only for oral immunisation programmes,
but also in relation to the aetiologies of smoking-related diseases.
236
Subjects and methods
The 22 adult healthy British volunteers involved in the study of the effect of the
oral typhoid vaccine Ty21a on gut immunity described in chapter 6 were also
recruited for this study. Volunteers were divided into 14 heavy smokers (one
female and 13 males) and 8 non-smokers (one female and 7 males). The mean
value of the age of the smokers group was 27.43 (± 5.00 SD) while the mean
of the age of the non-smokers group was 32.75 (± 7.27 SD). The mean value
of the number of cigarettes smoked by the smokers group was 21.43 (±4.13
SD) per day for at least the past 3 years. All volunteers drank less than 20 units
of alcohol per week.
Intestinal fluids (obtained by WGL technique) and venous blood samples were
obtained from all volunteers before and 3 weeks after the administration of the
oral typhoid vaccine Ty21a as described in chapter 6.
Assays performed
1. ELISA: for the quantitative measurement of total immunoglobulins in the
WGL fluid before and after vaccination.
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2. ELISA: for the quantitative measurement of anti-Salmonella typhi LPS
antibodies in WGL fluids and serum before and after vaccination.
The concentrations of total IgA, IgM, and anti-Salmonella typhi LPS IgA, IgM
and IgG in WGL fluid of the smokers group were compared with total
immunoglobulins and antigen-specific antibodies of the non-smokers group
before and 3 weeks after administration of the oral typhoid vaccine Ty21a.
Levels of serum total IgA, IgM, and IgG as well as anti-Salmonella typhi LPS
IgA, IgM and IgG antibodies of the smokers and non-smokers groups obtained
before and 3 weeks after vaccination were also studied comparing the
concentration of those immunoglobulins and antigen-specific antibodies in the
smokers and non-smokers groups.
Since the results obtained in this study were found to be non-parametric and
independent, the Mann-Whitney U-test was used for the statistical analysis of
the data.
Results
1. The concentration of TigA in WGL fluid of smokers and non-smokers
before and after vaccination: the median value of the pre-vaccination
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TIgA of the smokers group was 71.05 pg/ml with a range of 10.00-173.20
while the median of the pre-vaccination TIgA of the non-smokers group
was 83.80 pg/ml with a range of 24.00-110.40. The median value of the
post-vaccination TIgA of the smokers group was 72.00 pg/ml with a range
of 20.90-225.30 while the median of the post-vaccination TIgA of the non-
smokers group was 57.70 pg/ml with a range of 28.20-106.20. There was
no significant difference between the pre-vaccination TIgA of the smokers
and non-smokers groups (p=0.919) (Fig. 8.1). Likewise, there was no
significant difference between the post-vaccination TIgA of the smokers and
non-smokers groups (p =0.322). (Fig. 8.1).
2. The concentration of TIgM in WGL fluid of smokers and non-smokers
before and after vaccination: The median value of the pre-vaccination
TIgM of the smokers group was 1.75 pg/ml with a range of 0.10-9.50
while the median of the pre-vaccination TIgM of the non-smokers group
was 2.70 pg/ml with a range of 0.10-4.40. The median value of the post-
vaccination TIgM of the smokers group was 1.60 pg/ml with a range of
0.10-5.10 while the post-vaccination TIgM of the non-smokers group was
1.90 pg/ml with a range of 0.50-4.30. There was no significant difference
between the pre-vaccination TIgM of the smokers and non-smokers groups
(p =0.633). (Fig. 8.II). There was also no significant difference between
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the post-vaccination TIgM of smokers and non-smokers groups (p=0.609).
(Fig. 8.II).
3. \nti-Salmonella typhi LPS IgA antibodies in WGL fluid of smokers and
non-smokers before and after vaccination: the median value of the pre-
vaccination anti-Salmonella typhi LPS IgA antibodies of the smokers group
was 52.1 units/mg of TIgA with a range of 12.0-265.1 while the median of
the pre-vaccination IgA antibodies of the non-smokers group was 88.2
units/mg of TIgA with a range of 15.3-230.0. The median value of the
post-vaccination ani\-Salmonella typhi LPS IgA antibodies of the smokers
group was 91.8 units/mg of TIgA with a range of 6.9-205.7 while the
median of the post-vaccination IgA antibodies of the non-smokers group
was 132.4 units/mg of TIgA with a range of 18.0-1519.0. There was no
significant difference between the pre-vaccination anti-Salmonella typhi
LPS IgA antibodies of the smokers and non-smokers groups (p =0.290)
(Fig. 8.III). There was also no significant difference between the post-
vaccination IgA antibodies of the smokers and non-smokers groups
(p=0.109) (Fig. 8.III).
4. Changes in anti-Salmonella typhi LPS IgA antibodies in WGL fluid of
smokers and non-smokers before and after vaccination: studies
described in chapter 6 have shown that there was an overall significant
increase, after vaccination, in the titre of anti-Salmonella typhi LPS IgA
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antibodies in WGL fluid of the volunteers involved in the study. However,
when the changes in the ax\i\-Salmonella typhi LPS IgA antibodies in WGL
fluid of the smokers group was compared with the changes in IgA
antibodies in WGL fluid of the non-smokers group, the difference was
found to be not significant (p =0.562).
5. Anti-Salmonella typhi LPS IgM antibodies in WGL fluid of smokers
and non-smokers before and after vaccination: there was no significant
difference between anti-Salmonella typhi LPS IgM antibodies in WGL fluid
of smokers and non-smokers before or after vaccination (p values were
0.065, and 0.075 respectively).
6. Total IgA, IgM, and IgG in the serum of the smokers and non-smokers
before and after vaccination: there were no significant differences
between total IgA, IgM, and IgG in the sera of the smokers and non-
smokers groups before vaccination (p values were 0.172, 0.759, and 0.838
for IgA, IgM and IgG respectively) or after vaccination ( p values were
0.136, 0.574 and 0.719 for IgA, IgM and IgG respectively).
7. Anti-Salmonella typhi LPS IgA, IgM, and IgG antibodies in serum of
smokers and non-smokers before and after vaccination: the median
values of the pre-vaccination anti-Salmonella typhi LPS IgA, IgM, and IgG
antibodies in the serum of the smokers were 516.0, 790.5, and 524.5
units/ml respectively (ranges were 46.0-1438.0, 386.0-5540.0 and 167.0-
1403.0 respectively) while the median values of the pre-vaccination IgA,
IgM, and IgG antibodies in the serum of the non-smokers were 263.9,
740.2, and 460.8 units/ml respectively (ranges were 116.0-7150.0, 277.0-
1938.0 and 262.0-4499.0 respectively). The median value of the post-
vaccination anti-Salmonella typhi LPS IgA, IgM, and IgG antibodies in the
serum of the smokers were 674.9, 773.5 and 665.8 units/ml respectively
(ranges were 42.0-3375.0, 373.0-6446.0 and 169.0-5265.0 respectively)
while the median of the these antibodies in the serum of the non-smokers
were 1250.4, 1183.0, and 1170.7 units/ml respectively (ranges were 283.0-
7274.0, 460.0-3367.0 and 240.0-46267.0). There were no significant
differences between the pre-vaccination anti-Salmonella typhi LPS IgA,
IgM, and IgG antibodies in the serum of the smokers and non-smokers
groups (p values were 0.707, 0.657 and 0.759 respectively) (Fig. 8.IV).
Likewise, there were no significant differences between the post-vaccination
IgA, IgM, and IgG antibodies in the sera of the smokers and non-smokers
group (p value were 0.232, 0.394 and 0.517 respectively) (Fig. 8.IV).
Conclusion
The above results indicated that there were no significant differences between
the healthy heavy smokers and non-smokers volunteers in terms of intestinal as
well as systemic immunoglobulins and antigen-specific antibodies. In spite of
the fact that administration of an intestinal mucosal immunogen such as the oral
live typhoid vaccine Ty21a has been shown to produce an overall significant
increase in the intestinal (as well as systemic) antigen-specific antibodies of the
healthy volunteers (see chapter 6), yet the differences between the changes in
the smokers and non-smokers groups were found to be not significant.
The above findings suggest that smoking does not significantly suppress the
intestinal mucosal immunoglobulins nor the antigen-specific antibodies of the
healthy volunteers when challenged with live antigen. Therefore, the protective
effect of smoking, if any, in patients with ulcerative colitis may be due some





























Fig. 8.1. Concentrations of TIgA in WGL fluid of healthy smokers (n=14) and





























Fig. 8.II. Concentrations of TIgM in WGL fluid of healthy smokers (n= 14) and









































Fig. 8.III. Concentrations of anti-5. typhi LPS IgA antibodies in WGL fluid of
healthy smokers (n= 14) and non-smokers (n= 8) before and after vaccination with







































Fig. 8.IV. Concentrations of anti-51. typhi LPS IgG antibodies in sera of healthy




INTESTINAL MUCOSAL IgA DEFICIENCY
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Introduction
Normally, IgA is found in almost all body fluids. The overall production of IgA
was estimated as 66 mg/kg body weight per day compared to 34, 7.9, 0.4, 0.02
mg/kg body weight per day for IgG, IgM, IgD and IgE respectively (Mestecky and
McGhee, 1987; Hanson and Brandtzaeg, 1988). In serum, the level of IgA, with a
mean value of 200±61 mg/dl, is ranked as second after the IgG level which has a
mean value of 1158±31 mg/dl (Conley and Delacroix, 1987), while on the mucosal
surface IgA is by far the predominant immunoglobulin with the daily amount of
secretory IgA (SIgA) secreted into the gut lumen estimated as 40 mg/kg body
weight (i.e. more than the total daily production of IgG) (Conley and Delacroix,
1987). Levels of IgA in serum do not represent the overall rate of production of
IgA simply because approximately 2/3 of IgA is locally produced in the mucosa
and secreted into the external secretions and never enters the systemic pool. In
addition, the half-life of IgA was found to be relatively short (estimated as 3-6 days
compared to the half-life of 20-23 days of IgG) (Mestecky et al, 1991).
In serum, IgA is present mainly as the 7S monomeric form and is thought to be
produced by bone marrow plasma cells while IgA on the mucosal surfaces is
produced by local plasma cells and secreted onto the mucosal surfaces mainly as
the 11S dimeric form. The systemic and mucosal compartments have been shown
to be separate with little contribution, if any, of serum IgA to the mucosal
secretion (Conley and Delacroix, 1987; Mestecky, 1988; O'Mahony et al, 1991).
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In humans, the catabolic site(s) of IgA is/are not, as yet, known. However, an Fca
receptor (FcaR) has been recently identified on phagocytic white blood cells
(neutrophils and macrophages) and has been suggested to be involved in the
catabolism of IgA antibodies as well as clearance of IgA immune complexes from
serum (Schaffer et al, 1993). The structure and function of IgA were described in
chapter 2.
IgA deficiency
Systemic IgA deficiency. Classification of primary immunodeficiency diseases by
the World Health Organisation (WHO), in 1983, described at least 13 disorders
characterised predominantly by antibody deficiency (Buckley, 1986). Selective IgA
deficiency, i.e. 50 pg/ml or less of IgA in serum (Hong and Ammann, 1989), is
regarded as the most common type of primary immunodeficiency with a rate of
incidence of 1 in 600 (Hanson et al, 1983), predominantly among Caucasians and
more commonly in males than in females (Buckley, 1986). This type of antibody
deficiency has been found in asymptomatic individuals as well as patients with a
variety of infections including gastrointestinal, respiratory, and urinary tract
infections (West et al, 1962).
Selective IgA deficiency may also be acquired as a complication of certain drugs.
Administration of phenytoin, a drug used for the treatment of epileptic seizures,
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has been reported to cause IgA deficiency in 20-40% of patients treated with it
(Sorrell et al, 1971; Aarli, 1976). Other drugs such as sulphasalazine, used for the
treatment of rheumatoid arthritis and inflammatory bowel disease (Delamere et al,
1983), antimalarial agents (Schaffer et al, 1993) and captopril, used for the
treatment of hypertension and congestive heart failure (Hammarstrong et al, 1991)
have also been reported to be involved in the acquisition of IgA deficiency.
Environmental factors such as congenital and neonatal infections have been
implicated in the acquisition of IgA deficiency. Congenital infection with
cytomegalovirus and toxoplasma gondii were reported to be associated with
subsequent IgA deficiency (Rosen, 1980). Intrauterine infection with rubella virus
was also reported to be associated with subsequent IgA deficiency (Soothill et al,
1966). Healthy individuals may also have transient IgA deficiency following
infection with Epistein-Barr virus (EBV) (Saulsbury, 1989).
The association with IgA deficiency of ataxia telangiectasia, an autosomal recessive
syndrome that is characterised by progressive ataxia and occulo-cutaneous
telangiectasia, autoimmune and atopic diseases (Swift, 1990) has attracted attention
to the possibility that a genetic factor may be the cause of IgA deficiency. A
genetic factor may cause a defect in the expression of certain regulatory mediators
which are important for maturation and differentiation of IgA-producing cells. IgA
deficiency may be associated with certain human leukocyte antigens (HLA) which
encode genes that have an immunoregulatory function particularly those genes
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involved in antigen presentation and in the interaction between T cells and B cells
(Schaffer et al, 1993). Of particular interest, are antigens of the HLA-A and -B
classes such as HLA-A1, -A2 and -B8 antigens (Ambrus et al, 1977). Whether the
presence of these HLA antigens is a predisposing factor to both IgA deficiency as
well as to the underlying diseases or is primarily associated with the underlying
diseases rather than IgA deficiency, is not, as yet, clear.
Selective IgA deficiency has been reported to be associated with a marked increase
in IgM-producing cells and, to a lesser extent, IgG-producing cells in the lamina
propria of the intestinal mucosa (Brandtzaeg et al, 1968; Savilhati, 1973). The
increase in the number of IgM-producing cells in the lamina propria of subjects
with IgA deficiency was found to be associated with an increase in the local
production of secretory IgM (SIgM) in saliva (Brandtzaeg et al, 1968) and
intestinal secretions (Haneberg and Aarskog, 1975) probably as a compensatory
mechanism. Compensatory SIgM may act as a protective antibody on the mucosal
surfaces of individuals with IgA deficiency and this may account for the lack of
gastrointestinal symptoms in some subjects with IgA deficiency (Arnold et al,
1977). However, the binding of IgM to the secretory component (SC) was found to
be less stable than the binding of IgA (Brandtzaeg, 1975) rendering SIgM less
effective than SIgA in protection of mucosal surfaces of the gut.
The clinical implications of IgA deficiency are markedly variable: many subjects
with IgA deficiency are otherwise healthy. However, patients with IgA deficiency
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have been reported to have a variety of infections such as recurrent respiratory
infections (South et al, 1965; Burks and Steel, 1986), chronic gastrointestinal
infections (Schaffer et al, 1993) viral hepatitis (Ammann and Hong, 1971),
septicaemia (Klemola, 1987) and meningoencephalitis (Cursons et al, 1979).
Allergic disorders such as allergic conjunctivitis, rhinitis, urticaria, atopic eczema
and bronchial asthma have been reported to be associated with IgA deficiency
(Ostermaard, 1980; Burks and Steel, 1986). Rheumatoid arthritis and systemic
lupus erythematosus (SLE) were also reported to occur in patients with IgA
deficiency. The latter disease was reported to occur in 5-7% of subjects with IgA
deficiency (Cassidy et al, 1969).
A variety of gastrointestinal disorders such as coeliac disease, pancreatic
insufficiency (Penny et al, 1971), regional enteritis and ulcerative colitis (Ammann
and Hong, 1971), have been found to be associated with IgA deficiency. Primary
biliary cirrhosis and chronic active hepatitis are hepatic disorders reported to be
associated with IgA deficiency (James et al, 1986; Klemola, 1987).
Subjects with IgA deficiency have been reported to have high levels of IgG
antibodies against cow's milk and serum proteins (Buckley, 1986).
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Skin disorders that may be found in subjects with IgA deficiency include pyoderma
gangrenosum, vitiligo (Wolf and Wolf, 1982), haemorrhagic purpura (Bundino and
Zina, 1984) and Henoch-Schoenlein syndrome (Martini et al, 1985).
Mucosal IgA deficiency. The statement "IgA deficiency" has always referred to
IgA deficiency in serum and little, if anything, is known about mucosal IgA
deficiency. Patients with selective IgA deficiency usually exhibit the absence or
near absence of IgA in both serum and mucosal surfaces. Therefore, it was an
interesting observation to find, during research into gut immunity, that there were
some subjects who had very low levels or absence of IgA in their WGL fluid but
had normal levels of IgA in their serum.
In one case report (Strober et al, 1976), the lack of IgA in the intestinal fluid in a
15-year old boy who had very low level of intestinal (jejunal) IgA (but had a
normal level of IgA in serum) was attributed to the lack of the SC which prevented
the normal secretion of locally produced IgA into the intestinal lumen.
Apart from the above case report, the phenomenon of normal levels of IgA in
serum but low levels or absence of IgA in the intestinal secretions has not been
investigated before. Such investigation may provide instructive insights into the
physiology of IgA production and may result in a better understanding of the
immunoregulatory mechanisms behind this disorder.
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Aim of the study
The discovery of subjects, during my research into gastrointestinal immunity, who
had normal levels of IgA in serum but had low levels or absence of IgA in their
WGL fluid was a chance finding of a previously unrecognised form of humoral
immunodeficiency. Therefore, it was important to investigate this phenomenon in
healthy subjects and patients who had low levels or absence of IgA in their
intestinal fluids (WGL fluid or jejunal aspirate) highlighting subjects who had
normal levels of IgA in serum. Counting of IgA-containing cells in the lamina
propria of those subjects was carried out in their duodenal or jejunal biopsies.
Patients and methods
Specimens of WGL fluid obtained from healthy individuals and patients with a
variety of gastrointestinal diseases during 1991 and 1992 were screened looking for
specimens with very low levels or absence of IgA. A total of 391 WGL specimens
were assayed and the concentrations of TIgA in these specimens were measured.
Specimens containing concentrations of < 10 pg/ml of total IgA (TIgA) in WGL
fluid were regarded as IgA deficient. This is because analysis of the concentration
of TIgA in WGL fluid of healthy volunteers, patients with IBD or salmonella
infection (chapters 5, 6 and 7) has shown that a concentration of TIgA of <10
pg/ml is a very low level compared to the levels obtained from the above
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mentioned groups (Table 9.IV). Specimens of WGL fluid obtained during 1991
and 1992 were collected and processed as described in chapter 3 and stored at -70
°C.
Jejunal aspirates collected (by Sister Crichton, G.I Annex using Crosby's capsule)
during 1991 and 1992 from patients with a variety of gastrointestinal diseases were
screened looking for IgA deficient specimens. A total of 238 specimens of jejunal
aspirates were assayed (by Dr. Arranz, a research fellow and Mr. Anderson, a
technician in the G.I laboratory). Specimens containing < 10 p.g/ml of TIgA were
regarded as IgA deficient. Analysis of the concentration of TIgA in jejunal
aspirates in normal controls and patients with treated or untreated coeliac disease
(Arranz, 1993) has shown that a concentration of TIgA in jejunal aspirate of < 10
g/ml is a low value compared to the levels of TIgA in other groups (Table 9.V).
ELISA was used for the quantitative measurements of TIgA and TIgM in WGL
fluid and jejunal aspirates. The concentrations of IgA, IgM and IgG in serum
collected at the same time as the WGL fluids or jejunal aspirates, of those subjects
who were found to have intestinal IgA deficiency were measured by the
Department of Clinical Biochemistry.
The number of IgA-containing plasma cells was counted in the lamina propria of 4
duodenal biopsies and one colonic biopsy obtained from 5 cases found to have zero
or very low levels of TIgA in their WGL fluids but normal levels of IgA in serum.
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No relevant biopsy was available for one case found to have no TIgA in WGL fluid
but a normal level of IgA in serum. A set of slides containing 11 jejunal biopsies
from 11 patients who had very low levels or absent TIgA in jejunal aspirates and 3
biopsies from 3 normal subjects who had normal levels of TIgA in jejunal aspirates
and in serum (TIgA in jejunal aspirates ranged between 70.2 and 178.7 p.g/ml and
in serum between 1.91 and 2.03 mg/ml) was mixed and screened blindly looking
for IgA-containing cells in the lamina propria after assigning a special code for
every slide. Slides containing the duodenal or jejunal biopsies were stained
immunohistochemically (by Mr. Bode, a MLSO in the G.I laboratory) and cell
counting was carried out using an image analyser as described in chapter 3. In
every slide, about 50 fields were examined systematically in horizontal and vertical
directions under the xlOO objective lens.
IgA-containing plasma cells in duodenal biopsies of 10 young subjects (aged <50
years) were counted (by Dr. Bruce, a research fellow) using the image analyser and
the range of the numbers obtained was used as a normal control. These subjects
presented to the out-patient clinic with a variety of symptoms but investigation
revealed no abnormality and they were found to be immunologically normal.
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Results
Measurement of the concentrations of TIgA and TIgM in the specimens of WGL
fluid of the normal individuals and patients with a variety of gastrointestinal
diseases collected during 1991 and 1992 revealed the presence of 7 patients with
levels of TIgA ranged between zero and 5.2 tig/ml (table 9.1) and levels of TIgM
ranged between zero and 7.1 (within normal limits for IgM). Apart from one
subject, who had pan-hypogammaglobulinaemia, the concentrations of IgA, IgM
and IgG in the sera of the above 7 subjects were found to be within the normal
ranges and ranged between 2.01 and 4.14, 0.50 and 3.10 and between 8.00 and
21.83 mg/ml for IgA, IgM and IgG respectively.
Measurement of the concentrations of TIgA and TIgM in the jejunal aspirates of
normal individuals and patients with a variety of gastrointestinal diseases collected
during 1991 and 1992 revealed the presence of 15 patients with levels of TIgA
ranged between zero and 9.7 p.g/ml (table 9.II) and levels of TIgM ranged between
zero and 10 pg/ml. Apart from one subject who had selective IgA deficiency, the
concentrations of IgA, IgM and IgG in the sera of those subjects who had very low
levels or absent IgA in their jejunal aspirates were found to be within the normal
range and ranged between 1.49 and 3.41, 0.40 and 3.00 and between 7.74 and
16.18 mg/ml for IgA, IgM and IgG respectively.
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In the group of subjects who had very low levels or absence of IgA in their WGL
fluids, counting of IgA-containing plasma cells in the lamina propria of a duodenal
biopsy of one subject revealed the presence of 9 IgA-containing plasma cells/mm"
lamina propria while counting of IgA-containing plasma cells in the lamina propria
of a duodenal biopsy of another subject revealed the presence of 19 cells/mm"
lamina propria (Table 9.1).
In the group of subjects who had very low levels or absence of IgA in their jejunal
aspirates, counting of IgA-containing plasma cells in the lamina propria of 11
jejunal biopsies revealed the presence of numbers of IgA-containing plasma cells
ranged between zero and 900 cells/mm2 lamina propria with 3 subjects having no
IgA-containing plasma cells in the lamina propria (Table 9.II). Counting of IgA-
containing plasma cells in the lamina propria of the three subjects used as a normal
control revealed the presence of numbers of IgA-containing cells ranged between
17 and 423 cell/mm2 lamina propria (Table 9.Ill) (Fig. 9.1).
The three subjects who had low levels or absent TIgA in jejunal aspirates (2 had
normal levels of IgA in serum but the third subject had selective IgA deficiency)
and had no IgA-containing plasma cells in the lamina propria had presented with
abdominal pain accompanied by loose stools or diarrhoea. Apart from one case
who had selective IgA deficiency (and a history of non-insulin dependent diabetes
mellitus), clinical investigation revealed no abnormality.
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Counting of IgA-containing plasma cells in the duodenal biopsies of 10 subjects,
used as a normal controls, showed the presence of numbers ranged between 255
and 948 cells/mm2 lamina propria.
Conclusion
Studies on WGL fluid of normal individuals and patients with a variety of
gastrointestinal diseases collected during 1991 and 1992 revealed the presence of
subjects with absent or near absent levels of IgA in their WGL fluids but with
normal levels of IgA in serum. Counting of IgA-containing plasma cells in the
lamina propria of 2 duodenal biopsies from 2 subjects who had zero levels of TIgA
in their WGL fluid revealed the presence of a very small number of cells/mm'
lamina propria. The above results suggested the presence of a previously
unrecognised form of IgA immunodeficiency i.e. intestinal IgA deficiency, the
implication of which is, as yet, unknown.
Screening of jejunal aspirates of patients and normal individuals collected during
1991 and 1992 revealed the presence of subjects with very low levels or absence of
IgA in their jejunal aspirates but normal levels of IgA in serum. Counting IgA-
containing plasma cells in the lamina propria of jejunal biopsies from these subjects
revealed the presence of 3 subjects who had no IgA-containing cells. However,
counting of IgA-containing plasma cells in the lamina propria of jejunal biopsies
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from other subjects who had absent or near absent levels of TIgA in jejunal
aspirates showed that some biopsies contained a number of IgA-containing plasma
cells that overlapped with the numbers of IgA-containing plasma cells in the lamina
propria of normal controls with normal levels of TIgA in jejunal aspirates.
Furthermore, one subject (control 3, table 9.Ill) had a small number of IgA-
containing plasma cells/mm2 lamina propria although he had normal level of TIgA
in his jejunal aspirate.
These results indicated that the jejunal aspirates used in this study were not reliable
material in which to study immunoglobulin concentrations in the gut. Jejunal
aspirate collection was not one of the protocols of my study: a scientist in the G.I
laboratory has reported that the technical steps by which jejunal aspirates were
collected may result in variable but marked dilution of the jejunal fluid during the
process of collection, resulting in false low values or absence of IgA measured in
some of the samples collected by the above method. This was due to a technical
error involving flushing of Crosby's capsule tubes with normal saline just before
obtaining jejunal biopsies (to clear the intubation system from any mucous or other
tissue debris). Thereafter, when jejunal aspirate was collected, the remnants of the
flushing fluid were collected with the jejunal fluid resulting in its dilution.
Whether the unexplained abdominal pain and idiopathic diarrhoea found in three
subjects found to have low levels or absent TIgA in jejunal aspirates and had no
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IgA-containing plasma cells in the lamina propria is related to the intestinal IgA
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Fig. 9.1. Scatterogram showing the relationship between the IgA concentration and
the IgA-containing plasma cells in jejunal biopsies of subjects with low levels of
IgA in jejunal aspirate (n= 11) and normal controls (n=3). *=subjects with low
IgA concentrations in jejunal aspirate. o = normal controls.
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Chapter X




Establishing WGL fluid as a perfusate was important to validate its use in the
research work described in this thesis as well as in other areas of clinical research
into gut immunity. O'Mahony et al (1990) showed that once WGL specimens
became clear there were no significant differences between levels of TIgA in two
sequential lavage specimens. However, the analysis of a single parameter in just
two sequential lavage specimens may not be sufficient to establish WGL fluid as a
perfusate. Therefore, in the serial lavage study (described in chapter 4), 5 or 6
specimens were taken from every participant. The results showed that once the
effluent fluid became clear there were no significant differences between levels of
TIgA in the 5 or 6 serial lavage specimens collected over a period of about 1 Vi to 2
hours. In addition, levels of TIgM, albumin, a-l-antitrypsin, protease enzymes
activity and anti-Salmonella typhi LPS antibodies were studied in 5 or 6 clear
sequential lavage specimens and it was found that there were no significant
differences between the first clear specimen and the succeeding 4 or 5 serial lavage
specimens.
Regarding TIgG, there were no significant differences between sample number 1
and samples number 2 or 3 but there were significant differences between samples
number 1 and samples number 4 and 5 of WGL fluid. Likewise, there were
significant differences between levels of total proteins in sample number 1 and
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sample number 5 of the sequential lavage specimens. This variation may be
because WGL may actually be reducing gastrointestinal protein loss e.g. by
removing an agent which damages or changes the permeability of the intestinal
epithelium. However, inspection of the actual data makes the above explanation
unlikely. This important issue is now being investigated further in the G.I
laboratory, using the protocol I developed, in a group of patients with active IBD.
Another explanation for the variations in the concentrations of TIgG and total
proteins reported in the serial lavage study is that these are chance statistical
findings in view of the many statistical comparisons made.
WGL fluid is now being used in the G.I. laboratory as material in which to study
the cellular contents (such as neutrophils) and cytokines (such as IL-1, IL-6 and IL-
8) of the intestinal secretions. However, the cellular and interleukin contents of
WGL fluid in serial lavage specimens have not been studied and whether the
cellular and cytokine contents are steady in the gut perfusate or not, is to be further
investigated.
In another study, investigating the effects of the oral typhoid vaccine Ty21a on gut
immunity of 22 healthy British volunteers (see chapter 6), the concentration of
TIgA and TIgM in WGL fluid of the volunteers were measured before and 3 weeks
after administering the vaccine. There were no significant differences between
levels of TIgA or TIgM in WGL fluid of the volunteers before and after
vaccination. The median value of the concentrations of TIgA in WGL fluid of the
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22 healthy volunteers was found to be 73.25 pg/ml. The similarity in the
concentrations of TIgA in WGL fluid collected before and 3 weeks after
vaccination support the hypothesis that, when a standard and nurse-supervised
protocol is used, WGL fluid is a perfusate and not just a bolus of material obtained
during the process of WGL.
Several investigators have studied intestinal immunity by obtaining intestinal
secretions (duodenal or jejunal aspirates) through intestinal intubation (see chapter
2). In those studies, the concentration of TIgA in intestinal secretions was
estimated as 40 mg/kg body weight per day (Conley and Delacroix, 1987). In the
technique of WGL the gut is perfused at a rate of 20 ml/minute. Therefore the
daily production of TIgA, in an adult of 70 kg body weight, can be calculated as
follows: TIgA in WGL fluid (pg/ml) X 20 X 60 X 24. The mean value of the rate
of daily production of TIgA was found to be approximately 2.11 g/day. This value
is close to the generally accepted value of the rate of daily production of TIgA of
2.8 g/day based on intestinal secretion of 40 mg/kg body weight/day.
Recently, a new technique for segmental jejunal (Knutson et al, 1989) or rectal and
colonic (Raab et al, 1992) perfusion at a rate of 3 ml/minute has been described to
study the quantitative release of soluble substances and cells in the perfusate. The
volumes of perfusate recovered were reported to be equal to the infused volumes.
Although the rate of production of TIgA in the above studies was not reported, the
concentration of albumin in the jejunal perfusate was estimated as 31 pg/ml i.e.
271
0.134 g/day. This value is close to the mean of the concentrations of albumin in
WGL fluid obtained from the healthy volunteers of 0.144 g/day. The technique of
segmental perfusion of the gut is an invasive, inconvenient and demanding
procedure that requires endoscopy and manipulative skills to position the tube in
the target segment. Nevertheless, the above technique showed that a steady state of
perfusion of a segment of the gut can be obtained.
Drinking the lavage solution at a standard rate seems to be important for obtaining
optimal concentrations of intestinal immunoglobulins and antibodies in WGL fluid.
A study in the G.I laboratory (unpublished work) has shown that drinking the
lavage solution at 3 different rates produced 3 different concentrations of TIgA.
Just as in the studies described in this thesis, concentrations of TIgA were similar
in the sequentially collected WGL fluid specimens for any given session. In the
above study, 3 healthy volunteers drank the lavage solution at rates of 1 litre/75
minutes, 1 litre/50 minutes and 1 litre/25 minutes each in 3 different sessions. It
has been found that the shorter the period of drinking the same amount of the
lavage solution the more diluted became the concentrations of TIgA. The above
study emphasises the importance of standardisation of the rate of drinking the
lavage solution and further supports the hypothesis of WGL fluid as a perfusate.
The use of the concentration of TIgG in WGL fluid as an index of disease activity
in inflammatory bowel disease is an important application of the use of WGL fluid
in clinical tests. Another potential application for WGL is investigating occult
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blood loss from the gut of patients with a variety of gastrointestinal diseases by
measuring the haemoglobin contents of WGL fluid. However, none of the 8 cases
from whom serial lavage specimens were found to be technically suitable to be
included in the study was frankly bleeding during the serial lavage study.
Therefore, further study is required to confirm that blood content of WGL fluid is
steady in serial lavage specimens.
In a review of the WGL technique performed in the G.I. Unit during a period of
18 months in 252 patients and 24 healthy volunteers (personal communication,
Professor Ferguson, University of Edinburgh) the success rate, defined as passage
of clear fluid per rectum, achieved was found to be 96%. The high success rate
may be due to the fact that the procedure of WGL was supervised by experienced
nurses who ensured accurate recording of the fluid intake and output as well as
encouraging subjects to continue drinking till clear fluid passed per rectum.
Results of 3 out of 11 cases recruited for the serial lavage study were excluded
from the final analysis of the data. An eighty two-year old lady (patient number 5,
table 1) was excluded because at least 2 specimens of WGL fluid from this lady
were found to be contaminated with urine. A twenty three-year old lady who had a
diagnosis of ulcerative colitis (patient number 10, table 1) was excluded because
she had excessive bleeding per rectum during the procedure of WGL resulting in
high blood contents in WGL specimens. Results obtained from patient number 4
(table 1) were excluded because this patient failed to continue the experiment after
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passing 4 small volumes clear lavage fluid. However, apart from TIgG in the WGL
fluid of patient number 5, the raw data as well as the graphical representation of
the results obtained from the above mentioned excluded cases were found to be
consistent with those results obtained from the 8 cases included in the study.
The 3 excluded cases highlight difficulties which may be encountered during the
procedure of WGL and illustrate situations where results should be carefully
interpreted. For instance, specimens from very old subjects or from bleeding
patients may produce confusing results during analysis of WGL specimens.
Likewise, subjects may, for various reasons, fail to continue drinking the lavage
solution.
Although WGL technique is a non-invasive, safe and useful method for obtaining
intestinal secretions for use in clinical research into gut immunity, it is still, at this
stage, not a practical method to be used for clinical diagnosis. Furthermore, WGL
is not suitable for use in large-scale field studies. WGL is contraindicated in cases
suspected to have intestinal obstruction. The salty taste of the lavage solution used
in my research rendered the solution not very palatable for some subjects and may
cause nausea and/or abdominal discomfort. However, the above symptoms were
experienced only by one (out of 25) healthy volunteer and few elderly patients. An
experienced nurse is required to supervise the intake and output of the lavage fluid
to encourage subjects, particularly the elderly, to continue drinking the lavage
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solution at a regular rate and to make sure that only clear fluid stools passed per
rectum will be collected.
Generally, WGL technique was found to be a useful method for obtaining intestinal
fluid which is essentially a gut perfusate for research into gut immunity and may
have potential for clinical applications.
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Section 2
INTESTINAL IgA, IgM AND IgG IN INFLAMMATORY BOWEL
DISEASE AS COMPARED TO HEALTHY VOLUNTEERS
Concentrations of immunoglobulins, particularly TigA as the predominant
immunoglobulin in the intestinal secretions, have been measured directly in
intestinal fluids obtained by WGL technique or intestinal intubation, or even in
faecal material. Because intestinal fluids are not easily accessible, investigators
have used saliva as a material to study concentrations of secreted immunoglobulins
(see chapter 2).
Previous research in the G.I laboratory (O'Mahony et al, 1990) investigated levels
of immunoglobulins in WGL fluid obtained from patients with a variety of
gastrointestinal diseases and compared these levels with levels of immunoglobulins
in WGL fluid of normal controls who were described as "immunologically normal"
patients (see below). In the above mentioned study, the mean value of the
concentrations of TIgA in WGL fluid of the normal control was found to be 136.9
±20.6 pg/ml with a range of 7.9-403. Compared with levels of TIgA in WGL fluid
of patients with Crohn's disease (with a mean of 176.1±58.0 pg/ml), there were no
significant differences between levels of TIgA in WGL fluid of patients with
Crohn's disease and the normal control while levels of TIgM and TIgG in WGL
fluid of patients with Crohn's disease were found to be significantly higher than
those of the normal control. Similar results were obtained by Mwantembe (1992)
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who found that the median of levels of TIgA in WGL fluid of normal controls
(immunologically normal patients) was 143 pg/ml with a range of 12-478 with no
significant differences between levels of TIgA in WGL fluid of normal controls
and patients with IBD (either Crohn's disease or ulcerative colitis) while levels of
TIgM and TIgG in WGL fluid of patients with IBD were found to be significantly
higher than those of the normal control.
Studies on jejunal aspirates (Arranz, 1993) have shown that IgA is the predominant
immunoglobulin followed by IgM and IgG and the median of the concentrations of
TIgA in a group of normal controls was reported as 102.5 pg/ml with a range of
23-540.6. Based on the concept of the common mucosal immune system, the
concentration of TIgA was measured in saliva (Barton et al, 1990) on the ground
that salivary immunoglobulins may represent the humoral immunity in the gut. The
median of levels of TIgA in pure parotid saliva was found to be 165.8 pg/ml with
a range of 66.5-606.9. However, further studies showed that levels of salivary
immunoglobulins were not consistent with levels of immunoglobulins in the gut
(O'Mahony et al, 1991a).
Concentrations of TIgA have also been also measured in faecal material using
single radial immunodiffusion (Haneberg and Aarskog, 1975) and ELISA
(Ferguson et al, 1994). However, results obtained from analysis of faecal material
in the former study were found to be unreliable because specimens were not treated
with protease inhibitors and the assay used is relatively insensitive. Results
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obtained from the latter study showed that levels of TIgA in faecal material
contained only about 4% of the amount produced in the gut as compared with
levels of TIgA in WGL fluid. Furthermore, O'Mahony and colleagues (1990)
showed that faecally contaminated specimens obtained during the early stage of
WGL contained much less TIgA (2.0-3.8 pg/ml) than did clear specimens (16.3-
91.4 pg/ml). The low profile of TIgA in faecal material may be due to mechanical
and/or biological interference with the immunoassays by substances present in the
faecal material. Furthermore, the immunological findings in the faecal material
may represent only the findings in the colon.
The above studies reported higher levels of TIgA than those found in WGL fluid of
22 healthy British volunteers cited in chapter 6 of this thesis (where the median was
73.25 pg/ml). Likewise, the ranges of levels of TIgA reported in the above studies
were found to be more widely scattered than the range of the concentrations of
TIgA in WGL fluid of the healthy volunteers (a range of 10.00-173.20).
Furthermore, the previous studies on the concentrations of immunoglobulins in
WGL fluid found no significant differences between levels of TIgA in IBD patients
and the normal controls (O'Mahony et al, 1990; Mwantembe, 1992) while my
research into the total immunoglobulins in WGL fluid of healthy volunteers and
IBD patients showed that healthy volunteers had significantly lower levels of TIgA.
The reasons for the differences between the findings of the previous studies and the
findings of my research are described below. Subjects used as normal controls in
the work of O'Mahony et al (1990) and Mwantembe (1992) were a mixture of
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patients who had a diagnosis of irritable bowel syndrome (IBS) or constipation.
Others had presented with a variety of gastrointestinal disorders but various clinical
investigations failed to detect any abnormality. The aetiology of IBS is still
unknown and patients with IBS are usually prescribed spasmolytic drugs the effect
of which on gut immunity is unknown. Likewise, constipated patients are usually
on laxatives the effects of which on gut immunity have not been revealed.
Therefore, levels of immunoglobulins obtained from the above subjects may not be
suitable to be used as normal controls. Subjects used as controls in my research
were young (age ranged between 22 and 44 years) healthy volunteers.
The method of collecting and processing of WGL fluids as well as the ELISA used
for the measurement of immunoglobulins in the lavage fluids have been markedly
improved since the introduction of WGL technique into the G.I unit in 1988. As
described above, WGL is now supervised by experienced nurses to encourage
subjects to drink 200 ml of the lavage solution every 10-15 minutes and to ensure
accurate recording of the volumes of the fluid intake and output as well as to make
sure that only clear fluid passed per rectum is collected. The method of processing
WGL fluid has also been technically improved and the volumes of protease
enzymes inhibitors added to the lavage fluid have been adjusted to minimise the
activity of these enzymes. Filtering WGL fluid through special filter paper rather
than centrifuging it has resulted in shortening the time required for WGL fluid
processing.
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It seems likely that the above technical development in the methods of collecting,
processing and assaying WGL fluid has produced more accurate results than those
obtained in previous studies. Comparing the results of the analysis of intestinal
secretions obtained by the current WGL technique and those obtained by invasive
methods, such as intestinal intubation for obtaining jejunal aspirate or for
segmental gut perfusion, the results of WGL seems to be comparable to the other
methods. Furthermore, WGL has the advantage of being non-invasive and well-
tolerated.
Although the median level of TIgA in WGL fluid obtained from healthy volunteers
in my research were shown to be lower than the medians and means reported
previously, yet the range of the concentrations of TIgA was found to be relatively
widely distributed (between 10.00 and 173.20 p,g/ml). Whether the wide range of
the concentrations of TIgA is due to a real biological phenomenon or due to other
unknown factors is not, as yet, known. Effects of age, nutritional status and
smoking habit on gut immunity are possible factors that may have confounding
effects on levels of intestinal immunoglobulins. The effect of smoking/non¬
smoking on gut immunity of healthy volunteers was investigated (see chapter 8)
and it was found that smoking does not seem to be one of the factors responsible
for the wide range of TIgA in healthy subjects.
The main aim of administering oral vaccines is to stimulate intestinal immunity,
particularly IgA, against enteric pathogens. Therefore, an important implication of
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the wide range of levels of TIgA in the gut is the effect of oral vaccination on
intestinal immunity. This is because a given dosage of the oral vaccine that may
stimulate intestinal immunity against enteric pathogens in some individuals may not
do so in others. Studies on the effect of oral vaccines on gut immunity (chapter 6
and personal communication, Dr Ahren, University of Goteborg, Sweden) showed
that individuals who had very low or high levels of IgA antibodies in intestinal
fluids did not respond to the oral vaccine as did others with optimal baseline levels
of IgA antibodies. Therefore, further research into the factors affecting levels of




THE INTESTINAL IMMUNE RESPONSES TO THE
ORAL TYPHOID VACCINE Ty21a
Since the gut is the portal of entry of the enteric pathogens, it is hoped that oral
vaccines will protect against these pathogens by stimulating the production of IgA
antibodies, the major component of the mucosal immune system. Introduction of
the oral poliovirus vaccine (OPV) has resulted in elimination of the paralytic
disease from many advanced countries and this encouraged workers to examine the
possibility of developing oral vaccines against other enteric pathogens. However,
oral vaccination against Salmonella typhi, the causative organism of typhoid fever,
has produced equivocal results. The protective efficacy of the oral typhoid vaccine
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Ty21a, given at dosages containing 10 live Salmonella typhi organisms, varied
from 42 to 96% in Indonesia and Egypt respectively. Experimental studies have
shown that the vaccine Ty21a, given at the same dosages to healthy subjects from a
non-typhoid area, produced either unmeasurable (Forrest et al, 1991) or meagre
intestinal immune responses (Bartholomeusz et al, 1986).
Field trials investigated the protective efficacy of the oral typhoid vaccine Ty21a in
areas endemic with typhoid fever using different formulas, schedules and dosages
of the vaccine. However, the baseline intestinal antibody status of subjects from
typhoid-endemic areas may be different from that of subjects living in non-endemic
areas and the protective efficacy calculated from these field trials cannot be
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extrapolated to populations from non-typhoid areas. Therefore, it was important to
investigate the effect of the oral typhoid vaccine Ty21a on the intestinal immunity
of healthy volunteers from non-typhoid areas. Previous studies investigated the
immune responses to the oral typhoid vaccine in serum and saliva (see chapter 2).
However, there is now increasing evidence that the findings in serum and saliva do
not necessarily reflect the findings in the gut and it will be misleading to
extrapolate the findings in the systemic immune system to the gut.
Forrest et al (1991) investigated the intestinal immune responses to the oral typhoid
vaccine Ty21a in healthy volunteers from a non-endemic typhoid area excluding
subjects who had had natural typhoid infection or had been vaccinated against
typhoid fever. The above study showed that peak intestinal antibody responses
were produced 2-3 weeks after oral vaccination with Ty21a vaccine. The above
findings were useful in determining the time at which the post-vaccination
specimens of WGL fluid should be collected from the British healthy volunteers in
my study.
WGL fluids, essentially gut perfusate, were obtained from 22 British healthy
volunteers before and 3 weeks after oral vaccination with Ty21a vaccine. In my
studies, WGL technique was found to be safe, non-invasive and well-tolerated.
However, WGL technique may not be suitable for evaluation of intestinal immune
responses in large populations for field trials. The oral typhoid vaccine Ty21a,
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given at a dose of 2 X 10 viable Salmonella typhi Ty21a organisms in the form of
enteric-coated capsules on alternate days was found to be safe and well-tolerated.
No significant differences were found between levels of TIgA, TIgM and anti-Re
mutant of Salmonella typhimurium IgA antibodies in WGL fluid of the healthy
volunteers before and 3 weeks after oral vaccination with Ty21a vaccine. These
findings indicated that changes in zx\i\-Salmonella typhi LPS antibodies were
antigen-specific and not due to a polyclonal immune response. Furthermore, the
above findings support the hypothesis of WGL fluid as a perfusate (see chapter 4).
The significant increase in anti-Salmonella typhi LPS IgA antibodies in WGL fluid
of 14 out of 22 (63.6%) healthy volunteers after vaccination with the oral typhoid
vaccine Ty21a may be regarded as a relatively modest increase compared to the
increase in the intestinal IgA antibodies (anti-LPS antibodies) in gut lavage fluid of
12 out of 13 (92%) healthy volunteers after administration of the oral cholera
vaccine (a combination of B-subunit of cholera toxin and whole cell organisms)
(Svennerholm et al, 1984b). The finding, in my study, of a modest increase in the
intestinal immune responses against the oral typhoid vaccine Ty21a is consistent
with a previous study (Bartholomeusz et al, 1986) which investigated the intestinal
immune responses to the vaccine Ty21a, taken as 3 gelatine-coated capsules
9
containing 10 viable organisms each, in jejunal aspirate. Serological studies
investigating the immune responses against the oral typhoid vaccine Ty21a have
also shown modest responses in serum. The seroconversion (IgG and IgM
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antibodies, measured by ELISA) produced by the vaccine Ty21a, taken as enteric-
9
coated capsules containing 10 live organisms, in adult healthy American volunteers
was approximately 44% (Black et al, 1983).
Several studies investigated the possibility of using the oral typhoid vaccine Ty21a
as a vector to carry other vaccines for the protection against other enteric infections
such as Shigella and cholera. However, in the light of the above findings the use of
Ty21a vaccine as a carrier for other vaccines may not be encouraged. Indeed, the
use of the vaccine Ty21a as a carrier for a vaccine against cholera (V. cholera 01
serotype Inaba O antigen) produced only 25% protection and the use of Ty21a
vaccine as a carrier for a vaccine against Shigella (Shigella sonnei O antigen)
produced a wide range of protective efficacy (Morris et al, 1992). The modest
immunogenicity of the vaccine Ty21a may be because it is too attenuated to survive
long enough in the gut, to interact enough with lymphoid tissues for efficient
stimulation of intestinal antibodies. More immunogenic but less attenuated vaccines
may be more invasive and more likely to produce adverse reactions. Therefore, it
seems that a balance is required between the optimal immune responses and the
adverse reactions produced by a successful candidate vaccine. Another possible
explanation for the modest immunogenicity of the vaccine Ty21a is the low dose of
viable organisms per enteric-coated capsule. Forrest et al (1991) showed that there
was a significant increase in the intestinal (as well as systemic) antibodies of
healthy volunteers after oral vaccination with Ty21a vaccine when given at doses
containing lo" viable Salmonella typhi organisms per enteric-coated capsule but no
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responses were obtained when the vaccine was given at doses containing 10 viable
organisms.
Genetic factors that render some individuals restricted in their immune responses to
the vaccine may also be considered during interpretation of the immune responses
against Ty21a vaccine. In mice, studies showed that the mouse strain CH3/HeJ
does not respond to some kinds of LPS (Forui and Coutinho, 1978). This was
attributed to a genetic disorder causing the absence of specific receptors on
macrophages and lymphocytes of the mouse strain CH3/HeJ resulting in
unrecognition of some types of LPS.
The concentrations of anti-Salmonella typhi LPS IgA antibodies in WGL fluid of 4
volunteers showed no significant changes 3 weeks after oral vaccination with
Ty21a vaccine while the concentrations of these antibodies in WGL fluid of
another 4 volunteers showed a significant decrease 3 weeks after vaccination.
Subjects who had no changes or decrease in their intestinal antibodies after oral
vaccination were mostly subjects who had very high or very low baseline intestinal
antibody levels. These results are in accord with findings obtained by a Swedish
group (personal communication, Dr. Ahren, University of Goteborg, Sweden)
during research into the intestinal immune responses against oral cholera and E.
coli vaccines.
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The absence of significant increase in the levels of intestinal IgA antibodies in
WGL fluid of subjects who had high baseline levels intestinal antibodies may
indicate that the magnitude of the intestinal immune responses to the orally
administered vaccine Ty21a inversely dependent on the pre-existing specific
antibodies which had most likely been acquired, in subjects from non-endemic
areas, through subclinical exposure to non-typhoidal Salmonella spp. sharing O
antigens similar to those of Salmonella typhi. Forrest (1992c) showed that the
presence of high levels of cross-reacting intestinal antibodies in healthy subjects
significantly reduced the magnitude of local intestinal immune responses to the oral
typhoid vaccine Ty21a. The blocking effect of the cross-reacting antibodies was
attributed to the presence of high levels of Salmonella typhi LPS IgA
antibodies which prevented boosting of primary intestinal immune response by a
further dose of Ty21a vaccine. Therefore, it seems that obtaining a satisfactory
local immune response may requires a fine balance between immunological
priming and the presence of cross-reacting antibodies.
Subjects who had very low levels of baseline intestinal antibodies failed to have a
significant increase in the concentrations of the intestinal IgA antibodies against the
oral typhoid vaccine Ty21a. These findings are consistent with previous work by
Murphy et al (1991) who showed that, unlike school-age children and adults,
young children (infants and toddlers) from a typhoid-endemic area (Chile) failed to
respond to the oral typhoid vaccine Ty21a. These findings suggest that levels of
pre-vaccination cross-reacting intestinal antibodies should be taken into
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consideration in the interpretation of the immunogenicity of the vaccine Ty21a.
Therefore, it seems that the presence of an optimal levels of pre-existing intestinal
antibodies may be an important factor in determining the outcome of the intestinal
challenge to a defined oral vaccine. Subjects who had a decrease in the levels of
anti-S. typhi LPS IgA antibodies may have had their peak concentration of
intestinal antibodies at a time earlier than the date of the post-vaccination WGL
sampling.
There was an overall increase in serum antibody titres of IgA, IgM and IgG.
However, this increase was not correlated with the increase or decrease in the
intestinal antibody titres in the individual subjects. The above findings are
consistent with the increasing number of studies showing that systemic and
intestinal immune systems are separate, but related, systems. It is now well-
established that although serum antibodies are commonly detected after oral
vaccination or enteric infection, including non-invasive infections, determination of
the concentrations of serum antibody titres and local intestinal antibody titres are
poorly correlated. In addition, Forrest et al (1992) showed that priming with
parenteral vaccination, using killed typhoid vaccine, neither enhanced nor
suppressed the subsequent intestinal IgA immune responses to a booster course of
the live oral typhoid vaccine Ty21a. Therefore, it seems that levels of serum
antibodies are dissociated from levels of intestinal antibodies and that serum
antibodies may not play an important role in the protection against enteric
infection.
288
The quantitative studies of the antigen-specific antibodies in WGL fluid (as well as
in serum) using the modified ELISA developed in this research seems to be a
satisfactory approach for the evaluation of the local intestinal immunity and to
investigate the effect of orally administered vaccine on gut immunity. The
specificity of the ELISA method used in this research was investigated by testing
the WGL fluid of the volunteers before and 3 weeks after vaccination against Rc
mutant of Salmonella typhimurium. As cited above, the absence of significant
differences between levels of anti-Rc mutant of Salmonella typhimurium IgA
antibodies in WGL fluid of the healthy volunteers before and 3 weeks after
vaccination (while there was significant difference between levels of anti-
Salmonella typhi LPS IgA antibodies before and 3 weeks after vaccination)
indicated that changes in antibody titres after vaccination with Ty21a vaccine were
specific and not due to a polyclonal up-regulation of the intestinal immune system.
In Salmonella, as in other Gram-negative bacteria, LPS is regarded as a major
antigen in the outer membrane of the cell wall (Jawetz et al, 1987). The O-somatic
polysaccharide side chains (O antigen) of LPS is known to be an important factor
involved in the virulence of many Gram-negative bacteria, particularly of
Salmonella (Hammond etal, 1984; Eisenstein, 1975; Svenson and Lindberg, 1979;
Collins, 1974; Levine et al, 1983). Strains of Salmonella typhimurium lacking the
complete O antigen (rough forms) were found to be less virulent than strains with
complete LPS structure (smooth forms) (Hammond et al, 1984). The loss of O
antigen from LPS of Salmonella typhimurium mutants resulted in an increase in the
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ingestion of these mutants by macrophages when compared to parent strains (with
complete LPS structure) both in vivo, as measured by the clearance of bacteria
from the blood, and in vitro, as measured by the uptake of these strains by mouse
intraperitoneal macrophages (Hammond et al, 1984). Uptake of bacteria by
phagocytic cells requires activation of complement by the alternative pathway, a
process involving interaction between C3b macromolecules on the bacterial surface
and C3b receptors on the macrophages (Roitt et al, 1985; Roitt, 1994). Since
strains of Salmonella typhimurium with complete LPS are relatively resistant to
phagocytosis, it has been suggested that O antigen is involved in the resistance to
ingestion by macrophages by covering the bacterial cell with a surface layer which
does not allow the products of the complement on the bacterial surface to interact
with C3b receptors on the macrophages, thus avoiding phagocytosis (Hammond et
al, 1984; Roitt, 1994).
In animals, immunisation of rabbits with O antigen obtained from different
Salmonella serotypes resulted in stimulation of anti-0 antigen antibody titres nearly
as high as those elicited by injection of heat-killed whole cell vaccine (Svenson et
al, 1979; Svenson and Lindberg, 1981). In the above studies, anti-0 antigen
antibodies produced in rabbits protected mice against experimentally induced
mouse typhoid (by intraperitoneal injection of Salmonella typhimurium SH 2201).
Deletion of O antigen from LPS of gal E mutants of Salmonella typhimurium, used
as an experimental vaccine, resulted in the loss of the protective efficacy of the
vaccine against pathogenic strains of Salmonella typhimurium injected
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intraperitoneally in mice (Germanier, 1970; Germanier and Fiirer, 1971). The
importance of LPS in the pathogenesis of some other Gram-negative bacterial
infections is well-documented (Levine et al, 1983; Svennerholm, 1975;
Svennerholm et al, 1975; Kopecko et al, 1980). LPS of V. Cholerae has been
reported to be an important factor involved in the pathogenesis of cholera infection
(Levine et al, 1983) and it has been shown that anti-K Cholerae LPS antibodies
provided animals with protection against experimentally induced cholera
(Svennerholm, 1975; Svennerholm et al, 1975). In Shigella, the importance of LPS
as one of the virulence factors is best illustrated by the phase variation shown by
Shigella sonnei. Shigella sonnei phase I have the complete LPS structure and are
usually virulent while Shigella sonnei phase II have incomplete LPS (without O
antigen) and are non-pathogenic (Kopecko et al, 1980). In the above study,
variation of Shigella sonnei between phases I and II was associated with the loss of
a large plasmid known as 120-Mdal (120 Megadaltons in size).
The above studies highlighted the importance of LPS of Salmonella (and some
other Gram-negative bacteria) as a major factor involved in the virulence of Gram-
negative bacteria and have suggested that anti-LPS antibodies provided animals
with serotype-specific protection against experimentally induced infection.
However, mice are not the definitive host of Salmonella typhi and humans are the
only known host of the organism. Furthermore, the exact pathogenesis of typhoid
fever is not well-understood. Therefore, the findings in the above studies may only
be applicable to animals.
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Since the oral typhoid vaccine Ty21a lacks the capsular antigen (Vi antigen)
(Germanier and Ftirer, 1975; Gilman et al, 1977), measurement of antibodies
against Vi antigen would not be relevant. Porin antigens of the outer membrane of
the cell wall of Salmonella are not subspecies-specific (Svenson et al, 1979) and
high titres of cross-reacting antibodies against porin antigens of E. coli may be
obtained (personal communication, Dr. I Poxton, University of Edinburgh).
Because the precise mechanism by which the oral typhoid vaccine Ty21a may
protect against typhoid fever is not, as yet, well-understood, the intestinal immune
responses against other Salmonella antigens should be investigated. For instance,
the flagella of Salmonella typhimurium were reported to be an important virulence
factor in the murine typhoid model (Carsiotis et al, 1984). In an in vitro
macrophage assay, flagellated salmonellae survived within macrophages more than
did non-flagellated organisms (Weinstein et al, 1984). Since the oral typhoid
vaccine Ty21a possesses the flagellar antigen (H antigen) (Gilman et al, 1977),
investigation of the presence of anti-Salmonella typhi H antigen antibodies in the
intestinal secretions, using WGL technique, may provide further information about
the intestinal immune responses against the vaccine.
I would like to emphasise the fact that my research into the effect of the oral
typhoid vaccine Ty21a on intestinal immunity involved the quantitative
measurements of intestinal immunoglobulins and antigen-specific antibodies as
parameters of the intestinal immune responses against the vaccine and not as
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parameters of the protective efficacy of the vaccine. This is because the correlation
between the magnitude of the intestinal immune responses and the clinical
protection against infection has not, as yet, been established.
Since better understanding of intestinal immunity may help in developing vaccines
against enteric infections, the findings in this study may have important
implications for the oral vaccination programmes. Because the main target of
vaccination programmes is the control of infectious diseases in countries of the
developing world where subjects are under continuous exposure to a wide spectrum
of intestinal pathogens, further research into the intestinal immune status of these
subjects is required. Intestinal immunity together with the nutritional status may be
important determinants of the outcome of vaccination programmes.
As cited above, the precise mechanism(s) by which the intestine is protected
against the wide range of intestinal pathogens is(are) not, as yet, well-understood.
In addition to humoral intestinal immunity, cell-mediated immunity has been
suggested to play an important role in the protection against enteric pathogens,
such as Salmonella typhi and Shigella infections. Intestinal infection with
Salmonella typhi, Shigella or oral vaccination with Ty21a has been found to induce
IgA-dependent cellular cytotoxic activity (Tagliabue et al, 1984). Cytokine-
mediated cellular immunity has also been suggested to play a role in the protection
against Salmonella typhi (Levine and Nataro, 1994). However, the above studies
were carried out using peripheral blood and, as described before, the findings in
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serum may not reflect the findings in the gut. Non-invasive methods for
investigation of cell-mediated immunity in the gut are not available and the role of




THE INTESTINAL IMMUNE RESPONSES TO
NATURALLY-ACQUIRED SALMONELLA INFECTION
Bacterial infection of the gut lumen has been reported to prime the intestinal
immune system to produce SIgA which is believed to provide specific immune
protection for the gut to subsequent infection by a mechanism known as "immune
exclusion". This mechanism involves the prevention of binding and colonisation of
the mucosal surface by the causative organisms as well as the neutralisation of
bacterial toxins. In addition, invasive organisms such as Salmonella and Shigella
have been reported to stimulate IgA-dependent cellular cytotoxicity and the major
histocompatibility (MHC) class I-restricted cellular cytotoxicity (Kauffmann,
1988). In my research into the effect of naturally-acquired salmonella infection on
gut immunity, patients who had had salmonella infection were found to have
measurable concentrations of intestinal anti-S. typhi LPS IgA (and IgM) antibodies
in WGL fluid. However, there were no significant differences between levels of
anti-S1. typhi LPS IgA antibodies (expressed either as units/ml or units/mg of TIgA)
in WGL fluid of patients who had had salmonella infection and those of healthy
British volunteers.
The absence of significant differences between levels of anti-Salmonella typhi LPS
IgA antibodies in WGL fluid of patients who had had salmonella infection and
those of the healthy volunteers may be due to the relatively long period between
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the date of infection and that of WGL sampling. This was mainly due to practical
difficulties in recruiting the above patients. Therefore, the peak of the intestinal
immune responses, when there had been responses, may have passed so that the
levels of the intestinal antibodies found in WGL fluid of the above patients did not
represent the actual values of the intestinal antibodies induced by the infection.
The absence of significant differences between the concentrations of anti-
Salmonella typhi LPS IgA antibodies in WGL fluid of patients who had had
salmonella infection and those of the healthy volunteers may also be due to low
affinity of the immune responses of the above patients. As cited before, studies in
mice showed that a genetic disorder may result in the absence of LPS-specific
receptors on the macrophages and lymphocytes. The lack of interactions between
antigen-presenting cells and LPS may result in low affinity immune responses.
However, findings in animals cannot always be extrapolated to man and whether
genetic factors are responsible for low profile immune responses in man or not is
not, as yet, clear.
Another possible explanation for the absence of significant differences between
levels of anti-Salmonella typhi LPS IgA antibodies in WGL fluid of patients who
had had salmonella infection and those of the healthy volunteers may be the
presence of relatively high baseline levels of cross-reacting intestinal antibodies in
the healthy volunteers. This may be due to the exposure of the healthy volunteers
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to a previous infection (either overt or subclinical) with non-typhoidal Salmonella
spp (salmonellosis).
The relatively small sample size of patients who had had salmonella infection
(n= 8) may be another explanation for the absence of statistically significant
differences between levels of anti-Salmonella typhi LPS IgA antibodies in WGL
fluid of these patients and those in WGL fluid of the healthy volunteers.
Typhoid fever has been reported to stimulate both intestinal and systemic, humoral
and cell-mediated, immune responses. Specific intestinal SIgA antibodies are
thought to play an important role in the prevention of mucosal penetration by
Salmonella typhi organisms during the infection. Therefore, it was surprising to
find out that one patient who had had typhoid fever had very low anti-Salmonella
typhi LPS IgA antibodies expressed either as units/ml or units/mg of TIgA.
Furthermore, the above patient was found to have the minimum value in the range
of TIgA of patients who had had salmonella infection. The above findings may
suggest that infection with typhoid fever does not always result in the induction of
significant levels of specific intestinal IgA antibodies against Salmonella typhi.
They may also have important implications for the vaccination programmes against
typhoid fever because typhoid vaccines, particularly oral vaccines, are expected to
stimulate intestinal IgA antibodies.
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Although there have been many descriptive studies of the immune responses
associated with Salmonella typhi infections or after immunisation against typhoid
fever, yet these studies mostly described the immune responses in serum, IgA-
secreting cell in the peripheral blood or in faeces. As discussed before in this
thesis, the use of serum, peripheral blood lymphocytes (PBLs) or faeces to
investigate intestinal immunity may not be valid.
Although intestinal IgA antibodies have been reported to appear within one week
after enteric infection and as early as 3 days after re-immunisation (Svennerholm et
al, 1984a), the duration of the presence of these antibodies in the intestinal
secretions has not been investigated before. My study investigated the presence of
intestinal antibodies against Salmonella typhi LPS for a period of up to 12 months
after salmonella infection. However, because the optimal time at which the peak of
the intestinal immune responses appear after naturally-acquired salmonella infection
is not known and also, as cited above, because WGL sampling may have been
obtained 'too late' to study the intestinal immune responses against Salmonella
typhi LPS, the peak of the intestinal immune responses may had been "missed".
The antigen against which the WGL fluids were tested was LPS of Salmonella
typhi which belongs to group D in the Kauffmann-White classification of the genus
Salmonella. WGL fluid of patients who had had infection with Salmonella
enteritidis (which also belongs to group D) may contain antibodies against two O
antigens shared with Salmonella typhi. These antigens are O antigen factor 9 and O
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antigen factor 12. Therefore, it is conceivable that antibodies measured in WGL
fluid of patients who had had Salmonella enteritidis infection were more likely to
be cross-reacting antibodies. The main reason for including patients who had had
non-typhoidal with those who had had typhoidal salmonella infection was the small
number of patients who could be recruited for the study. Given that the group
contained a mixture of patients who had had either typhoidal or non-typhoidal
salmonella infection, investigation of intestinal immune responses against a more
common antigen such as Rc mutant of Salmonella typhimurium might have been
more appropriate. In future work, a range of bacterial antigens (e.g. of bacteria not
found in the gut) should be used. I would like to emphasise that the aim of this
study was to measure intestinal immunoglobulins and antigen-specific antibodies in
WGL fluid of patients who had had naturally-acquired salmonella infection as a
parameter of intestinal immune responses and not as a direct evidence of the
presence of protective immunity in the gut.
It was important to examine the intestinal immune status of healthy individuals
from a non-endemic area because these individuals may have been infected with
one or more serotypes of non-typhoidal Salmonella (salmonellosis) due to food
poisoning and their intestinal antibody status may have never been investigated.
Investigation of the intestinal antibody status in the above subjects is important
because, as mentioned in the previous section, levels of pre-existing antibodies may
be an important determinant of the outcome of vaccination against enteric
infections.
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Patients with IBD are known to have polyclonal up-regulation of intestinal
immunoglobulin production. However, the presence of pre-existing antibodies
against Salmonella typhi LPS has not been investigated before in such patients.
Therefore, it was important to investigate the presence of antigen-specific intestinal
antibodies in WGL fluid of IBD patients and to compare levels of these antibodies
with those of healthy volunteers. The presence of significant differences between
levels of TIgA in WGL fluid of IBD patients and those of patients who had had
salmonella infections may be due to the fact that patients with IBD have, for
unknown reasons, high levels of intestinal (and systemic) immunoglobulins.
There was no correlation between systemic and intestinal immune responses of
patients who had had salmonella infection. These findings are consistent with the
findings in the previous chapters of this thesis as well as with the findings of many
other studies (see chapter 2).
Generally, the findings in this study indicated that there is a great need for further
studies into the intestinal immune responses of patients who have had natural
infection with enteric pathogens with a more careful approach into the optimal time
at which intestinal antibody levels are likely to peak. Such studies should consider
the wide range of levels of the pre-existing intestinal antibodies described in this
study. In my study, WGL fluid was used as material to study gut immunity in
British healthy volunteers, patients who had had salmonella infection and patients
with IBD, and WGL technique was well-tolerated by all subjects involved in the
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study. Therefore, the use ofWGL technique, to obtain intestinal secretions, and the
modified ELISA described in this thesis to study antigen-specific antibodies would
make studies on gut immunity after enteric infections more feasible.
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Section 5
EFFECT OF CIGARETTE SMOKING ON GUT IMMUNITY:
DOES SMOKING SUPPRESS INTESTINAL IMMUNE RESPONSES ?
Tobacco smoking has been shown to modify the primary and secondary immune
responses in animals and humans and has been suggested to influence the clinical
course of inflammatory bowel disease (IBD) (see chapter 2). Nevertheless, most of
the studies have investigated the effect of cigarette smoking on the systemic rather
than the mucosal immune system. The effect of cigarette smoking has also been
studied in pure parotid saliva and it was found that levels of salivary IgA of
smokers is significantly lower than those of non-smokers or ex-smokers (Barton et
al, 1990). However, further studies on saliva, in comparison with WGL fluid,
showed that the immunological findings in saliva do not necessarily reflect those of
the gut.
Therefore, investigating directly the effect of cigarette smoking on the intestinal
mucosal immune system had become necessary due to a variety of reasons
described below. Any modification of the mucosal immune system of the gut, by
cigarette smoking, could have considerable implications on the intestinal immunity
against enteric infections as well as on the efficacy of oral vaccines. Furthermore,
cigarette smoking is an increasingly common habit in third world countries where
malnutrition and poor health care standard are already major health problems.
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The relationship, if any, between cigarette smoking and the clinical course of
ulcerative colitis will also have important implications for the disease management.
For instance, administration of nicotine to patients with ulcerative colitis may help
in the management of this disease.
One study investigated the effect of cigarette smoking on the intestinal immune
responses against three gut commensals (Escherichia coli, Candida albicans and
Proteus mirabilis) using WGL in healthy subjects and patients with ulcerative
colitis. However, the smokers in the above study had smoked a small number of
cigarettes per day for a relatively short period of time (one year). Therefore, it was
important to examine the effect of heavy smoking on gut immunity in young
healthy subjects who had smoked >20 cigarette/day for more than three years
comparing the results with those of young healthy non-smokers.
The results obtained in my study indicated that smoking did not suppress levels of
intestinal IgA, IgM or antigen-specific IgA antibodies (anti-Salmonella typhi LPS
IgA) as compared to the results obtained from non-smokers. Furthermore, when
the oral typhoid vaccine Ty21a was used to induce gut immunity of both smokers
and non-smokers, there was no significant difference between levels of anti-
Salmonella typhi LPS IgA antibodies in WGL fluid (as well as in serum) of both
groups. These findings exclude cigarette smoking as an important factor that may
affect the magnitude of the intestinal immune responses to the oral vaccines and
enteric infections. Therefore, other factors such as age and the nutritional status
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may be important in determining the outcome of an antigenic challenge to the
intestinal immune system. Such factors are to be investigated further.
The above findings may also indicate that the reported modification of the clinical
course of ulcerative colitis in smokers is not mediated through suppression of
intestinal immunoglobulins and antibodies. Possible mechanisms of how cigarette
smoking might influence the clinical course of ulcerative colitis are described
below.
Cigarette smoking has been reported to significantly decrease rectal blood flow in a
group of patients with ulcerative colitis as compared to healthy non-smokers
(Srivastava et al, 1990). In the above study, rectal blood flow was found to be
inversely related to the concentration of nicotine in plasma. A decrease in rectal
blood flow during smoking may be due to nicotine-induced vasoconstriction. A
decrease in blood flow will result in a decrease in the amount of inflammatory
mediators, such as prostaglandin E2 (PGE2) and leukotriene B4, reaching the
mucosal surface with the subsequent decrease in free radicals (extremely reactive
chemicals) and tissue damage.
Another possible mechanism that may be involved in the protection of cigarette
smokers against ulcerative colitis is the increase in colonic mucous production
reported to be found in smokers. Non-smokers with ulcerative colitis were found to
have reduced amounts of colonic mucous as compared with non-smokers controls
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while patients with ulcerative colitis who did smoke had a similar rate of colonic
mucous production to that of the controls (Cope et al, 1986). Increased mucous
production in the colon will improve the mucous barrier function, an important
protective barrier on the intestinal mucosal surface.
Finally, smoking has been found to decrease the intercellular junction of the
intestinal epithelium enforcing the effectiveness and integrity of an important line
of the mucosal defence beneath the mucous layer. Therefore, cigarette smoking
may 'tighten' the intestinal epithelium.
The effect of cigarette smoking on the cellular aspect of the intestinal mucosal
immune system has not been investigated. Systemically, cigarette smoking has been
found to produce pronounced effects on cell-mediated immunity with a marked
increase in the leukocytic count "smokers leukocytosis". The polymorphonuclear
leukocyte count in cigarette smokers has been reported to be increased by up to
44 % and the total number of T lymphocytes in the peripheral blood of smokers has
also been found to be increased with a significant increase in CD4+/CD8+ ratio
(Tollerud et al, 1989). The peripheral blood monocyte count in smokers has also
been reported to be increased and the cells are defective in their capacity to kill
intracellular Candida (Nielsen, 1985). Furthermore, heavy smokers have been
found to have depressed natural killer cell activity and reduced antibody-dependent
cellular cytotoxicity (Ferson et al, 1979).
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In the respiratory tract, cigarette smoking has been found to increase significantly
the number and secretory function of the alveolar macrophages (Harris et al, 1970)
while in the cervical mucosa cigarette smoking was reported to produce a
significant decrease in the number and activity of Langerhan's cells, which are
important antigen-presenting cells involved in several chronic inflammatory
conditions (Barton et al, 1988).
Therefore, further research into the effect of cigarette smoking on the antigen-
presenting cells, such as macrophages, as well as on other cells in the gut may help
in understanding the mechanism(s) by which cigarette smoking may affect the
intestinal mucosal immune system.
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Section 6
INTESTINAL MUCOSAL IgA DEFICIENCY
IgA deficiency is commonly defined as low levels or absence of this
immunoglobulin class in serum. Subjects with IgA deficiency are also known to
have very low numbers (or even absence) of IgA-producing cells in the intestinal
mucosa, often associated with a "compensatory" increase in IgM-producing cells
(see chapter 2). However, the paucity or absence of IgA in the intestinal secretions
of subjects who have normal levels of IgA in serum has not been described before.
Possible reasons that might have hampered previous recognition of intestinal IgA
deficiency are described below.
Levels of immunoglobulins have always been measured in serum assuming that the
findings in serum may reflect the findings in the gut. Measurements of the
concentrations of intestinal immunoglobulins have been hampered by the difficulty
in obtaining intestinal secretions. Previous studies reported wide ranges of
intestinal IgA levels: the actual data showed the presence of very low levels of or
even absent IgA in the intestinal secretions but these findings were ignored by the
investigators presumably because they thought that these findings occurred due to
technical errors or inadequate sampling.
The availability of non-invasive methods, such as WGL, for obtaining intestinal
secretions as material in which to study gut immunity has increased the number of
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subjects involved in research into gut immunity. Furthermore, the increasing use of
WGL in cleansing of the bowel as a preparation for barium enema, colonoscopy or
colon surgery as well as in the treatment of intractable constipation has increased
the number of WGL specimens available for research into the intestinal mucosal
immune system.
Since there was no standard range for the concentration of IgA in the intestinal
secretions and because of the wide range of TIgA found in WGL fluid and in
jejunal aspirates of subjects involved in my research into intestinal IgA deficiency,
determination of the minimal levels of TIgA below which specimens were regarded
as IgA deficient was based on the minimal value in the range of TIgA in WGL
fluid of the 22 healthy volunteers (10-173 pg/ml) described in chapter 6.
Out of 391 WGL specimens in which concentrations of TIgA were measured, 6
specimens (1.5%) were found to have concentrations of TIgA ranged between zero
and 5.2 pg/ml and were from subjects known to have normal levels of IgA in
serum. One more subject was found to have no TIgA in WGL fluid but was also
found to have hypogammaglobulinaemia.
Counting of IgA-producing plasma cells in the lamina propria of the above
mentioned 6 cases revealed the presence of 2 different sets of subjects. There were
subjects who had low levels of IgA in WGL fluid but counting of IgA-containing
cells in the lamina propria of intestinal biopsies from these subjects revealed the
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presence of numbers of plasma cells that fell within the range of plasma cells in the
normal controls. The other set contained subjects who had low levels or absent IgA
in WGL fluid and very low numbers of IgA-containing cells in the intestinal
biopsies i.e. these subjects had a true intestinal IgA deficiency as shown in WGL
fluid and IgA cell counting.
The discrepancy between the findings in WGL fluid and the intestinal biopsies in
the first set of data may be due to technical error in collecting or processing of
WGL fluid which resulted in false negative results. As described in chapter 4,
analysis of PEG contents in sequential lavage samples of one patient involved in
the study showed that some samples had very low contents of PEG and further
investigation showed that these samples were contaminated (diluted) with urine.
Another possible technical error that might have occurred is collecting faecally
contaminated rather than clear fluid WGL specimens. Analysis, by Dr. Croft (a
research fellow), of faecally contaminated WGL specimens collected from
constipated children revealed the presence of low IgA levels in these specimens.
Deliberate addition, by some children, of pure lavage solution into the WGL
specimens resulting in marked dilution and false low levels or negative IgA was
also been found to be one of the difficulties encountered during WGL in children.
It is conceivable, although unlikely, that those cases with low levels or absent IgA
in WGL fluid but with a normal IgA-producing cell count had a defect in the
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transport of polymeric IgA into the external secretions due to deficiency in
secretory component (SC) (see below). Therefore, if repeated measurements of IgA
levels in WGL specimens of subjects with normal numbers of IgA-producing cells
in the lamina propria revealed the presence of low levels of IgA in these specimens
then the transport system of polymeric IgA into the intestinal secretions should be
investigated further.
The subject with hypogammaglobulinaemia (who had absent IgA in WGL fluid)
was found to have no IgA-producing plasma cells in duodenal biopsy. This result
validated the technique used for counting plasma cells in the biopsies of the other
subjects involved in this study.
One of the difficulties encountered in this study was finding relevant biopsies for
the subjects who were found to have low levels or absent IgA in WGL fluid.
Although most of the subjects had had duodenal biopsies taken at dates close to the
dates of WGL fluid collection, the duodenal biopsy of one subject was found to be
old (in relation to the date of WGL) and this biopsy may not have been relevant to
the findings in the WGL fluid. Therefore, jejunal biopsies that corresponded
closely in date to the dates of the WGL fluid were used for plasma cell counting.
Nevertheless, immunohistochemical studies (Brandtzaeg, 1994) showed that
duodenal and jejunal mucosa contain the same percentage of IgA, IgM and IgG-
producing plasma cells (79, 18 and 3 % for IgA, IgM and IgG respectively).
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Another subject was found to have an old duodenal biopsy but no jejunal biopsy
available for plasma cell counting. However, a colonic biopsy had been taken at a
date close to the date of WGL fluid collection and it was used for the plasma cell
counting. A third subject who had no IgA in WGL fluid was found to have had no
relevant intestinal biopsy taken at a date close to the date of WGL fluid collection.
The above subject was a 91-year old lady with active severe perianal Crohn's
disease and intractable constipation. Therefore, obtaining an intestinal biopsy from
the above lady was considered to be practically difficult. It is likely that the
absence of IgA in the intestinal fluid of the above lady was due to the specimens
being faecally contaminated (see above).
Due to ethical and practical reasons, one of the difficulties that faces researchers
into gut immunity is obtaining relevant biopsies from healthy volunteers.
Therefore, the biopsies used in my study as normal controls were duodenal biopsies
from young subjects (aged <50 years) who had presented with a variety of
gastrointestinal disorders but in whom various investigations had detected no
abnormality. The number of IgA plasma cells in the biopsies of the above subjects
2
varied between 255 and 948 cells/mm lamina propria.
Out of 6 subjects with absent or near absent IgA in WGL fluid, 2 subjects were
found to have 9 and 19 IgA-producing cells in duodenal biopsies. These 2 subjects
were patients who presented with abdominal pain associated with loose stool or
diarrhoea. Whether the intestinal and cellular findings of the above 2 subjects were
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related to their unexplained abdominal pain and diarrhoea or not, is not clear.
Considering the role of intestinal IgA in protection against a wide range of
intestinal pathogens and considering the balance that should be maintained between
intestinal IgA and the normal microbial flora to avoid compromising the mucosal
barrier of the gut then one can assume that the immunological findings in the gut
may be relevant to the clinical presentation of the above 2 subjects.
IgA2 is known to be more resistant to IgA proteases and has more capacity for
agglutination of Enterobacteriaceae than IgAl. Furthermore, the immune exclusion
mechanism has been reported to be suppressed in subjects with selective IgA
deficiency, and gut opportunistic infections seen in AIDS patients have been
suggested to be due to low levels of intestinal IgA (Brandtzaeg et al, 1991).
However, the relationship between the quantitative measurements of the intestinal
IgA and the clinical protection has not been well established.
One more subject who had no IgA in WGL fluid and was found to have no IgA-
producing cells in a duodenal biopsy had a similar clinical presentation to the above
2 subjects but also had diabetes mellitus and hypogammaglobulinaemia.
There were discrepancies between the results obtained from measurements of IgA
in jejunal aspirate and those of IgA plasma cells in the jejunal biopsies of subjects
who had low levels or absent IgA in jejunal aspirate. Apart from 3 subjects (one
had selective IgA deficiency), subjects who had low levels of IgA in jejunal
312
aspirates were found to have numbers of IgA plasma cells that fell within the range
of (or were even higher than) the normal control. Furthermore, the number of IgA
plasma cells in the jejunal biopsy of one control who had normal levels of IgA in
jejunal aspirate was found to be very low (17 cells/mm2 lamina propria). The above
findings may indicate that the specimens of jejunal aspirate used in this study for
the measurements of IgA were not reliable. As described before, jejunal aspirate
used in this study might have been markedly diluted, due to a technical error (see
page 261), during collection resulting in a false low levels or even absence of IgA
measured in these specimens (jejunal aspirate collection was not one of the
protocols of my study). However, the technique of collecting jejunal aspirate
specimens has now been revised to exclude this technical error.
Three subjects who had no IgA in their jejunal aspirates were found to have no
IgA-producing plasma cells in the lamina propria of their jejunal biopsies. These
three subjects had presented with abdominal pain with diarrhoea. One subject had
selective IgA deficiency and non-insulin dependent diabetes mellitus, but various
investigations carried out on the other two revealed no abnormality. As cited above
in cases who had similar clinical presentations and low levels of IgA in WGL fluid,
the relationship, if any, between the immunological findings and the clinical
presentation is not clear.
The presence of subjects with no IgA in their intestinal secretions but normal levels
of IgA in serum has also been reported by researchers in Sweden (personal
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communication, Dr. Ahren, University of Goteborg, Sweden). The above group
described similar findings in a healthy staff volunteer during research into the
intestinal immune responses against cholera and E. coli vaccines. Collaborative
research into gut immunity, including the phenomenon of absence of IgA from
intestinal secretions (in individuals who have normal levels of IgA in serum)
between the Swedish group and researchers from the G.I laboratory of the
University of Edinburgh is currently being carried out.
The mechanism by which intestinal IgA is secreted into the gut lumen involves a
series of developmental stages of B cells resulting in differentiation, maturation and
proliferation of these cells in the mucosa of the gut. Differentiation and maturation
of B cells involves cellular and molecular pathways before plasma cells produce the
polymeric IgA. Polymeric IgA then binds to the polymeric immunoglobulin
receptor (PIgR) on the basolateral surfaces of the intestinal epithelial cells and is
transported across these cells to be selectively secreted into the gut lumen attached
to the SC as SIgA. The cellular pathway of B cell differentiation requires the
presence of T cells, dendritic cells and stromal cells in Peyer's patches. Maturation
of B cells requires the presence of transforming growth factor-(3 (TGF-(3) and
interleukin 4 (IL-4).
Antigenic activation of B cells occurs in the presence of interleukin 5 (IL-5) while
interferon-y (IFN-y) may produce inhibitory signals resulting in down-regulation of
IL-4. Final maturation of B cells and the clonal expansion of IgA-producing cells
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require the presence of IL-2 and IL-6. J chain is required for the formation of
polymeric IgA and SC is required for the active transport of IgA into the gut
lumen. Therefore, a deficiency in one or more of the cytokines or a block in
cellular pathways involved in the production of SIgA may result in its absence in
the intestinal secretions.
Intestinal IgA deficiency is a newly discovered phenomenon that requires further
investigation. Cases found to have IgA deficiency should be carefully examined
with respect to nutritional status, previous infection and illness history, current
and/or drug therapy and age. As described before in this thesis, smoking habit




There has been an increasing need for a method by which the intestinal immune
system can be investigated directly, especially after the discovery that the intestinal
immunity is independent from the systemic immune system such that the findings
in the serum and other body fluids cannot be extrapolated to the gut. WGL
technique has been shown to be a non-invasive, safe and reliable method for
obtaining intestinal secretions in which to study gut immunity. The results of the
serial lavage study have shown that WGL fluid is a perfusate rather than just a
bolus of gut contents. Therefore, the above study validates the use of the first clear
sample passed per rectum as a representative of the rest of the lavage effluent for
use in clinical research into gut immunology and inflammation.
Although the WGL technique is useful in clinical research into gut immunology
and inflammatory bowel disease, it is not a practical method to use for clinical
diagnosis. The intake and output of the lavage fluid require close supervision by an
experienced nurse throughout the procedure. This makes the WGL technique
unsuitable for use in large-scale field studies.
Studies on the concentration of intestinal IgA in WGL fluid of patients with IBD
and adult British healthy volunteers has shown, unlike previous studies reported
from this centre, that levels of intestinal IgA in WGL fluid of patients with
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ulcerative colitis or Crohn's disease, regardless of the disease activity, are
significantly higher than those levels in WGL fluid of the healthy volunteers. While
WGL fluid of the healthy volunteers contained small traces of TIgM and TIgG,
levels of these immunoglobulins in WGL fluid of patients with 1BD were
significantly higher than those of the healthy volunteers. However, within the
subgroups, levels of TIgA and TIgM in WGL fluid of patients with active disease
(ulcerative colitis or Crohn's disease) did not differ significantly from levels of
these immunoglobulins in WGL fluid of patients with inactive disease indicating
that levels of IgA and/or IgM in WGL fluid cannot be used as indices of disease
activity in patients with IBD. These results confirm the association of IBD with a
major alteration in levels of intestinal immunoglobulins, particularly IgG. Whether
the up-regulation of the intestinal immunoglobulins associated with IBD is due to
leakage from the systemic immune system or due to increase in local production is
not clear. Generally, reliable analysis of intestinal immunoglobulins of patients
with IBD may provide important clues into the pathophysiology and
immunopathology of IBD.
9
The oral typhoid vaccine, given at dosages of 2 x 10 live Salmonella organisms on
3 alternate days in the form of enteric-coated capsules, has been shown to be safe
and well-tolerated by the vaccinees. However, the intestinal (and systemic) specific
immune response produced by this vaccine, although statistically significant, is a
modest increase if compared to the up-regulation of immune responses produced by
other oral vaccines. These results are consistent with clinical experimental studies
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investigating the intestinal immune responses against the vaccine in jejunal aspirate
and in accord with recent large-scale field studies investigating the protective
efficacy of the vaccine Ty21a. Therefore, the oral typhoid vaccine Ty21a may not
be suitable for use as a vector to carry other vaccines against enteric infections.
The absence of a significant correlation between the intestinal and systemic
immune responses confirms that the intestinal immune system is quite separate
from the systemic immune system.
Levels of intestinal polyclonal and anti-Salmonella typhi LPS IgA of patients who
had had naturally-acquired salmonella infection did not differ significantly from
levels of these immunoglobulins and antibodies in WGL fluid of British healthy
volunteers. Furthermore, in one patient, infection with Salmonella typhi stimulated
just meagre intestinal immune responses (both polyclonal and antigen-specific
IgA). The relatively long period between the dates of infection and investigation
may have resulted in missing the peak (if one existed) of the intestinal immune
response against salmonella infection indicating that for future work the optimal
timing of the study may be an important factor that may influence the outcome of
the study. Low affinity of the immune responses of patients who had had
salmonella infection, high baseline of cross-reacting intestinal antibodies, genetic
resistance against LPS of Salmonella spp. and the small size of the sample involved
in the study are other factors that may have resulted in the absence of a significant
difference between levels of intestinal IgA in WGL fluid of patients who had had
salmonella infection and the healthy volunteers. This study also showed that
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patients with IBD have high levels of antigen-specific antibodies as compared to the
healthy volunteers.
The findings in the studies on the oral typhoid vaccine and the intestinal immune
responses against naturally-acquired salmonella infection may indicate that other
factors such as the nutritional status, age and pre-existing intestinal cross-reacting
antibodies should be considered during interpretation of the immune responses
against oral vaccines and naturally-acquired salmonella infection.
Although studies on the effect of smoking on concentrations of IgA in saliva of
smokers/non-smokers had shown low salivary IgA levels in smokers, studies on the
effect of cigarette smoking on gut immunity of healthy volunteers indicated that
smoking does not modify significantly the levels of intestinal immunoglobulins or
specific antibodies against the oral typhoid vaccine Ty21a. Therefore, the
protective effect, if any, of cigarette smoking reported to be found in patients with
ulcerative colitis must be due to some other mechanism(s) than the levels of
intestinal immunity. These mechanisms may involve an increase in colonic mucous
production, decrease in rectal blood flow or a decrease in the para-cellular
junctions of the intestinal epithelium. Further studies on the effect of cigarette
smoking on the cellular aspects of the intestinal immune system are recommended.
Studies on WGL fluid and jejunal aspirate of patients and normal individuals
collected during 1991/92 revealed the presence of a few subjects with very low
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levels or absence of IgA in their intestinal secretions. These subjects were found to
have normal levels of IgA in serum. Immunohistochemical studies on intestinal
biopsies from the above subjects revealed the presence of only small numbers of
IgA-plasma cells in the lamina propria of some of these subjects suggesting the
presence of a previously unrecognised form of IgA deficiency. At this stage, the
implications of intestinal IgA deficiency for gut immune function are not clear and
the relationship between the clinical presentation of some subjects and this
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AN INFORMATION SHEET FOR THE STUDY OF INTESTINAL IMMUNE
RESPONSES TO THE ORAL TYPHOID VACCINE Ty21a
Name: D.O.B: Sex:
Hospital: Unit No: Cosultant:
Date of study:
Session (pre/post-vaccination):
History of infection (if any):
Treatment given (if any):
History of travelling abroad:
History of vaccination (oral and/or parenteral):




Drug history (if any):
Family history:
Social history:
Results of laboratory investigations (pre/post-vaccination)::
(1) Total immunoglobulines
Serum: TIgG TIgM TIgA
Whole gut lavage: TIgA TIgM
(2) Anti-Salmonella typhi LPS antibodoies
Serum: IgG IgM IgA
Whole gut lavage: IgA IgM
(3) Anti-Salmonella typhimurium Rc-mutant IgA antibodies
2
